---
document_datetime: 2025-12-18 08:50:47
document_pages: 80
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/invokana-h-c-002649-ii-0069-epar-assessment-report-variation_en.pdf
document_name: invokana-h-c-002649-ii-0069-epar-assessment-report-variation_en.pdf
version: success
processing_time: 101.8331363
conversion_datetime: 2025-12-23 05:16:55.454884
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

24 July 2025 EMA/273696/2025 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

Invokana

International non-proprietary name: Canagliflozin

Procedure No. EMEA/H/C/002649/II/0069

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                              | ..............................................6                                                          |
|-------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ................................................................................................ | 6                                                                                                        |
| 1.2. Steps taken for the assessment of the product                                                                      | ....................................................... 7                                                |
| 2. Scientific discussion                                                                                                | ................................................................................8                        |
| 2.1. Introduction                                                                                                       | ...................................................................................................... 8 |
| 2.1.1. Problem statement                                                                                                | .......................................................................................... 8             |
| 2.1.2. About the product                                                                                                | ........................................................................................... 9            |
| 2.1.3. The development programme............................................................................            | 9                                                                                                        |
| 2.1.4. General comments on compliance with GCP ......................................................                   | 10                                                                                                       |
| 2.2. Non-clinical aspects..........................................................................................     | 10                                                                                                       |
| 2.2.1. Ecotoxicity/environmental risk assessment........................................................                | 10                                                                                                       |
| 2.2.2. Discussion on non-clinical aspects....................................................................           | 10                                                                                                       |
| 2.2.3. Conclusion on the non-clinical aspects..............................................................             | 10                                                                                                       |
| 2.3. Clinical aspects ................................................................................................  | 11                                                                                                       |
| 2.3.1. Introduction                                                                                                     | ................................................................................................. 11     |
| 2.3.2. Pharmacokinetics                                                                                                 | .......................................................................................... 11            |
| 2.3.3. Pharmacodynamics........................................................................................         | 21                                                                                                       |
| 2.3.4. PK/PD modelling............................................................................................      | 24                                                                                                       |
| 2.3.5. Discussion on clinical pharmacology .................................................................            | 24                                                                                                       |
| 2.3.1. Conclusions on clinical pharmacology ...............................................................             | 25                                                                                                       |
| 2.4. Clinical efficacy                                                                                                  | ................................................................................................ 26      |
| 2.5. Main study ......................................................................................................  | 26                                                                                                       |
| 2.5.1. Discussion on clinical efficacy ..........................................................................       | 55                                                                                                       |
| 2.5.2. Conclusions on the clinical efficacy...................................................................          | 58                                                                                                       |
| 2.6. Clinical safety                                                                                                    | .................................................................................................. 59    |
| 2.6.1. Discussion on clinical safety ............................................................................       | 70                                                                                                       |
| 2.6.2. Conclusions on clinical safety ..........................................................................        | 71                                                                                                       |
| 2.6.3. PSUR cycle ...................................................................................................   | 72                                                                                                       |
| 3. Risk management plan                                                                                                 | ..........................................................................72                             |
| 3.1. Safety Specification ..........................................................................................    | 72                                                                                                       |
| 3.2. Pharmacovigilance plan.....................................................................................        | 72                                                                                                       |
| 3.3. Risk minimisation measures...............................................................................          | 72                                                                                                       |
| 3.4. Overall conclusion on the RMP............................................................................          | 72                                                                                                       |
| 4. Changes to the Product Information......................................................72                           |                                                                                                          |
| 4.1.1. User consultation...........................................................................................     | 72                                                                                                       |
| 4.2. Significance of paediatric studies ........................................................................        | 73                                                                                                       |
| 5. Benefit-Risk Balance..............................................................................73                 |                                                                                                          |
| 5.1. Therapeutic Context .........................................................................................      | 73                                                                                                       |
| 5.1.1. Disease or condition.......................................................................................      | 73                                                                                                       |
| 5.1.2. Available therapies and unmet medical need                                                                       | ..................................................... 73                                                 |
| 5.1.3. Main clinical studies                                                                                            | ....................................................................................... 74               |
| 5.2. Favourable effects............................................................................................     | 74                                                                                                       |

<div style=\"page-break-after: always\"></div>

5.3. Uncertainties and limitations about favourable effects ........................................... 74

5.4. Unfavourable effects  ......................................................................................... 75

5.5. Uncertainties and limitations about unfavourable effects ........................................ 75

5.6. Effects Table ................................................................................................... 75

5.7. Benefit-risk assessment and discussion ............................................................... 77

5.7.1. Importance of favourable and unfavourable effects ............................................ 77

5.7.2. Balance of benefits and risks  ........................................................................... 78

5.8. Conclusions  ..................................................................................................... 79

6. Recommendations .................................................................................  79

7. EPAR changes  ........................................................................................  80

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| ADR(s) adverse drug reaction                               |
|------------------------------------------------------------|
| AE(s) adverse event(s)                                     |
| AHA antihyperglycemic agent                                |
| BID bis in die (twice a day)                               |
| BMI body mass index                                        |
| CI confidence interval                                     |
| CSR clinical study report                                  |
| DKA diabetic ketoacidosis                                  |
| ECG electrocardiogram                                      |
| eGFR estimated glomerular filtration rate                  |
| EOT end-of-treatment                                       |
| EU European Union                                          |
| FAS full analysis set                                      |
| FOIA Freedom of Information Act                            |
| FPG fasting plasma glucose                                 |
| GLP-1 RA glucagon-like peptide-1 receptor agonist          |
| HbA1c glycated hemoglobin                                  |
| ICH International Conference for Harmonisation             |
| IIV Inter-individual variability                           |
| IR immediate-release                                       |
| LS least squares                                           |
| MedDRA Medical Dictionary for Regulatory Activities        |
| MODY Maturity onset diabetes of the young                  |
| MTD maximum tolerated dose                                 |
| PD(s) pharmacodynamic(s)                                   |
| PDCO Pediatric Committee                                   |
| PIP pediatric investigation plan                           |
| PK(s) pharmacokinetic(s)                                   |
| PopPK population pharmacokinetics                          |
| PT preferred term                                          |
| QD quaque die (once daily)                                 |
| RTG renal threshold for                                    |
| glucose excretion RUV residual unexplained variability     |
| SCE summary of clinical efficacy                           |
| SCP summary of clinical pharmacology                       |
| SCS summary of clinical safety                             |
| SGLT1 sodium-glucose co-transporter 1                      |
| SGLT2 sodium-glucose co-transporter                        |
| 2                                                          |
| TEAE(s) treatment emergent adverse event(s)                |
| T2DM Type 2 Diabetes Mellitus                              |
| TODAY Treatment Options for Type 2 Diabetes in Adolescents |
| UTI urinary tract infection                                |

<div style=\"page-break-after: always\"></div>

## Definitions of Terms

| AUC area under the plasma concentration-time curve                                                        |
|-----------------------------------------------------------------------------------------------------------|
| AUC24h area under the plasma concentration-time curve from time 0 to 24 hours                             |
| AUC τ area under the plasma concentration-time curve during a dosing interval ( τ)                        |
| Cmax maximum plasma concentration                                                                         |
| Efp effect of placebo treatment on HbA1c at steady-state for a typical participant                        |
| Emax maximum placebo-corrected effect of canagliflozin on HbA1c at steady-state for a typical participant |
| t1/2 half-life                                                                                            |
| tmax time to reach the maximum concentration                                                              |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Janssen-Cilag International N.V. submitted to the European Medicines Agency on 11 July 2024 an application for a variation.

The following changes were proposed:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Extension of indication to include treatment of paediatric patients with type 2 diabetes mellitus aged 10 years old and older for INVOKANA, based on final results from study JNJ-28431754DIA3018 as well as study JNJ-28431754DIA1055. Study JNJ-28431754DIA3018 is a double-blind, placebo-controlled, 2-arm, parallel-group, multicenter Phase 3 study in participants with T2DM &gt;10 and &lt;18 years of age who had inadequate glycemic control (ie, HbA1c of &gt;6.5% to &lt;11.0%).

As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 13.1 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce minor changes to the PI and update the list of local representatives in the Package Leaflet.

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0208/2022 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0208/2022 was completed.

The PDCO issued an opinion on compliance for the PIP P/0208/2022 (EMEA-C-001030-PIP01-10-M10).

## Information relating to orphan market exclusivity

NA.

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The MAH did not seek Scientific Advice at the CHMP.

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Janet Koenig

| Timetable                                            | Actual dates     |
|------------------------------------------------------|------------------|
| Submission date                                      | 11 July 2024     |
| Start of procedure                                   | 17 August 2024   |
| CHMP Rapporteur Assessment Report                    | 10 October 2024  |
| PRAC Rapporteur Assessment Report                    | 10 October 2024  |
| PRAC Outcome                                         | 31 October 2024  |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 7 November 2024  |
| Request for supplementary information (RSI)          | 14 November 2024 |
| CHMP Rapporteur Assessment Report                    | 26 February 2025 |
| PRAC Rapporteur Assessment Report                    | 26 February 2025 |
| PRAC Outcome                                         | 13 March 2025    |
| 2 nd Request for supplementary information (RSI)     | 27 March 2025    |
| CHMP Rapporteur Assessment Report                    | 30 June 2025     |
| Updated CHMP Rapporteur Assessment Report            | 16 July 2025     |
| CHMP opinion                                         | 24 July 2025     |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

Currently Invokana is approved in adults in the following indication:

INVOKANA (canagliflozin) is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
- in addition to other medicinal products for the treatment of diabetes.

For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see SmPC sections 4.4, 4.5 and 5.1.

The MAH is proposing to extend the indication to the paediatric population as follows ( in bold ): INVOKANA (canagliflozin) is indicated for the treatment of adults and children aged 10 years and older with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
- in addition to other medicinal products for the treatment of diabetes.

For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see SmPC sections 4.4, 4.5 and 5.1.

The applicant does not propose any changes to the dosage form, route of administration, or dosing regimen via this application.

## Epidemiology

Type 2 diabetes mellitus (T2DM) in children and adolescents is increasing worldwide, and the main driver is the increased prevalence and degree of childhood obesity. Childhood T2DM is still relatively rare in Europe.

In  Germany,  a  three-fold  increase  in  the  prevalence  of  T2DM  was  reported  for  10-  to  19-year-olds between 2002 and 2020 (3.4 to 10.8 per 100,000) (Stahl-Pehe A et al. J Diabetes 2022; 14:840-850).

## Biologic features, Aetiology and pathogenesis

In view of the pathophysiological similarities between T2DM in adults and children and adolescents aged 10 to less than 18 years, it is hypothesized that canagliflozin will also have efficacy in this paediatric population with a similar safety profile.

<div style=\"page-break-after: always\"></div>

## Clinical presentation, diagnosis

Four diagnostic tests for T2DM are currently recommended, including measurement of fasting plasma glucose, 2-hour (2-h) post-load plasma glucose after a 75 g oral glucose tolerance test (OGTT), HbA1c and a random blood glucose in the presence of signs and symptoms of diabetes.

People with fasting plasma glucose values of ≥ 7.0 mmol/L (126 mg/dl), 2-h post-load plasma glucose ≥ 11.1 mmol/L (200 mg/dl), HbA1c ≥ 6.5% (48 mmol/mol) or a random blood glucose ≥ 11.1 mmol/L (200 mg/dl) in the presence of signs and symptoms are considered to have diabetes (WHO 2019).

## Management

The recommended treatment for paediatric T2DM is similar to the one in adults, with emphasis on a step-wise approach starting with lifestyle modifications, particularly diet and exercise, followed by the use of a single medical therapy and later by two therapies in combination. The aim is that the patient achieves and maintains low levels of glucose in the blood in order to prevent long-term complications.

For a long time, the only two approved treatment options for paediatric patients with T2DM in most countries were metformin and insulin. Recently, additional treatment options have become available in the EU for children and adolescents aged 10 to less than 18 years with type 2 diabetes, e.g. the GLP-1 receptor agonists Liraglutide (Victoza), Exenatide extended-release once-weekly injection (Bydureon), Dulaglutide (Trulicity) and the SGLT-2 inhibitors Dapagliflozin (Forxiga) and Empagliflozin (Jardiance).

## 2.1.2. About the product

INVOKANA (canagliflozin) is an inhibitor of sodium-glucose transporter 2 (SGLT2). The low-affinity/ high-capacity SGLT2 transporter in the proximal renal tubule reabsorbs the majority of glucose filtered by the renal glomerulus. Pharmacological inhibition of SGLT2 decreases renal glucose re-absorption and thereby increases urinary glucose excretion and lower plasma glucose in patients with T2DM. Canagliflozin as a single agent was first approved for marketing on 29 March 2013 in the US under the trade name of INVOKANA (available in 2 dose strengths of 100 mg and 300 mg) as an adjunct to diet and exercise in the treatment of T2DM in adults. The EU Marketing Authorization for canagliflozin was granted on 15 November 2013. Canagliflozin 100 mg and 300 mg film-coated tablets is currently authorized in more than 60 countries.

## 2.1.3. The development programme

The following table summarizes the studies supporting the present application of INVOKANA (canagliflozin) for the treatment of T2DM in children and adolescents aged 10 to less than 18 years.

| Step in Development or Study                                                                                                     | Paediatric Age Group    | Status           | Application where Report is submitted                                                            | Status of Application            |
|----------------------------------------------------------------------------------------------------------------------------------|-------------------------|------------------|--------------------------------------------------------------------------------------------------|----------------------------------|
| Clinical studies                                                                                                                 | Clinical studies        | Clinical studies | Clinical studies                                                                                 | Clinical studies                 |
| Study 3 28431754DIA1055 Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and | ≥10 to <18 years of age | Completed        | Study results submitted under Type 2 Variation submitted in eCTD seq. 077 (EMEA/H/002649/II/023) | Procedure approved on 15/09/2016 |

<div style=\"page-break-after: always\"></div>

| Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 years of age with Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin                                                                                     |                         |           |                                                                                                              |                         |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|-----------|--------------------------------------------------------------------------------------------------------------|-------------------------|
| Study 4 28431754DIA3018 A Randomized, Multicenter, Double- Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (≥10 to <18 years) with Type 2 Diabetes Mellitus | ≥10 to <18 years of age | Completed | Study Results submitted on 13 March 2024, under Art.46 application - eCTD seq. 0217 (EMEA/H/C/002649/P46/19) | Assessment is on- going |

## 2.1.4. General comments on compliance with GCP

All clinical studies included in this submission were conducted and reported in accordance with the ethical principles originating from the Declaration of Helsinki and in accordance with ICH Good Clinical Practice guidelines, applicable regulatory requirements, and in compliance with the respective protocols.

## 2.2. Non-clinical aspects

No new clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

For the environmental risk assessment, the MAH refers to the ERA submitted as part of the previous variation for Invokana (EMEA/H/C/2649/II/46). This is acceptable since in the previous ERA, the PECsurfacewater was calculated with the default Fpen (1 %) which includes the new patient group applied for here, i.e. paediatric patients ≥ 10 to &lt;18 years of age. The assessment of the data previously provided for ERA indicated no risks were identified; Consequently, this is still valid for this variation application.

## 2.2.2. Discussion on non-clinical aspects

The provided rationale for not providing an updated ERA is acceptable.

## 2.2.3. Conclusion on the non-clinical aspects

No new clinical data have been submitted in this application, which was considered acceptable by the CHMP. The provided rationale for not providing an updated ERA is also considered acceptable.

<div style=\"page-break-after: always\"></div>

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

## Study DIA1055

The study sites were not inspected. The company confirms that this study was conducted in line with the requirements of Directive 2001/20/EC, the ethical principles in the Declaration of Helsinki and with the Good Clinical Practice and applicable regulatory requirements.

## Study DIA3018

The company confirms that the study was conducted in accordance with the ethical principles in the Declaration of Helsinki and consistent with Good Clinical Practices and applicable regulatory requirements. Known instances of non-conformance were documented and are not considered to have an impact on the overall conclusions of this study.

## 2.3.2. Pharmacokinetics

## Study 28431754DIA1055 (DIA1055)

## Title of study

Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥ 10 to &lt;18 years of age with Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin

## Objectives/Endpoints

## Primary objective

To evaluate the pharmacokinetics of canagliflozin after multiple oral doses of canagliflozin in children and adolescent subjects with Type 2 Diabetes Mellitus (T2DM) who were ≥ 10 to &lt;18 years of age and on a stable dose of metformin.

Pharmacokinetic parameters to be determined:

| C max,ss                                                                                                                                | maximum observed plasma concentration during a dosing interval at steady-state                                                                                                      |
|-----------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| t max plasma                                                                                                                            | time to reach the maximum observed concentration                                                                                                                                    |
| AUC τ area under the plasma concentration-time                                                                                          | curve during a dosing interval ( τ)                                                                                                                                                 |
| t 1/2, elimination half-life associated with the time curve, calculated as 0.693/ λ                                                     | λ terminal slope ( λ z ) of the semilogarithmic drug concentration-                                                                                                                 |
| λ z                                                                                                                                     | first-order rate constant associated with the terminal portion of the curve, determined as the negative slope of the terminal log-linear phase of the drug concentration-time curve |
| CL ss /F total clearance of drug at steady-state after extravascular administration, uncorrected bioavailability calculated as: D/AUC τ | for absolute                                                                                                                                                                        |

Secondary objectives:

<div style=\"page-break-after: always\"></div>

- Evaluate  the  pharmacodynamic  effects  of  canagliflozin  on  plasma  glucose  levels,  urinary  glucose excretion, and the renal threshold for glucose after multiple oral doses. For details, please see section below on pharmacodynamics.
- Assess the acceptability of the canagliflozin tablets
- Assess the safety and tolerability

## Design

Open-label, sequential, multiple-dose (14 days of dosing), multi-center study of canagliflozin in 2 dose groups of approximately 8 subjects per dose group (up to approximately 16 children and adolescents in total). Subjects who were diagnosed with T2DM and on a stable regimen of metformin (≥1,000 mg per day) for ≥8 weeks before screening were enrolled. Subjects were instructed to continue to take their stable dose of metformin throughout the study.

The study consisted of 4 phases:

- (1) Screening Phase: ~3 weeks (Days -25 to -4)
2. (2)
3. Baseline Phase: 3 days (Days -3 to -1)

Subjects received placebo with ~180 mL water on Day -1 after an overnight fast of ≥ 8 hours. About 10 min later, subjects received a standardized breakfast. Serial blood samples were drawn immediately before dosing and at selected time points for up to 24 hours.

- (3) Open-Label Treatment Phase: 17-day Treatment Period (Days 1 through 17)
- Dose Group 1: Eight subjects received one 100-mg tablet of canagliflozin daily for 14 days.
- Dose Group 2: Based upon PK, PD and safety data from the first 5 subjects who completed Dose Group 1, nine (9) additional subjects were enrolled into Dose Group 2 to receive one 300 mg tablet of canagliflozin daily for 14 days.

In both groups, the first dose of study drug was administered in the morning of Day 1 after an overnight fast of ≥ 8 hours. About 10 min later, subjects received a standardized breakfast. Subjects were instructed to continue daily oral doses of canagliflozin with metformin for Day 2 to Day 13 at approximately the same time each morning before the first meal of the day. The clinical study center contacted the subjects each day to remind them to take their dose of study medication as well as metformin,  to  query  potential  adverse  events  and  to  ensure  compliance  with  study-related procedures. Time and amount of each dose as well as the daily fasting self-glucose monitoring value was documented in a study diary.

Subjects received their final dose of study drug in the morning of Day 14 (after an overnight fast of ≥ 8 hours), immediately followed by administration of a questionnaire to assess the acceptability of the canagliflozin tablet. Approximately 10 minutes after dosing, subjects received a standardized breakfast and remained at the study center for collection of PK, PD and safety assessments for 24 hours (until the morning of Day 15).

- (4) Safety Follow-up Phase: 7 - 10 days after the last study-related procedure on day 17 or at the time of early withdrawal

During the last 3 days of Screening (ie., Days -6, -5, and -4) and on a daily basis during the entire treatment outpatient period (Day 2 to Day 13 and Day 15 to follow-up), subjects were to record the fasting self-monitored fingerstick glucose levels (before the first meal of the day). The subjects had to report the results to the clinic weekly, or at any time where values exceeded pre-specified limits (&gt;270 mg/dL or &lt;50 mg/dL). On Day -1, Day 1 and again on Day 14 and Day 15, the study staff monitored the subject's fasting glucose levels via a fingerstick blood sample.

## Changes in conduct - study amendments

<div style=\"page-break-after: always\"></div>

The original protocol (issued 26 September 2013) had 5 amendments as specified below.

- Amendment INT-5 (21 September 2015): The overall reason for the amendment was to enhance study recruitment. The window period for screening safety assessments was widened from 7 days to 10 days. Updated information on diabetic ketoacidosis and handling of subjects surrounding this event was added. Subjects who were on metformin XR for at least 8 weeks prior to screening and switched to metformin immediate release (IR; at the same total daily dose) which was well tolerated for at least 2 weeks prior to Day -1 were allowed to participate in the study. The concurrent use of insulin with metformin to achieve sufficient glycemic control was allowed.
- Amendment INT-4 (16 September 2014): The overall  reason  for  the  amendment  was  to  ensure protocol consistency with health authority agreements for study design. Administration of AHAs for up to 7 days in the 8 to 2 weeks prior to the screening visit was not permitted as per this amendment.
- Amendment INT-3 (09 September 2014): The overall reason for the amendment was to adjust and clarify  the  language  of  the  Inclusion  and  Exclusion  criteria,  modify  rules  related  to  concomitant medications, and update the calculation of estimated glomerular filtration rate (eGFR; using Schwartz formula).
- Amendment INT-2 (30 Oct 2013): The overall reason for the amendment was to correct a typo defining the value of a non-acceptable eGFR in exclusion criterion 8 and Inclusion of contraceptive injection as an effective birth control method.
- Amendment INT-1 (18 October 2013): The overall reason for  the  amendment  was  to  address  a comment from the US FDA regarding the definition of renal function inclusion criteria and general clarifications of admission days and a few procedures. The restriction on male subjects for use of effective birth control method was removed as per this amendment.

## Study drug, dose, and mode of administration

The formulations supplied for this study were:

- Canagliflozin, 100 mg (1 × 100 mg), capsule-shaped yellow tablets - oral
- Canagliflozin, 300 mg (1 × 300-mg), capsule-shaped white tablets - oral
- Placebo capsule-shaped white tablets (Day -1 dosing only).

## Background therapy

Stable regimen of metformin immediate release (IR) monotherapy of at least 1,000 mg/day for at least 8 weeks before screening

## Number of patients

Planned: A total of 16 subjects were planned to be enrolled in the study.

Analyzed: A total of 17 subjects (8 subjects from Group 1 receiving 100 mg and 9 subjects from Group 2 receiving 300 mg canagliflozin) completed the study and were included in the analysis.

## Main inclusion and exclusion criteria

Diagnosis and Main Criteria for Inclusion: Medically stable male or female subjects ranging in age from ≥10 to &lt;18 years, with diagnosis of T2DM without pancreatic autoimmunity and who were on a stable regimen of metformin immediate release (IR) monotherapy of at least 1,000 mg/day for at least 8 weeks before screening. Subjects had to be able to swallow whole tablets and had to have normal renal function (estimated glomerular filtration rate [eGFR] ≥ 90 ml/min/1.73 m 2  as assessed by Schwartz formula), ALT or AST &lt;2.0×ULN and a HbA1c of ≥6.1% to ≤ 10%.

<div style=\"page-break-after: always\"></div>

Subjects with history of type 1 diabetes mellitus (T1DM), history of maturity onset diabetes of the young (MODY) and any secondary form of diabetes were excluded.

## Pharmacokinetic Results

A total of 17 subjects were enrolled, the majority were black or African American, female, with a median age of 15 years. The 3-fold range between minimum and maximum BMI (range: 18.0 to 55.3 kg/m 2 ; mean: 38.17 kg/m 2 ) and body weight (range: 48.5 to 168.6 kg; mean: 107.15 kg) from subjects included within this study was notable and is representative of adult BMI and body weight ranges.

## Pharmacokinetic

## Mean (SD) Plasma Canagliflozin Pharmacokinetic Parameters

(Study 28431754DIA1055: Pharmacokinetic Analysis Set)

| Parameters               | Canagliflozin 100 mg (Group 1) n= 8   | Canagliflozin 300 mg (Group 2) n= 9   |
|--------------------------|---------------------------------------|---------------------------------------|
| C max (ng/mL)            | 951 (429)                             | 3,260 (1,330)                         |
| C max /Dose (ng/mL/mg)   | 9.51 (4.29)                           | 10.9 (4.42)                           |
| t max (h) a              | 1.64 (1.00 - 1.98)                    | 2.44 (1.00 - 4.00)                    |
| AUC τ (h*ng/mL)          | 6,190 (1,770)                         | 28,392 (12,412)                       |
| AUC τ /Dose (h*ng/mL/mg) | 61.9 (17.7)                           | 94.6 (41.4)                           |
| t 1/2 (h)                | 11.3 (2.5)                            | 15.2 (6.9)                            |
| λ z (1/h)                | 0.0644 (0.0151)                       | 0.0528 (0.0183)                       |
| CL ss /F (L/h)           | 17.5 (5.78)                           | 12.3 (6.90)                           |

a  Mean (range)

<div style=\"page-break-after: always\"></div>

Dose-Normalized Cmax Values of Canagliflozin Following Multiple-Dose Administration of 50 to 400 mg QD in Healthy Adult Subjects and Subjects with T2DM and Pediatric T2DM Subjects Receiving 100 mg or 300 mg (DIA-1055)

<!-- image -->

Note: different sampling time-points were utilized between studies, and may impact estimation of Cmax

<div style=\"page-break-after: always\"></div>

Dose-Normalized AUCtau Values of Canagliflozin Following Multiple-Dose Administration of 50 to 400 mg QD in Healthy Adult Subjects and Subjects with T2DM and Pediatric T2DM Subjects Receiving 100 mg or 300 mg (DIA-1055)

<!-- image -->

Note: different sampling time-points were utilized between studies, and may impact estimation of AUCtau

<div style=\"page-break-after: always\"></div>

Dose-Normalized AUC24h Values of Canagliflozin vs. Body Weight Following Multiple-Dose Administration of 25 to 1600 mg in Healthy Subjects, Subjects with T2DM, and Obese Subjects

<!-- image -->

Note: Population PK and DIA-1055 defined AUC defined as AUC = Dose/CL)

## Study 28431754DIA3018 (DIA3018)

Study DIA3018 was conducted in children and adolescents ( ≥ 10 to &lt;18 years) with T2DM who had inadequate glycaemic control. The primary objectives of the study were:

- a) To assess the effect of canagliflozin relative to placebo on HbA1c after 26 weeks of treatment, and
- b) to assess the overall safety and tolerability of canagliflozin.

(For further details please see the Clinical Efficacy section below).

PK blood samples were collected at Week 12, Week 26, Week 52 (EOT) and at the early withdrawal visit for determination of plasma trough concentrations of canagliflozin in all participants.

The mean plasma canagliflozin concentrations were higher for the 300 mg dose vs the 100 mg dose. The data suggest that the mean plasma canagliflozin concentration for the 100 mg dose is consistent between the Week 12 and Week 26 visits. The mean plasma canagliflozin concentration at Week 52 is lower, probably due to the inclusion of EOT values that may not have been taken in a similar time frame following the last dose of study intervention. The data were variable across all visits and doses, but overall, were within the concentration range observed in the canagliflozin adult dataset and in paediatric participants during Study DIA1055.

Descriptive Statistics of Canagliflozin Plasma Concentration (ng/mL) Data; Full Analysis Set

|        |   100 mg |        |   Week 52/EOT |   300 mg Week 26 |   Week 52/EOT |
|--------|----------|--------|---------------|------------------|---------------|
| N      |     80   |   57   |          56   |             15   |          14   |
| Mean   |    344.2 |  304.3 |         186.5 |            503.7 |         988.5 |
| CV (%) |    202.9 |  425.9 |         294.4 |            185.1 |         209.8 |
| SE     |     78.1 |  171.7 |          73.4 |            240.8 |         554.2 |
| SD     |    698.4 | 1296   |         549.2 |            932.5 |        2073.7 |
| Median |     90.7 |   65.5 |          59.4 |              5.3 |         160.8 |

<div style=\"page-break-after: always\"></div>

| Minimum a   |    0 |    0 |    0 |    0 |    0 |
|-------------|------|------|------|------|------|
| Maximum     | 4640 | 9530 | 3910 | 3330 | 7540 |

BQL=below the lower limit of quantification; CV=coefficient of variation; EOT=end of treatment; SD=standard deviation; SE=standard error.

a BQL data are represented by concentration values of 0.

## Population pharmacokinetic analysis

Previously, a PopPK model for canagliflozin for adults had been developed based on data from nine Phase 1 (ie, DIA1001, DIA1002, DIA1003, DIA1007, DIA1008, DIA1019, DIA1023, DIA1030, and TA7284-02), two Phase 2 (ie, DIA2001, OBE2001), and three Phase 3 (ie, DIA3004, DIA3005, and DIA3009) clinical studies in healthy adults and adult patients with T2DM. The dataset used for model development included 9,061 rich and sparse plasma concentrations from a total of 1,616 participants. This PopPK model for adults consisted of an open 2-compartment disposition model with first-order elimination and a sequential zero- and first-order absorption after a lag time. Inter-individual variability (IIV) was quantified on the model parameters for Vc/F, ke, k32, ka, and Tlag, assuming a lognormal distribution. The CL/F was derived from the estimated apparent volume of distribution and the estimated ke through CL/F=Vc/F*ke. An additive error model was used to quantify the residual unexplained variability (RUV) on the log-transformed plasma concentration scale, assuming different variances for rich and sparse PK data. As the Phase 2 and 3 PK data were sparse and therefore less informative with respect to the absorption and distribution characteristics of canagliflozin, the PopPK parameters describing absorption (ka, Tlag, and D1) and distribution (Vc/F, k23, and k32), including their covariate and random effects, were fixed to the estimated values from the PopPK model built on Phase 1 data.

Non-linear mixed effects modeling software NONMEM (Version 7.4 and higher, ICON plc) and the FOCE with INTERACTION (FOCE-I) estimation option was used for the PopPK analysis.

The final adult PopPK model included statistically significant covariates of sex, age, and body weight on Vc/F, BMI on ka, BMI and over-encapsulation (over-encapsulated versus non-encapsulated tablets) on Tlag, and eGFR and total daily dose on ke. The covariate effects were deemed not clinically relevant and therefore no dose adjustment based on those covariates was warranted.

An external model evaluation was performed to verify the predictive performance of the previously developed adult PopPK model for paediatric studies DIA1055 and DIA3018. In total, 330 canagliflozin concentrations from 90 paediatric patients with T2DM were included in the PopPK analysis dataset (age range 10.0 - 17.0 years, body weight range 44.8 - 170 kg). Based on the results of the external evaluation, the previously developed PopPK model in adults was not deemed to adequately describe the data in paediatric patients with T2DM from studies DIA1055 and DIA3018. In particular, the model appeared to underestimate the general trend of the paediatric data at a population level, while at an individual level the paediatric data were well described by the model. Therefore, a model update was performed.

The base model structure remained the same for the updated paediatric model, but the inclusion of covariates was retested. Compared with the adult PopPK model, covariate effects of age, eGFR, and BMI were removed, while covariate effects of body weight and sex on Vc, over-encapsulation on Tlag, and total daily dose on ke were retained in the paediatric PopPK model. No additional covariate effects were identified in the paediatric PopPK model. In order to estimate PK metrics for the paediatric patients, all parameters were fixed to the estimates from the adult model except for the residual error variances, which were re-estimated based on the data from studies DIA1055 and DIA3018. Final model parameters for the paediatric-adjusted model are displayed in Table 1 below.

<div style=\"page-break-after: always\"></div>

Table 1 Parameter estimates of the final paediatric PopPK Model for Canagliflozin (run124)

| Parameter                       | Population Mean Estimate   | RSE (%)   | IIV (CV%)   | Shrinkage (%)   |
|---------------------------------|----------------------------|-----------|-------------|-----------------|
| V/F (L) (males)                 | 99.3 FIX                   |           | 14.6 FIX    | 70.1            |
| ke (h-l)                        | 0.145 FIX                  |           | 23.1 FIX    | 39.1            |
| ka (h-1)                        | 3.68 FIX                   |           | 188 FIX     | 51.6            |
| Tiag (h) (non-encaps. tablets)  | 0.147 FIX                  |           | 93.6 FIX    | 65.7            |
| D, (b)                          | 0.604 FIX                  |           |             |                 |
| k23 (hr1)                       | 0.101 FIX                  |           |             |                 |
| k32 (h-1)                       | 0.0856 FIX                 |           | 36.2 FIX    | 65.1            |
| V/F (L) (females)               | 82.6 FIX                   |           |             |                 |
| Tiag (h) (over-encaps. tablets) | 0.262 FIX                  |           |             |                 |
| Body weight on V/F              | 0.583 FIX                  |           |             |                 |
| Total daily dose on ke          | -0.0631 FIX                |           |             |                 |
| Residual error (SD %)           | 22.7                       | 13.4      |             |                 |
| Phase 1 pediatric               |                            |           |             |                 |
| Residual error (SD %)           | 114                        | 9.12      |             |                 |
| Phase 2 and 3 pediatric         |                            |           |             |                 |

FIX = model parameters, including covariate and random effects, were fixed to the estimates obtained from the adult PopPK model1

CV% calculated as (/exp(o2) - 1) * 100

Visual predictive checks (pcVPCs) are shown in Figure 1 below.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Observed concentrations (red dots) with median (solid lines) and 1ot, 9ot percentiles (dashed lines). Areas show the simulation-based 95% PIs, in grey for the median and in blue for the 10\" and 90th percentiles (N=1,000)

Figure 1: pcVPC of the Final paediatric PopPK Model (run 124) for Canagliflozin in DIA1055 (Top) and DIA3018 (Bottom) by Dose

## Simulations

Based on the final paediatric PopPK model (run124) and the previously developed adult PopPK model, canagliflozin exposure metrics AUC24h and Cmax at steady state were simulated in paediatric and adult patients with T2DM, respectively in order to support bridging from QD to BID dosing of canagliflozin for the use of CANA/MET in paediatric patients with T2DM. The concentration - time profiles at steady state following 50 mg BID, 100 mg QD, 150 mg BID, and 300 mg QD canagliflozin administration were simulated. Canagliflozin PK was simulated including IIV and Phase 1 RUV, as the simulations should reflect an adequately characterized PK profile based on a rich sampling schedule. The MAH concluded that the simulations show that AUC24h at steady state, reflecting the total daily exposure, is similar between QD and BID dosing for the same total daily dose of canagliflozin, in both paediatric and adult T2DM patients.

<div style=\"page-break-after: always\"></div>

## 2.3.3. Pharmacodynamics

## Study DIA1055

One of the secondary objectives of Study DIA1055 was to evaluate the pharmacodynamic effects of canagliflozin on plasma glucose levels, urinary glucose excretion, and the renal threshold for glucose after  multiple  oral  doses  (for  study  description  see  Pharmacokinetics  section  above).  The  following parameters were addressed:

| Renal Threshold for Glucose   | Renal Threshold for Glucose                                                                                                                                                                                                                                                                                      |
|-------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| RT G,t1-t2                    | Renal threshold for glucose excretion calculated over the 0-12 and 12-24h time intervals.                                                                                                                                                                                                                        |
| 24-h mean RT G                | The 24-h mean renal threshold for glucose excretion, calculated as the average of the values obtained over the 0-12h and 12-24h intervals.                                                                                                                                                                       |
| Plasma Glucose                | Plasma Glucose                                                                                                                                                                                                                                                                                                   |
| FPG                           | Fasting plasma glucose.                                                                                                                                                                                                                                                                                          |
| M Δ PG 0-2h                   | Mean concentration for postprandial incremental plasma glucose excursion during the 0- to 2-hour interval, calculated as the positive incremental (above pre-meal) AUC over 0-2h divided by the 2 h time interval.                                                                                               |
| M Δ PG 0-4h                   | Mean concentration for postprandial incremental plasma glucose excursion during the 0- to 4-hour interval, calculated as the positive incremental (above pre-meal) AUC over 0-4h divided by the 4 h time interval.                                                                                               |
| MPG 0-4h                      | Mean concentration of plasma glucose during the 0- to 4-hour interval, calculated as AUC over 0 to 4h divided by the 4-hour time interval.                                                                                                                                                                       |
| MPG 0-24h                     | Mean concentration for plasma glucose during the 0- to 24-hour interval, calculated as AUC over 0 to 24h divided by the 24-hour time interval.                                                                                                                                                                   |
| Urinary Glucose Excretion     | Urinary Glucose Excretion                                                                                                                                                                                                                                                                                        |
| UGE t1-t2                     | urinary glucose excretion, equal to the amount of urine glucose excreted into the urine over the time intervals 0 to 12 hours and 12 to 24 hours, abbreviated as UGE 0-12h and UGE 12-24h , respectively, calculated for each interval by multiplying the urinary volume with the urinary glucose concentration. |
| UGE 0-24h                     | cumulative daily urinary glucose excretion, equal to the amount of plasma glucose excreted into the urine over the entire urine collection interval, 0 to 24 hours, calculated as the sum of UGE 0-12h and UGE 12-24h .                                                                                          |

## Results:

Renal Threshold for Glucose (RTG)

On day 14, 100 mg of canagliflozin resulted in a mean RTG of

- -74 mg/dL (4.11 mmol/L) from 0 to 12 h
- -95 mg/dL (5.27 mmol/L) from 12 to 24 h
- -85 mg/dL (4.72 mmol/L) over 24 h (24-hour mean RTG)

On day 14, 300 mg of canagliflozin resulted in a mean RTG of

- -67 mg/dL (3.72 mmol/L) from 0 to 12 h
- -72 mg/dL (4 mmol/L) from 12 to 24 h
- -69 mg/dL (3.83 mmol/L) over 24 h (24-hour mean RTG)

The results are depicted in Figure 1 below:

<div style=\"page-break-after: always\"></div>

Figure 1: Mean (SD) RTG values on day 14 after 100 mg (left) and 300 mg (right) of Canagliflozin

<!-- image -->

## Urinary Glucose Excretion

## Day -1:

15 of the 17 subjects had UGE0-24h &lt;0.18 g; 2 subjects in the 100 mg cohort had high plasma glucose concentrations and an UGE of 13 g and 29 g.

Day 14:

Mean ± SD for UGE0-24h

100 mg canagliflozin: 74 ± 37 g; 300 mg canagliflozin: 69 ± 27 g

With both doses, UGE was higher in the 0-12-hour period than from 12 to 24 hours - see Figure 2 below.

Figure 2: Mean (SD) UGE values on day 1 (left) and day 14 (right) for subjects receiving 100 mg or 300 mg of canagliflozin

<!-- image -->

## Plasma Glucose

Both doses of canagliflozin reduced plasma glucose throughout the full 24 h period, leading to reduced mean plasma glucose (MPG0-4h and MPG0-24h) between Day -1 and 14 in each group (see Figure 3 below).

MPG0-4h (mean ± SD):

- 100 mg: reduction from 164 ± 69 mg/dL (9.1 mmol/L) to 120 ± 32 mg/dL (6.7 mmol/L)
- 300 mg: reduction from 119 ± 18 mg/dL (6.6 mmol/L) to 104 ± 12 mg/dL (5.8 mmol/L)

<div style=\"page-break-after: always\"></div>

## MPG0-24h (mean ± SD):

- 100 mg: reduction from 147 ± 59 mg/dL (8.1 mmol/L) to 115 ± 23 mg/dL (6.4 mmol/L)
- 300 mg: reduction from 110 ± 11 mg/dL (6.1 mmol/L) to   96 ± 10 mg/dL (5.3 mmol/L)

Figure 3: Mean (+SE) plasma glucose profiles on day-1 and day 14 after 100 mg (left) or 300 mg (right) of canagliflozin

<!-- image -->

The MAH has provided an additional analysis (Figure 4 below) to investigate the effects of canagliflozin in subjects with different baseline plasma glucose. Relatively small reductions in plasma glucose were seen in subjects with only modest hyperglycemia at baseline, but much greater reductions in subjects with higher baseline plasma glucose.

Figure 4: Mean (+SE) plasma glucose profiles on day-1 and day 14 for subjects with baseline fasting plasma glucose levels below (left) and above (right) 126 mg/dL. All four subjects in the higher baseline plasma glucose group were in the 100 mg cohort.

<!-- image -->

## Fasting Plasma Glucose (FPG)

At both the 100 mg and the 300 mg dose, canagliflozin led to clear reductions in FPG (mean ± SD):

- 100 mg: reduction from 143 ± 58 mg/dL (Day -1; n=7) to 110 ± 24 mg/dL (Day 14; n=8)
- 300 mg: reduction from 107 ± 10 mg/dL (Day -1; n=7) to 100 ± 11 mg/dL (Day 14; n=8)

<div style=\"page-break-after: always\"></div>

## Mean incremental plasma glucose concentrations (M Δ PG0-2 h and M Δ PG0-4 h)

Numerical reductions in incremental plasma glucose concentrations were observed in both dose groups, with no clear differential effect of the 300 mg dose compared to the 100 mg group on the postprandial excursions in these subjects - see Table 1 below:

Table 1: Mean (SD) incremental plasma glucose values (M∆PG 0-2h and M∆PG 0-4h) following breakfast, on Day-1 and Day 14 for subjects receiving 100 mg or 300 mg of canagliflozin

|        |   N | Day -1, Mean (SD)   | Day 14, Mean (SD)   |
|--------|-----|---------------------|---------------------|
| 100 mg |   8 | 28 (20)             | 19 (12)             |
| 300 mg |   9 | 25 (14)             | 16 (11)             |
| 100 mg |   8 | 28 (29)             | 15 (13)             |
| 300 mg |   9 | 17 (10)             | 12 (11)             |

## Acceptability of canagliflozin tablets:

Administration of canagliflozin 100 mg and 300 mg tablets appeared to be acceptable with reference to perception of taste, smell, ability to swallow, or feelings after taking the dosage in paediatric T2DM subjects in the age range studied in this study.

## 2.3.4. PK/PD modelling

For population PK analysis of study DIA3018, please see section above.

## 2.3.5. Discussion on clinical pharmacology

PK exposures in paediatric T2DM subjects receiving 100 mg once-daily and 300 mg once-daily doses of canagliflozin were consistent with those of adult subjects.

In study DIA1055, the pharmacodynamic effects of canagliflozin (100 mg and 300 mg) on RTG, UGE and plasma glucose concentration were determined as secondary endpoints. Both doses caused a similar reduction of RTG during the first 12 hours, but only the 300 mg dose maintained the effect throughout the entire 24-hour period. This is consistent with the findings in adults, where 100 mg yielded nearmaximal effects over the first 12 hours with a modest attenuation of the effect in the overnight period, while doses of ≥ 300 mg resulted in sustained near-maximal effects throughout the full 24 hours.

Urine glucose excretion (UGE) was almost undetectable at baseline in most of the subjects. The increase in UGE by canagliflozin was higher in the 0-12 h period, but less pronounced from 12 to 24 h, which might be due to higher plasma glucose concentrations during daytime as compared to the overnight period. Mean UGE in the pediatric population was modestly lower than in most of the Phase 1 studies in adult T2DM populations, which may be due to the relatively low plasma glucose concentrations seen in the subjects in this study. Of note, mean RTG was suppressed to a range of ~65-95 mg/dL (3.6-5.3 mmol/L), which is similar to the effects seen in adults with T2DM. The 100 mg and the 300 mg dose did not  differ  relevantly  in  their  effect  on  UGE,  possibly  because  the  plasma  glucose  concentrations  at baseline  were  considerably  lower  in  the  300  mg-group  than  in  the  100  mg  group.  This  might  have precluded the detection of an additional effect of the 300 mg dose. This also pertains to MPG0-4h and MPG0-24h, where this imbalance between the two dosing groups with regard to baseline glucose may also have confounded the comparison between the effect of the 100 mg and the 300 mg dose.

<div style=\"page-break-after: always\"></div>

Many of the subjects started with plasma glucose concentrations below the values typically found in T2DM subjects, and the overall magnitude of the mean reductions in plasma glucose was only modest. When  the  effects  of  canagliflozin  were  analyzed  in  dependence  on  the  levels  of  glucose  control  at baseline, consistent with the results from adult populations, relatively small reductions in plasma glucose were seen in subjects who had only modest hyperglycemia at baseline, but much greater reductions in plasma glucose were seen in subjects with higher baseline plasma glucose. Of note, all four subjects with higher baseline plasma glucose were in the 100 mg cohort, while all individuals treated with 300 mg were in the group with lower plasma glucose at baseline. Thus, again, this renders it rather difficult to conclude on any additional benefit provided by the 300 mg dose.

The blood glucose-lowering effects of canagliflozin were confirmed by the reduction in FPG as well as of post-prandial glucose excursions after 2 and 4 hours (M Δ PG0-2 h and M Δ PG0-4 h). However, as already mentioned above, baseline plasma glucose was higher in the 100 mg than in the 300 mg cohort, and no relevant difference was seen between the 100 mg and the 300 mg dose.

A population pharmacokinetic analysis for study DIA 3018 was submitted. It is noted that the estimated relationship between body weight and clearance and body weight and volume from the adult popPK model  was  retained  in  the  pediatric  popPK  model  (estimated  exponent  of  0.583  for  volume  and clearance). As a sensitivity analysis, paediatric popPK model has been updated to include fixed allometric exponents (exponent of body weight on Vc/F of 1.0 and -0.25 on ke (corresponding to a body weight effect on CL/F with an exponent of 0.75; run131).

The figures indicate that exposure in lower weight paediatric patients exceeds exposure in adults with the approved doses. Thus, a warning was inserted in section 4.4 regarding potentially increased DKA risk  in  children  receiving  300  mg  of  canagliflozin.  Moreover,  information  was  added  to  section  4.2 (subsection on 'Paediatric population') indicating  that  caution  is  advised,  when  the  300  mg  dose  is administered, specifically in children with a body weight &lt;50 kg and in section 5.2.

## 2.3.1. Conclusions on clinical pharmacology

PK exposures in paediatric T2DM subjects receiving 100 mg once-daily and 300 mg once-daily doses of canagliflozin appears to be consistent with those of adult subjects. Similarly as in adults, canagliflozin reduced  RTG,  increased  UGE,  lowered  plasma  glucose  concentrations  and  reduced  the  post-prandial excursions in plasma glucose in the pediatric population. A separate analysis according to high and low baseline plasma glucose showed that the plasma glucose-lowering effect of canagliflozin is increased in subjects with higher plasma glucose levels. Except for a more prolonged effect of 300 mg in comparison to 100 mg on RTG, no relevant difference was seen between the two dosing groups in the other analyses. This may be due to the lower baseline plasma glucose in the 300 mg as compared to the 100 mg cohort, which may confound the detection of a potential additional effect of the 300 mg dose.

<div style=\"page-break-after: always\"></div>

## 2.4. Clinical efficacy

## 2.5. Main study

## Study JNJ-28431754DIA3018 (DIA3018)

## Title of study

A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents ( ≥ 10 to &lt;18 years) with Type 2 Diabetes Mellitus

## Methods

## Design

DIA3018 was a randomized, double blind, placebo-controlled, 2-arm, parallel group, multi-center study that evaluated canagliflozin in male or female participants ≥ 10 to&lt;18 years of age with type 2 diabetes mellitus (T2DM). The study lasted approximately 59 weeks and comprised the following parts:

## Pre-treatment phase

- 1-week screening phase (screening visit at week -3)
- 2-week single-blind placebo run-in period (week -2 to baseline/day 1 - one placebo tablet matching canagliflozin 100 mg once daily)

## Double-blind treatment phase

- 52-week double-blind placebo-controlled treatment phase (incl. a 26-week core double-blind treatment period and a 26-week double-blind extension treatment period)
- Re-randomization at week 13: Subjects who have a Week 12 HbA1c of ≥ 7.0% and eGFR ≥ 60 mL/min/1.73m 2  are re-randomized 1:1 to either remain on double-blind canagliflozin 100 mg (or matching placebo) or to up-titrate to double-blind canagliflozin 300 mg (or matching placebo). A double-dummy approach is used to maintain the subjects blinded to dose assignments. For details, please see section on 'Blinding' below.

## Post-treatment phase

- 30-day follow-up post-treatment (telephone follow-up contact or optional study visit, at the discretion of the investigator, 30 days after the last dose)

The design is depicted in the Figure 1 below (taken from study protocol):

<div style=\"page-break-after: always\"></div>

Figure 1: Design of Study JNJ28431754-DIA3018

<!-- image -->

## Study participants

## Main inclusion criteria

- Male or female ≥ 10 to&lt;18 years of age at the time of screening
- Diagnosis of T2DM
- Random C-peptide at screening &gt;0.6 ng/mL/&gt;0.2 nmol/L
- Absence of pancreatic autoimmunity (GAD, and islet cell antigen 2 [IA2] antibody negative)
- Inadequate glycemic control (i.e., HbA1c of ≥ 6.5% to ≤ 11.0%) and
- -on diet and exercise only for at least 4 weeks prior to screening, or
- -on diet and exercise and a stable dose of metformin monotherapy ≥ 1,000 mg per day or MTD per day (defined by the investigator) for ≥ 8 weeks prior to screening, or
- -on diet and exercise and a stable insulin monotherapy regimen for at least 8 weeks prior to screening and ≤ 15% change in the total daily dose of insulin [averaged over 1 week to account for day to day variability]), or
- -on diet and exercise and a stable combination therapy with metformin and insulin for at least 8 weeks prior to screening. It is noted that metformin prolonged release was replaced by the immediate release form at the same/nearest appropriate daily dose).

## Main exclusion criteria (shortened list)

Participants were not eligible for this study if they

- had a history of diabetic ketoacidosis [DKA], T1DM, pancreas or β -cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy or MODY.
- were on any antihyperglycemic agents [AHA] other than metformin or insulin within 8 weeks of the first dose of study agent
- had severe hypoglycemia within 6 months prior to Day 1
- had renal and cardiovascular issues
- had gastrointestinal issues (known significant liver disease)

<div style=\"page-break-after: always\"></div>

- had laboratory results (including persistent elevated ketone levels, eGFR&lt;60mL/min/1.73m 2 , alanine aminotransferase level &gt;5.0 times the upper limit of normal (ULN) or total bilirubin &gt;1.5 times the ULN at screening)
- had other conditions (e.g., history of malignancy within 5 years before screening, major surgery within 12 weeks before screening or planned surgery during study participation, non-traumatic amputation within past 12 months etc.)
- were on certain medications (SGLT2 inhibitors, corticosteroids or immunosuppressive agents, anticonvulsants, any active investigational drug or medical device within 12 weeks before start of treatment)
- had general exclusions listed in the protocol.

## Treatments

## Study drug, dose, and mode of administration

Canagliflozin 100 mg and 300 mg tablets with matching placebo tablets for each dose strength were supplied for this study. The study agent was to be swallowed as a whole with liquid and not chewed, divided, dissolved, or crushed.

On Day 1, participants  were  randomly  assigned  in  a  1:1  ratio  to  canagliflozin  100  mg  or  matching placebo. At Week 13, participants who had a Week 12 HbA1c of ≥7.0% and an eGFR ≥60 mL/min/1.73m 2 were re-randomized to either remain on double-blind canagliflozin 100 mg (or matching placebo) or uptitrated to double-blind canagliflozin 300 mg (or matching placebo).

## Background therapy

Please see inclusion criteria and stratification criteria used at randomization.

## Objectives

## Primary

- To assess the effect of canagliflozin relative to placebo on glycated hemoglobin (HbA1c) after 26 weeks of treatment (change in HbA1c from baseline at Week 26)
- To assess the overall safety and tolerability of canagliflozin, based on:
- -Collection/monitoring of adverse events
- -Collection of potential hypoglycemic episodes (from diary provided to participants)
- -Ketone monitoring
- -Physical examinations
- -Body weight
- -Vital signs (blood pressure, pulse rate)
- -Safety laboratory tests (incl. chemistry, hematology, urinalysis)
- -Self-measured blood glucose (SMBG)
- -Bone turnover markers (serum osteocalcin and serum collagen type 1 CTx)
- -Markers of calcium and phosphate homeostasis (calcium, magnesium, phosphate, PTH 25hydroxy Vitamin D, calcitonin, urinary excretion of calcium and phosphate)
- -Urinary ACR
- -Assessment of growth velocity and Tanner Staging

## Major Secondary

<div style=\"page-break-after: always\"></div>

- After 26 weeks of treatment, to assess the effect of canagliflozin relative to placebo for the subset of participants taking background metformin (with or without insulin) on HbA1c
- After 26 weeks of treatment, to assess the effect of canagliflozin relative to placebo on:
- -Fasting plasma glucose (FPG)
- -Proportion of participants with HbA1c &lt;7.5%, &lt;7.0% and &lt;6.5%
- -Time to rescue therapy and proportion of participants receiving rescue therapy
- -Body weight
- After 52 weeks of treatment, to assess the effect of canagliflozin relative to placebo on:
- -HbA1c and FPG
- -Proportion of participants with HbA1c &lt;7.5%, &lt;7.0% and &lt;6.5%
- -Time to rescue therapy and proportion of participants receiving rescue therapy
- -Body weight

## Additional Secondary

- After 12 weeks of treatment to assess the effects of canagliflozin relative to placebo on HbA1c
- After 26 weeks of treatment, to assess the effect of canagliflozin 100 mg relative to placebo on HbA1c
- After 26 weeks of treatment, to assess the effect of canagliflozin 100 mg followed by a dose increase to 300 mg relative to placebo on HbA1c
- After 26 weeks and 52 weeks of treatment, to assess the effect of canagliflozin relative to placebo on:
- -Body mass index (BMI)
- -Fasting plasma lipids (i.e., LDL-C, HDL-C, total cholesterol, non-HDL-C, LDL-C to HDL-C ratio, non-HDL-C to LDL-C ratio, and triglycerides)
- -Systolic and diastolic blood pressure
- -Growth velocity and Tanner Staging
- -Markers of calcium and phosphate homeostasis, (calcium, magnesium, phosphate, parathyroid hormone [PTH], 25-hydroxy Vitamin D, calcitonin; urinary excretion of calcium and phosphate)
- -Bone turnover markers (serum osteocalcin and serum collagen type 1 carboxy-telopeptide [CTx])
- -Urinary albumin/creatinine ratio (ACR)

Note: Growth velocity and Tanner staging, markers of calcium and phosphate homeostasis as well as bone turnover markers and urinary albumin/creatinine ratio (ACR) are discussed in the Safety section of this AR.

## Estimands

Clinical scientific question: What is the mean treatment difference at Week 26 on change from baseline in HbA1c from treatment assignment to either canagliflozin or placebo in children and adolescents with T2DM who have inadequate glycemic control, regardless of treatment discontinuation or initiation of rescue medication?

The primary efficacy estimand is described according to the following attributes:

- Population: children and adolescents ( ≥ 10 to &lt;18 years) with T2DM who have an HbA1c ≥ 6.5% to ≤ 11.0%.
- Variable: change in HbA1c from baseline to Week 26.
- Treatment: canagliflozin (100 mg or 300 mg) vs placebo.

<div style=\"page-break-after: always\"></div>

- Intercurrent events (ICEs) (events that preclude observation of the variable or affect its interpretation): treatment discontinuation or initiation of rescue medication; ICEs are addressed with the treatment policy strategy, targeting the effect of treatment assignment, regardless of the occurrence of ICE.
- Population-level summary: difference in means versus placebo.

A similar estimand deviating only in the population attribute was defined for the evaluation of the primary endpoint in the subset of participants with background metformin (with or without insulin).

## Sample size

## Number of patients

Number of Participants (planned and analyzed):

- Number planned: 146 (73 per arm);
- Number analysed: 171 (87 receiving placebo and 84 receiving canagliflozin)

## Randomisation

Participants were randomly assigned in a 1:1 ratio to once daily administration of canagliflozin 100 mg, or placebo. Dynamic randomization (i.e., covariate-adjusted randomization) was used in an effort to maintain balance between treatment groups with respect to the following stratification factors:

- AHA background
- -diet and exercise only
- -metformin monotherapy (while on diet and exercise)
- -insulin monotherapy (while on diet and exercise)
- -combination of metformin and insulin (while on diet and exercise)
- Age group
- -≥ 10 to &lt;15 years old
- -≥ 15 to &lt;18 years old

In dynamic randomization, a new participant was sequentially assigned to a particular treatment group by taking into account the specific covariates and previous assignments of participants. This approach used the method of minimization by assessing the imbalance of sample size among the covariates listed above.

Participants  who  at  Week  12  had  an  HbA1c  of ≥ 7.0% and  an  eGFR ≥ 60  mL/min/1.73m 2   were  rerandomized in a 1:1 ratio to either remain on double-blind canagliflozin 100 mg (or matching placebo) or to up-titrate to double-blind canagliflozin 300 mg (or matching placebo).

## Blinding

A placebo control was used, and randomization was employed to minimize bias in the assignment of subjects to treatment groups, to increase the likelihood that known and unknown subject attributes are evenly balanced across treatment groups. Blinded treatment helped to reduce potential bias during data collection  and  evaluation  of  clinical  endpoints.  The  2-week  single-blind  placebo  run-in  period  before randomization  allows  sufficient  time  for  investigators  to  assess  whether  subjects  demonstrate compliance with study procedures and have no difficulty with administration of the study drug.

<div style=\"page-break-after: always\"></div>

Blinding remains ensured after re-randomization at week 13 (see section on Study design above) by using the following double-dummy approach:

- Subjects initially randomized to placebo and undergoing re-randomization at Week 13, will continue receiving 1 tablet of placebo matching canagliflozin 100 mg and will ADD 1 tablet of placebo matching canagliflozin 300 mg for the remainder of the double-blind treatment period.
- Subjects initially randomized to canagliflozin 100 mg and re-randomized to remain on canagliflozin 100 mg at Week 13, will continue receiving 1 tablet of canagliflozin 100 mg and will ADD 1 tablet of placebo matching canagliflozin 300 mg for the remainder of the double-blind treatment period.
- Subjects initially randomized to canagliflozin 100 mg and re-randomized to up-titrate to canagliflozin 300 mg at Week 13, will switch to 1 tablet of placebo matching canagliflozin 100 mg and will ADD 1 tablet of canagliflozin 300 mg for the remainder of the double-blind treatment period.

Subjects not undergoing re-randomization (i.e, HbA1c of &lt;7.0% or eGFR &lt;60 mL/min/1.73m 2 ) at Week 13 will continue to receive 1 tablet of canagliflozin 100 mg or 1 tablet of placebo matching canagliflozin 100 mg for the remainder of the double-blind treatment period.

## Statistical methods

## Analysis sets

Unless otherwise specified, all analyses will use the Full Analysis set (FAS). The FAS includes all subjects who are randomly assigned to a treatment group, have received at least one dose of study drug and have a baseline HbA1c measurement (according to their randomized assignment).

The 26-week/52-week per protocol (PP) analysis set consists of all FAS subjects who complete the 26week/52-week double-blind treatment period and have no major protocol deviations.

The subjects who complete the 26-week/52-week double-blind treatment period are defined as those subjects who receive study drug and have non-missing HbA1c measurement at Week 26/52.

The safety analysis set consists of the subjects who are randomized and take at least 1 dose of study drug.

## Primary analysis

The primary efficacy endpoint was the change in HbA1c from baseline at Week 26 in the overall study population. The primary analysis was based on the FAS dataset, including all HbA1c measurements collected from randomization to Week 26, including the measurements collected after treatment discontinuation or initiation of rescue medication. The primary analysis was to be based on a pattern mixture model (PMM), that multiply imputed missing data following ICEs based on comparable subjects within the same treatment arm that had observations following the ICE. Data missing of patients not having an ICE were multiply imputed in a similar way but based on the overall study population. A total of 1000 multiple imputations will be performed. Each of the multiply imputed datasets will be analyzed using analysis of covariance (ANCOVA) with terms for treatment, stratification factors, and baseline HbA1c and results will be combined with Rubin's rules.

## Secondary analysis of the primary efficacy endpoint

The secondary analysis was based on a subset of participants on background metformin (with or without insulin) from the FAS dataset. Evaluation was otherwise identical to the primary analysis.

## Sensitivity analyses

<div style=\"page-break-after: always\"></div>

- Multiple imputation based on the 'copy reference' approach
- A tipping point analysis: This analysis starts with a MAR MI model. Then each imputed value is made worse by a difference Delta in increments of 0.1 starting at zero until results reach statistical non-significance.
- The primary efficacy endpoint will be analysed using an MMRM
- Use of last observation carried forward (LOCF) method for missing week 26 data followed by an ANCOVA model as described for the primary analysis.
- A re-randomization test (Proschan 2011) (utilizing the MMRM) will be used to determine the pvalue for the treatment comparison of the primary efficacy endpoint accounting for the same minimization algorithm as employed in the study.
- Analysis of the primary endpoint based on the 26-week PP analysis set using an MMRM.

## Comparison by dose

The comparisons by dose (canagliflozin 100 mg without up-titration after Week 12 and canagliflozin 100 mg up-titrate to 300 mg after Week 12) to placebo will be tested for reference purpose by using the weights in the analyses described below.

- Canagliflozin 100 mg with no dose increase versus placebo: All subjects start with a weight of 1. After Week 12, subjects who are re-randomized to continue canagliflozin 100 mg will have a weight of 2. The subjects who are re-randomized to up-titrate to canagliflozin 300 mg will have a weight of 0.
- Canagliflozin 100 mg followed by a dose increase to 300 mg versus placebo: All subjects start with a weight of 1. After Week 12, subjects who are re-randomized to continue canagliflozin 100 mg will have a weight of 0. The subjects who are re-randomized to up-titrate to canagliflozin 300 mg will have a weight of 2.

## Multiplicity

To strongly control the family-wise error rate at the 5% significance level, a sequential testing procedure was applied. The primary endpoint was first tested in all participants (i.e, full analysis set [FAS]) (primary analysis of the primary efficacy endpoint), and if the results were significant (2-sided alpha level of 0.05), a test for the subset of participants on a background of metformin (with or without insulin) followed (secondary analysis of the primary efficacy endpoint). All other endpoints/evaluations are exploratory and supportive in nature.

## Analyses of secondary endpoints

Continuous endpoints will be analysed with an MMRM model. For the endpoints with post-baseline assessments taken only at Week 26 and Week 52, an analysis of covariance (ANCOVA) model similar to the primary efficacy endpoint will be used at Week 26.

The categorical secondary efficacy endpoint of maintaining HbA1c &lt;7.0% (and HbA1c &lt;6.5% and HbA1c &lt;7.5%) will be analysed longitudinally using a generalized linear mixed model in the FAS population.

<div style=\"page-break-after: always\"></div>

The time to event data (e.g., time to receiving rescue therapy or discontinuing due to need for rescue therapy) will be plotted using the KM method. The difference in proportion of subjects receiving rescue therapy or discontinuing due to need for rescue therapy between canagliflozin and placebo with 95% confidence intervals will be provided.

## Results

## Participant flow

## Study Disposition

## Overall study population

Table  1  below  shows  the  disposition  of  subjects  within  the  overall  study  population.  The  study randomized  171  participants  (canagliflozin  100  mg/300  mg:  n=84;  placebo:  n=87).  Of  the  84 participants on canagliflozin, 33 participants were re-randomized at Week 13 (100 mg canagliflozin: n=16; 300 mg canagliflozin: n=17).

The number of participants who completed the 26-week core treatment period was balanced between both treatment groups (placebo: n=77 [88.5%]; canagliflozin: n=72 [85.7%]). Comparable numbers of participants completed the 52-week treatment period (73 participants [83.9%] receiving placebo vs 69 participants [82.1%] receiving canagliflozin).

For the overall study, 24/87 participants (27.6%) receiving placebo were initiated on rescue medication prior to Week 26, compared to 5/84 participants (6.0%) receiving canagliflozin.

Table 1: Study Disposition (overall study), Study JNJ28431754-DIA3018; all Randomized Subjects

|                                                  | Placebo                       | Canagliflozin                 | Canagliflozin                 | Canagliflozin                 | Total                         |
|--------------------------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|
|                                                  |                               | 100 mg                        | 300 mg                        | Combined                      |                               |
| Analysis set: All Randomized                     | 87                            | 67                            | 17                            | 84                            | 171                           |
| Safety Analysis Set                              | 87 (100.0%)                   | 67 (100.0%)                   | 17 (100.0%)                   | 84 (100.0%)                   | 171 (100.0%)                  |
| Full Analysis Set                                | 87 (100.0%)                   | 67 (100.0%)                   | 17 (100.0%)                   | 84 (100.0%)                   | 171 (100.0%)                  |
| 26-Week Core Treatment Period                    | 26-Week Core Treatment Period | 26-Week Core Treatment Period | 26-Week Core Treatment Period | 26-Week Core Treatment Period | 26-Week Core Treatment Period |
| Subjects re-randomized at week 13                | 60 (69.0%)                    | 16 (23.9%)                    | 17 (100.0%)                   | 33 (39.3%)                    | 93 (54.4%)                    |
| Initiated rescue medication prior to week 26 a   | 24 (27.6%)                    | 3 (4.5%)                      | 2 (11.8%)                     | 5 (6.0%)                      | 29 (17.0%)                    |
| Completed 26-week core treatment period b        | 77 (88.5%)                    | 58 (86.6%)                    | 14 (82.4%)                    | 72 (85.7%)                    | 149 (87.1%)                   |
| PP analysis set in 26-week core treatment period | 50 (57.5%)                    | 53 (79.1%)                    | 10 (58.8%)                    | 63 (75.0%)                    | 113 (66.1%)                   |
| 52-Week Treatment Period                         | 52-Week Treatment Period      | 52-Week Treatment Period      | 52-Week Treatment Period      | 52-Week Treatment Period      | 52-Week Treatment Period      |
| Initiated rescue medication prior to week 52     | 40 (46.0%)                    | 7 (10.4%)                     | 3 (17.6%)                     | 10 (11.9%)                    | 50 (29.2%)                    |
| Completed 52-week treatment period b             | 73 (83.9%)                    | 55 (82.1%)                    | 14 (82.4%)                    | 69 (82.1%)                    | 142 (83.0%)                   |
| PP analysis set in 52-week treatment period      | 31 (35.6%)                    | 48 (71.6%)                    | 11 (64.7%)                    | 59 (70.2%)                    | 90 (52.6%)                    |
| Completed 52-week trial period                   | 75 (86.2%)                    | 60 (89.6%)                    | 14 (82.4%)                    | 74 (88.1%)                    | 149 (87.1%)                   |
| Discontinued treatment prior to week 52          | 14 (16.1%)                    | 12 (17.9%)                    | 3 (17.6%)                     | 15 (17.9%)                    | 29 (17.0%)                    |
| Discontinued trial prior to week 52              | 12 (13.8%)                    | 7 (10.4%)                     | 3 (17.6%)                     | 10 (11.9%)                    | 22 (12.9%)                    |

<div style=\"page-break-after: always\"></div>

a: A subject is considered to have initiated rescue medication prior to week 26 if the day of initiation of the medication is prior to the lower limit of Week 26 Analysis Visit window (Day 163 to 211).

b: It is possible that the number of subjects who completed 52-week treatment period is more than the number of subjects completed 26-week core treatment period due to the definition of the completed 26-week core treatment period. The subjects who complete the 26-week core double-blind treatment period are defined as those subjects who  receive  study  drug  and  have  non-missing  HbA1c  measurement  at  Week  26.  In  the  case  that  the  subjects discontinue from the treatment or have drug interruption at Week 26, the HbA1c measurement needs to be taken no later than the last dose of study drug at Week 26 plus 7 days and the subjects' last dose date needs to be on or after Day 163 based on the definition of analysis visit windows in the SAP.

## Disposition of participants in the individual treatment groups:

Add-on to metformin monotherapy: n=79 [46.2%] (placebo: n=40; canagliflozin: n=39):

- 92.5% on placebo and 84.6% on canagliflozin completed the 26-week core treatment period.
- 82.5% on placebo and 79.5% on canagliflozin completed the 52-week treatment period.
- 20.0% on placebo and 5.1% on canagliflozin: rescue medication prior to week 26.

Add-on to insulin monotherapy: n=19 [11.1%] (placebo: n=10; canagliflozin: n=9):

- 90.0% on placebo and 88.9% on canagliflozin completed the 26-week core treatment period.
- 90.0% on placebo (all who completed the 26-week core treatment period) and 66.7% on canagliflozin completed the 52-week treatment period.
- 30.0% on placebo and 11.1% on canagliflozin: rescue medication prior to Week 26.

Add-on to metformin and insulin: n=50 [29.2%] (placebo: n=27; canagliflozin: n=23):

- 81.5% on placebo and 82.6% on canagliflozin completed the 26-week core treatment period.
- All participants receiving placebo and canagliflozin, who completed the 26-week treatment period, also completed the 52-week treatment period.
- 44.4% on placebo and 4.3% on canagliflozin: rescue medication prior to Week 26.

Add-on to diet and exercise only: n=23 [13.5%] (placebo: n=10; canagliflozin: n=13):

- 90.0% on placebo and 92.3% on canagliflozin completed the 26-week treatment period.
- 90.0% on placebo and 100.0% on canagliflozin completed the 52-week treatment period
- 10.0% on placebo and 7.7% on canagliflozin: rescue medication prior to Week 26.

## Combination of add-on to metformin and add-on to metformin and insulin treatment groups

129 participants (75.4%) were on background metformin (with or without insulin), 67 of which received placebo and 62 received canagliflozin. Table 2 below shows the disposition of participants in the add-on to metformin treatment group (with or without insulin).

A  total  of  59/67  participants  (88.1%)  on  placebo  completed  the  26-week  core  treatment  period, compared to 52/62 participants (83.9%) on canagliflozin. The number of participants who completed the 52-week treatment period was comparable between the two groups (55/67 participants [82.1%] vs 50/62 participants [80.6%], respectively).

Twenty of 67 participants (29.9%) on placebo were initiated on rescue medication prior to Week 26, compared to 3/62 participants (4.8%) on canagliflozin.

Table 2: Study Disposition (Treatment group metformin with and w/o insulin), Study JNJ28431754DIA3018; all Randomized Subjects

|                              | Placebo   | Canagliflozin   | Canagliflozin   | Canagliflozin   | Total   |
|------------------------------|-----------|-----------------|-----------------|-----------------|---------|
|                              |           | 100 mg          | 300 mg          | Combined        |         |
| Analysis set: All Randomized | 67        | 50              | 12              | 62              | 129     |
| Safety Analysis Set          | 67        | 50              | 12              | 62              | 129     |

<div style=\"page-break-after: always\"></div>

|                                                  | (100.0%)                      | (100.0%)                      | (100.0%)                      | (100.0%)                      | (100.0%)                      |
|--------------------------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|
| Full Analysis Set                                | 67 (100.0%)                   | 50 (100.0%)                   | 12 (100.0%)                   | 62 (100.0%)                   | 129 (100.0%)                  |
| 26-Week Core Treatment Period                    | 26-Week Core Treatment Period | 26-Week Core Treatment Period | 26-Week Core Treatment Period | 26-Week Core Treatment Period | 26-Week Core Treatment Period |
| Subjects re-randomized at week 13                | 45 (67.2%)                    | 11 (22.0%)                    | 12 (100.0%)                   | 23 (37.1%)                    | 68 (52.7%)                    |
| Initiated rescue medication prior to week 26 a   | 20 (29.9%)                    | 1 (2.0%)                      | 2 (16.7%)                     | 3 (4.8%)                      | 23 (17.8%)                    |
| Completed 26-week core treatment                 | 59 (88.1%)                    | 43 (86.0%)                    | 9 (75.0%)                     | 52 (83.9%)                    | 111 (86.0%)                   |
| PP analysis set in 26-week core treatment period | 36 (53.7%)                    | 40 (80.0%)                    | 7 (58.3%)                     | 47 (75.8%)                    | 83 (64.3%)                    |
| 52-Week Treatment Period                         | 52-Week Treatment Period      | 52-Week Treatment Period      | 52-Week Treatment Period      | 52-Week Treatment Period      | 52-Week Treatment Period      |
| Initiated rescue medication prior to week 52     | 33 (49.3%)                    | 5 (10.0%)                     | 2 (16.7%)                     | 7 (11.3%)                     | 40 (31.0%)                    |
| Completed 52-week treatment period b             | 55 (82.1%)                    | 41 (82.0%)                    | 9 (75.0%)                     | 50 (80.6%)                    | 105 (81.4%)                   |
| PP analysis set in 52-week treatment period      | 20 (29.9%)                    | 35 (70.0%)                    | 9 (75.0%)                     | 44 (71.0%)                    | 64 (49.6%)                    |
| Completed 52-week trial period                   | 57 (85.1%)                    | 45 (90.0%)                    | 9 (75.0%)                     | 54 (87.1%)                    | 111 (86.0%)                   |
| Discontinued treatment prior to week 52          | 12 (17.9%)                    | 9 (18.0%)                     | 3 (25.0%)                     | 12 (19.4%)                    | 24 (18.6%)                    |
| Discontinued trial prior to week 52              | 10 (14.9%)                    | 5 (10.0%)                     | 3 (25.0%)                     | 8 (12.9%)                     | 18 (14.0%)                    |

a: A subject is considered to have initiated rescue medication prior to week 26 if the day of initiation of the medication is prior to the lower limit of Week 26 Analysis Visit window (Day 163 to 211).

b: It is possible that the number of subjects who completed 52-week treatment period is more than the number of subjects completed 26-week core treatment period due to the definition of the completed 26-week core treatment period. The subjects who complete the 26-week core double-blind treatment period are defined as those subjects who  receive  study  drug  and  have  non-missing  HbA1c  measurement  at  Week  26.  In  the  case  that  the  subjects discontinue from the treatment or have drug interruption at Week 26, the HbA1c measurement needs to be taken no later than the last dose of study drug at Week 26 plus 7 days and the subjects' last dose date needs to be on or after Day 163 based on the definition of analysis visit windows in the SAP.

## Treatment Disposition

## All randomized subjects

## Not re-randomized participants:

- Out of 51 participants, 43 (84.3%) completed treatment with canagliflozin 100 mg, while 8 (15.7%) discontinued treatment.
- Out of 27 participants on placebo, 19 (70.4%) completed treatment and 8 (29.6%) were discontinued.

## Participants re-randomized at week 13:

- Out of 16 participants who received canagliflozin 100 mg, 12 (75.0%) completed treatment.
- Out of 17 participants who received canagliflozin 300 mg, 14 (82.4%) completed treatment.
- Out of 60 participants on placebo, 54 (90%) completed treatment and 6 (10.0%) were discontinued.

In both above-mentioned participant groups, there were no apparent differences in reasons for discontinuation between participants on canagliflozin and those on placebo. Table 3 below summarizes the reasons for discontinuation of treatment:

Table 3: Subject Disposition; All Randomized Subjects (Study JNJ28431754-DIA3018)

|                              | Not Re-Randomized   | Not Re-Randomized   | Re-Randomized at Week 13   | Re-Randomized at Week 13   | Re-Randomized at Week 13   |
|------------------------------|---------------------|---------------------|----------------------------|----------------------------|----------------------------|
| Analysis set: All Randomized | Placebo             | Cana 100 mg         | Placebo                    | Cana 100 mg                | Cana 300 mg                |
|                              | 27                  | 51                  | 60                         | 16                         | 17                         |

<div style=\"page-break-after: always\"></div>

| Treated                                   | 27(100.0%)   | 51 (100.0%)   | 60 (100.0%)   | 16 (100.0%)   | 17 (100.0%)   |
|-------------------------------------------|--------------|---------------|---------------|---------------|---------------|
| On treatment                              | 0            | 0             | 0             | 0             | 0             |
| Completed treatment                       | 19 (70.4%)   | 43 (84.3%)    | 54 (90.0%)    | 12 (75.0%)    | 14 (82.4%)    |
| Discontinued treatment                    | 8 (29.6%)    | 8 (15.7%)     | 6 (10.0%)     | 4 (25.0%)     | 3 (17.6%)     |
| Reasons for treatment discontinuation     |              |               |               |               |               |
| Adverse event                             | 1 (3.7%)     | 1 (2.0%)      | 0             | 0             | 0             |
| Lost to follow-up                         | 3 (11.1%)    | 0             | 0             | 1 (6.3%)      | 0             |
| Non-compliance with study drug            | 0            | 0             | 1 (1.7%)      | 0             | 1 (5.9%)      |
| Physician decision                        | 1 (3.7%)     | 0             | 0             | 0             | 0             |
| Pregnancy                                 | 0            | 1 (2.0%)      | 0             | 0             | 0             |
| Protocol violation                        | 0            | 1 (2.0%)      | 0             | 0             | 0             |
| Site terminated by sponsor                | 0            | 1 (2.0%)      | 0             | 0             | 0             |
| Subject refused further study treatment   | 0            | 1 (2.0%)      | 0             | 1 (6.3%)      | 0             |
| Use of non-approved AHA as rescue therapy | 0            | 0             | 1 (1.7%)      | 0             | 0             |
| Withdrawal by parent/guardian             | 2 (7.4%)     | 0             | 1 (1.7%)      | 0             | 0             |
| Withdrawal by subject                     | 1 (3.7%)     | 1 (2.0%)      | 2 (3.3%)      | 2 (12.5%)     | 2 (11.8%)     |
| Other                                     | 0            | 2 (3.9%)      | 1 (1.7%)      | 0             | 0             |
| Discontinued study a                      | 8 (29.6%)    | 3 (5.9%)      | 4 (6.7%)      | 4 (25.0%)     | 3 (17.6%)     |
| Reasons for study discontinuation         |              |               |               |               |               |
| Lost to follow-up                         | 3 (11.1%)    | 0             | 1 (1.7%)      | 1 (6.3%)      | 0             |
| Non-compliance with study drug            | 0            | 0             | 1 (1.7%)      | 0             | 1 (5.9%)      |
| Physician decision                        | 1 (3.7%)     | 0             | 0             | 0             | 0             |
| Site terminated by sponsor                | 0            | 1 (2.0%)      | 0             | 0             | 0             |
| Withdrawal by parent/guardian             | 2 (7.4%)     | 0             | 0             | 0             | 0             |
| Withdrawal by subject                     | 2 (7.4%)     | 2 (3.9%)      | 2 (3.3%)      | 3 (18.8%)     | 2 (11.8%)     |
| Other                                     | 0            | 0             | 0             | 0             | 0             |
| Completed Week 52 Visit                   | 19 (70.4%)   | 49 (96.1%)    | 56 (93.3%)    | 12 (75.0%)    | 14 (82.4%)    |
| Died (from any data source) 0             |              | 0             | 0             | 0             | 0             |

a Subjects who discontinued from study are included in the 'discontinued from treatment' category. Only the reasons for study discontinuation with n≥1 instances are listed. Therefore, the following reasons for study discontinuation were omitted from the table: adverse event, refusal of further study treatment, use of non-approved AHA as rescue therapy, protocol violation and pregnancy.

## Background metformin (with or without insulin) group

The number of subjects in the add-on metformin group who completed treatment is provided in Table 4 below:

Table 4: Subject Disposition -Subjects on Background Metformin (with or without Insulin); All Randomized Subjects (Study JNJ28431754-DIA3018)

|                                       | Not Re-Randomized   | Not Re-Randomized   | Re-Randomized at Week 13   | Re-Randomized at Week 13   | Re-Randomized at Week 13   |
|---------------------------------------|---------------------|---------------------|----------------------------|----------------------------|----------------------------|
| Analysis set: All Randomized          | Placebo             | Cana 100 mg         | Placebo                    | Cana 100 mg                | Cana 300 mg                |
|                                       | 22                  | 39                  | 45                         | 11                         | 12                         |
| Treated                               | 22 (100.0%)         | 39 (100.0%)         | 45 (100.0%)                | 11 (100.0%)                | 12 (100.0%)                |
| On treatment                          | 0                   | 0                   | 0                          | 0                          | 0                          |
| Completed treatment                   | 14 (63.6%)          | 32 (82.1%)          | 41 (91.1%)                 | 9 (81.8%)                  | 9 (75.0%)                  |
| Discontinued treatment                | 8 (36.4%)           | 7(17.9%)            | 4 (8.9%)                   | 2 (18.2%)                  | 3 (25.0%)                  |
| Reasons for treatment discontinuation |                     |                     |                            |                            |                            |
| Adverse event                         | 1 (4.5%)            | 0                   | 0                          | 0                          | 0                          |
| Lost to follow-up                     | 3 (13.6%)           | 0                   | 0                          | 1 (9.1%)                   | 0                          |

<div style=\"page-break-after: always\"></div>

| Non-compliance with study drug            | 0          | 0         | 1 (2.2%)   | 0         | 1 (8.3%)   |
|-------------------------------------------|------------|-----------|------------|-----------|------------|
| Physician decision                        | 1 (4.5%)   | 0         | 0          | 0         | 0          |
| Pregnancy                                 | 0          | 1 (2.6%)  | 0          | 0         | 0          |
| Protocol violation                        | 0          | 1 (2.6%)  | 0          | 0         | 0          |
| Site terminated by sponsor                | 0          | 1 (2.6%)  | 0          | 0         | 0          |
| Subject refused further study treatment   | 0          | 1 (2.6%)  | 0          | 1 (9.1%)  | 0          |
| Use of non-approved AHA as rescue therapy | 0          | 0         | 1 (2.2%)   | 0         | 0          |
| Withdrawal by parent/guardian             | 2 (9.1%)   | 0         | 1 (2.2%)   | 0         | 0          |
| Withdrawal by subject                     | 1 (4.5%)   | 1 (2.6%)  | 0          | 0         | 2 (16.7%)  |
| Other                                     | 0          | 2 (5.1%)  | 1 (2.2%)   | 0         | 0          |
| Discontinued study a                      | 8 (36.4%)  | 3 (7.7%)  | 2 (4.4%)   | 2 (18.2%) | 3 (25.0%)  |
| Reasons for study discontinuation         |            |           |            |           |            |
| Lost to follow-up                         | 3 (13.6%)  | 0         | 1 (2.2%)   | 1 (9.1%)  | 0          |
| Non-compliance with study drug            | 0          | 0         | 1 (2.2%)   | 0         | 1 (8.3%)   |
| Physician decision                        | 1 (4.5%)   | 0         | 0          | 0         | 0          |
| Site terminated by sponsor                | 0          | 1 (2.6%)  | 0          | 0         | 0          |
| Withdrawal by parent/guardian             | 2 (9.1%)   | 0         | 0          | 0         | 0          |
| Withdrawal by subject                     | 2 (9.1%)   | 2 (5.1%)  | 0          | 1 (9.1%)  | 2 (16.7%)  |
| Other                                     | 0          | 0         | 0          | 0         | 0          |
| Completed Week 52 Visit                   | 14 (63.6%) | 37(94.9%) | 43 (95.6%) | 9 (81.8%) | 9 (75.0%)  |
| Died (from any data source)               | 0          | 0         | 0          | 0         | 0          |

a Subjects who discontinued from study are included in the 'discontinued from treatment' category. Only the reasons for study discontinuation with n≥1 instances are listed. Therefore, the following reasons for study discontinuation were omitted from the table: adverse event, refusal of further study treatment, use of non-approved AHA as rescue therapy, protocol violation and pregnancy.

## Participants who reached week 13

Table 5 shows that the number of participants who reached Week 13 were comparable for both treatment groups (83/87 [95.4%] vs 80/84 [95.2%]).

Sixty  participants  (69.0%)  receiving  placebo  were  re-randomized  at  Week  13  while  23  participants (26.4%) were not randomized. The most commonly reported reason for not-re-randomization was HbA1c &lt;7% (n=20; 87.0%).

Of the 80 participants who received canagliflozin 100 mg and reached Week 13, 16 participants (19.0%) remained on canagliflozin 100 mg and 17 (20.2%) were re-randomized to canagliflozin 300 mg. Fortyseven  participants  (56.0%)  were  not  re-randomized  (most  common  reason  in  43/47  [91.5%] participants: HbA1c &lt;7.0%).

Table 5: Summary of Re-Randomization; All Randomized Subjects (Study JNJ28431754DIA3018)

|                              | Prior to Re-Randomization   | Prior to Re-Randomization   |
|------------------------------|-----------------------------|-----------------------------|
|                              | Placebo                     | Cana 100 mg                 |
| Analysis set: All Randomized | 87                          | 84                          |
| Not Reached Week 13 a        | 4 (4.6%)                    | 4 (4.8%)                    |
| Reached Week 13              | 83 (95.4%)                  | 80 (95.2%)                  |
| Re-randomized at Week 13     | 60 (69.0%)                  | 33 (39.3%)                  |
| Remain on placebo            | 60 (69.0%)                  | 0                           |
| Remain on 100 mg cana        | 0                           | 16 (19.0%)                  |
| Re-randomized to 300 mg cana | 0                           | 17 (20.2%)                  |
| Not re-randomized            | 23 (26.4%)                  | 47 (56.0%)                  |
| Reason not re- randomized    |                             |                             |
| HbA1c value <7.0%            | 20 (87.0%)                  | 43 (91.5%)                  |

<div style=\"page-break-after: always\"></div>

| eGFR <60 mL/min/1.73 m2                            | 0        | 0        |
|----------------------------------------------------|----------|----------|
| Both HbA1c value <7.0% and eGFR <60 mL/min/1.73 m2 | 0        | 1 (2.1%) |
| Other                                              | 2 (8.7%) | 1 (2.1%) |
| <Missing>                                          | 1 (4.3%) | 2 (4.3%) |

a Subjects who reached Week 13 means the subjects had at least one visit after Week 12 and did not withdraw study drug before Week 12.

## Conduct of the study

## Changes in conduct - study amendments

## Global amendments

The study period was from 28 Jul 2017 to 20 Sept 2023. There were 4 amendments to the original protocol, the first and second of which were adopted before any study-related procedures had begun:

- (1) From 27 March 2017 (substantial): Modification of study design to allow the assessment of canagliflozin when used with and without titration which is more reflective of how canagliflozin may be used in this pediatric population, and to add ketone monitoring procedures, and some minor editorial changes
- (2) From 25 August 2017 (substantial): Changes in the statistical analysis and minor editorial changes
- (3) From 25 June 2018 (substantial): Independently powered subset of participants on a background of diet and exercise only, where superiority of canagliflozin vs placebo can be assessed
- (4) From 14 August 2020: Due to slower than expected recruitment and a high rate of screen failures, the power calculation was modified resulting in a reduced sample size. In addition, minor modifications to the inclusion and exclusion criteria have been made.

## Local amendments

- -2/EU-1 (25 August 2017): To amend the study protocol in EU countries to reflect the recommendation from the EMA PDCO on ketone monitoring, and inclusion of all changes associated with global Amendment 2.
- -2/ISR-1 (14 June 2018): reflects recommendations from Israel Ministry of Health on hypo- and hyperglycemia.
- -2/IND-1 (08 February 2018): upon request from CDSCO/India to add a BMI inclusion criterion.
- -3/IND-1 (10 October 2018), 3/ISR-1 (10 October 2018): same changes as in Amendment 3.
- -3/EU-1 (10 October 2018): reflected consistencies across all protocol amendments (ie, local vs. global).
- -4/EU-1 (10 November 2020), 4/IND-1 (27 August 2020): same changes as in Amendment 4, with power calculation modified with the EMA's approval in the European version.

## Protocol deviations

All major protocol deviations (pd) for the FAS are summarized in the below. A total of 53 participants (31%)  reported  major  deviations  (placebo:  n=30  [34.5%];  canagliflozin:  n=23  [27%]).  The  most common protocol deviations were 'Other' (n=37 [21.6%]) and participants who entered but did not satisfy criteria (n=21 [12.3%]). The remaining protocol deviations occurred in &lt;3% of participants. See Table 6 below.

Table  6: Summary  of  subjects  with  major  protocol  deviations  through  Week  26;  FAS  (Study JNJ28431754-DIA3018)

<div style=\"page-break-after: always\"></div>

|                                                 | Placebo    | Canagliflozin   | Canagliflozin   | Canagliflozin   | Total      |
|-------------------------------------------------|------------|-----------------|-----------------|-----------------|------------|
| Analysis set: Full                              |            | 100 mg          | 300 mg          | Combined        |            |
|                                                 | 87         | 67              | 17              | 84              | 171        |
| Subjects with major protocol deviations         | 30 (34.5%) | 19 (28.4%)      | 4 (23.5%)       | 23 (27.4%)      | 53 (31.0%) |
| Other a                                         | 20 (23.0%) | 15 (22.4%)      | 2 (11.8%)       | 17 (20.2%)      | 37(21.6%)  |
| Entered but did not satisfy criteria            | 11 (12.6%) | 8 (11.9%)       | 2 (11.8%)       | 10 (11.9%)      | 21 (12.3%) |
| Received a disallowed concomitant treatment     | 5 (5.7%)   | 0               | 0               | 0               | 5 (2.9%)   |
| Developed withdrawal criteria but not withdrawn | 1 (1.1%)   | 0               | 0               | 0               | 1 (0.6%)   |
| Minor pd - investigational product              | 0          | 1 (1.5%)        | 0               | 1 (1.2%)        | 1 (0.6%)   |
| Minor pd - study procedures                     | 1 (1.1%)   | 0               | 0               | 0               | 1 (0.6%)   |

a 'other': =protocol deviations like administrative issues, intermittent missed doses, and diary issues. Note: Subjects may appear in more than one category.

One participant receiving canagliflozin continued on a low dose of metformin XR throughout the duration of the study.

## Treatment compliance

Study  agent  compliance ≥ 75%  at  Week  26  was  comparable  across  treatment  groups  with  76/87 participants  [87.4%] receiving placebo and 75/84 participants [89.3%] receiving canagliflozin - see Table 7 below.

Table 7: Summary of study agent compliance through week 26; FAS (Study JNJ28431754-DIA3018)

|                          |            | Canagliflozin   | Canagliflozin   | Canagliflozin   |
|--------------------------|------------|-----------------|-----------------|-----------------|
| Analysis set: Full       | Placebo    | 100 mg          | 300 mg          | Combined        |
|                          | 87         | 67              | 17              | 84              |
| Compliance category <75% | 3 (3.4%)   | 4 (6.0%)        | 1 (5.9%)        | 5 (6.0%)        |
| ≥ 75%                    | 76 (87.4%) | 60 (89.6%)      | 15 (88.2%)      | 75 (89.3%)      |
| Missing                  | 8 (9.2%)   | 3 (4.5%)        | 1 (5.9%)        | 4 (4.8%)        |

Treatment compliance through Week 52 was similarly comparable between the groups (data not shown here).

## Baseline data

## Demographics and baseline disease characteristics

Overall, demographic and baseline characteristics were comparable across the treatment groups. More than two thirds of the patients were female in the placebo and total canagliflozin group. The proportion of female participants was 67.9% (n=55) in the age group ≥10 to &lt;15 years and 68.9% (n=62) in those aged ≥ 15 to &lt;18 years.

Mean baseline HbA1c was markedly lower (by 0.5 %) in the canagliflozin arm as compared to placebotreated patients (7.8 vs. 8.3, respectively), which went along with a slightly shorter mean duration of disease, a higher baseline eGFR and a higher fasting serum triglyceride value in the canagliflozin group in comparison to the placebo arm.

None of the subjects had any microvascular complication (i.e., medical history of diabetic neuropathy, diabetic retinopathy, or diabetic nephropathy) at baseline. In none of the subjects, severe hypoglycaemia was reported.

<div style=\"page-break-after: always\"></div>

Table 8 summarizes baseline demographics and clinical characteristics.

Table 8: Summary of demographics and baseline characteristics; FAS (Study JNJ-28431754DIA3018)

|                                  | Placebo                 | Canagliflozin    | Canagliflozin   | Canagliflozin   | Total        |
|----------------------------------|-------------------------|------------------|-----------------|-----------------|--------------|
| Analysis set: Full               |                         | 100 mg 67        | 300 mg 17       | Combined 84     | 171          |
| Age (years)                      | 87                      |                  |                 |                 |              |
| N                                | 87                      | 67               | 17              | 84              | 171          |
| Mean (SD)                        | 14.4 (2.04)             | 14.2 (2.00)      | 14.5 (2.07)     | 14.3 (2.00)     | 14.3 (2.02)  |
| Median                           | 15.0                    | 15.0             | 15.0            | 15.0            | 15.0         |
| Range                            | (10; 17)                | (10; 17)         | (10; 17)        | (10; 17)        | (10; 17)     |
| 10 to <15                        | 42 (48.3%)              | 33               | 6 (35.3%)       | 39 (46.4%)      | 81 (47.4%)   |
| 15 to <18                        | 45 (51.7%)              | (49.3%) 34       | 11 (64.7%)      | 45 (53.6%)      | 90 (52.6%)   |
| Sex                              |                         | (50.7%)          |                 |                 |              |
| N                                | 87                      | 67               | 17              | 84              | 171          |
| Female                           | 60 (69.0%)              | 49 (73.1%)       | 8 (47.1%)       | 57 (67.9%)      | 117 (68.4%)  |
| Male                             | 27 (31.0%)              | 18 (26.9%)       | 9 (52.9%)       | 27 (32.1%)      | 54 (31.6%)   |
| Race                             |                         |                  |                 |                 |              |
| N                                | 87                      | 67               | 17              | 84              | 171          |
| American Indian or Alaska Native | 4 (4.6%)                | 1 (1.5%)         | 3 (17.6%)       | 4 (4.8%)        | 8 (4.7%)     |
| Asian                            | 38 (43.7%)              | 29               | 5 (29.4%)       | 34 (40.5%)      | 72 (42.1%)   |
| Black or African American        | 13 (14.9%)              | (43.3%) 4 (6.0%) | 2 (11.8%)       | 6 (7.1%)        | 19 (11.1%)   |
| White                            | 31 (35.6%)              | 33 (49.3%)       | 7 (41.2%)       | 40 (47.6%)      | 71 (41.5%)   |
| Multiple                         | 1 (1.1%)                | 0                | 0               | 0               | 1 (0.6%)     |
| Ethnicity                        |                         |                  |                 |                 |              |
| N                                | 87                      | 67               | 17              | 84              | 171          |
| Hispanic or Latino               | 29 (33.3%)              | 23 (34.3%)       | 10 (58.8%)      | 33 (39.3%)      | 62 (36.3%)   |
| Not Hispanic or Latino           | 57 (65.5%)              | 44 (65.7%)       | 7 (41.2%)       | 51 (60.7%)      | 108 (63.2%)  |
| Not reported                     | 1 (1.1%)                | 0                | 0               | 0               | 1 (0.6%)     |
| Weight                           |                         |                  |                 |                 |              |
| N                                | 87                      | 67               | 17              | 84              | 171          |
| Mean (SD)                        | 79.9 (25.31)            | 81.8 (24.67)     | 81.0 (21.86)    | 81.6 (24.01)    | 80.8 (24.62) |
| Median                           | 75.2                    | 75.1             | 79.5            | 75.9            | 75.2         |
| Range                            | (41; 162)               | (47; 161)        | (45; 134)       | (45; 161)       | (41; 162)    |
| Height                           |                         |                  |                 |                 |              |
| N                                | 87                      | 67               | 17              | 84              | 171          |
| Mean (SD)                        | 160.9 (9.88)            | 160.7 (10.07)    | 163.3 (10.04)   | 161.2 (10.06)   | 161.0 (9.94) |
| Median                           | 161.0                   | 158.4            | 163.0           | 159.5           | 161.0        |
| Range                            | (141; 186)              | (144;            | (143; 186)      | (143; 190)      | (141; 190)   |
| Body Mass Index, kg/m 2          | Body Mass Index, kg/m 2 |                  |                 |                 |              |
| N                                | 87                      | 67               | 17              | 84              | 171          |
| Mean (SD)                        | 30.5 (7.66)             | 31.3             | 30.1 (6.61)     | 31.1 (7.21)     | 30.8 (7.43)  |
| Median                           | 29.2                    | (7.38) 30.4      | 28.2            | 29.9            | 29.8         |
| Range                            | (18; 57)                | (19; 50)         | (21; 42)        | (19; 50)        | (18; 57)     |
| Underweight <18.5                | 1 (1.1%)                | 0                | 0               | 0               | 1 (0.6%)     |
| Normal 18.5 to <25               | 20 (23.0%)              | 17 (25.4%)       | 4 (23.5%)       | 21 (25.0%)      | 41 (24.0%)   |
| Overweight 25 to <30             | 28 (32.2%)              | 15 (22.4%)       | 7 (41.2%)       | 22 (26.2%)      | 50 (29.2%)   |
| Obese ≥30                        | 38 (43.7%)              | 35               | 6 (35.3%)       | 41 (48.8%)      | 79 (46.2%)   |

<div style=\"page-break-after: always\"></div>

| Baseline HbA1c (%)                                                                               | Baseline HbA1c (%)                                                                               | Baseline HbA1c (%)                                                                               | Baseline HbA1c (%)                                                                               | Baseline HbA1c (%)                                                                               | Baseline HbA1c (%)                                                                               |
|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| N Mean (SD)                                                                                      | 87 8.3 (1.35)                                                                                    | 67                                                                                               | 17                                                                                               | 84                                                                                               | 171                                                                                              |
| Median                                                                                           | 8.0                                                                                              | 7.5 (1.20)                                                                                       | 8.8 (1.30)                                                                                       | 7.8 (1.31)                                                                                       | 8.0 (1.35)                                                                                       |
|                                                                                                  |                                                                                                  | 7.3                                                                                              | 8.7                                                                                              | 7.5 (6; 11)                                                                                      | 7.8                                                                                              |
| Range                                                                                            | (6; 11)                                                                                          | (6; 11)                                                                                          | (7; 11)                                                                                          |                                                                                                  | (6; 11)                                                                                          |
| <7%                                                                                              | 16 (18.4%)                                                                                       | 25                                                                                               | 1 (5.9%)                                                                                         | 26 (31.0%)                                                                                       | 42 (24.6%)                                                                                       |
| 7 to <8%                                                                                         | 25 (28.7%)                                                                                       | (37.3%) 21                                                                                       | 4 (23.5%)                                                                                        | 25 (29.8%)                                                                                       | 50 (29.2%)                                                                                       |
| 8 to <9%                                                                                         | 16 (18.4%)                                                                                       | (31.3%) 10 (14.9%)                                                                               | 5 (29.4%)                                                                                        | 15 (17.9%)                                                                                       | 31 (18.1%)                                                                                       |
| 9 to ≤10%                                                                                        | 19 (21.8%)                                                                                       | 9 (13.4%)                                                                                        | 4 (23.5%)                                                                                        | 13 (15.5%)                                                                                       | 32 (18.7%)                                                                                       |
| >10%                                                                                             | 11 (12.6%)                                                                                       | 2 (3.0%)                                                                                         | 3 (17.6%)                                                                                        | 5 (6.0%)                                                                                         | 16 (9.4%)                                                                                        |
| Baseline FPG (mmol/L)                                                                            | Baseline FPG (mmol/L)                                                                            | Baseline FPG (mmol/L)                                                                            | Baseline FPG (mmol/L)                                                                            | Baseline FPG (mmol/L)                                                                            | Baseline FPG (mmol/L)                                                                            |
| N                                                                                                | 85                                                                                               | 64                                                                                               | 17                                                                                               | 81                                                                                               | 166                                                                                              |
| Mean (SD)                                                                                        | 8.7 (3.67)                                                                                       | 8.1 (3.08)                                                                                       | 10.4 (2.97)                                                                                      | 8.6 (3.18)                                                                                       | 8.6 (3.43)                                                                                       |
| Median                                                                                           | 7.8                                                                                              | 7.0                                                                                              | 10.2                                                                                             | 7.5                                                                                              | 7.7                                                                                              |
|                                                                                                  |                                                                                                  |                                                                                                  |                                                                                                  |                                                                                                  | (3; 25)                                                                                          |
| Range                                                                                            | (3; 25)                                                                                          | (3; 18)                                                                                          | (6; 17)                                                                                          | (3; 18)                                                                                          |                                                                                                  |
| Duration of Diabetes (years)                                                                     | Duration of Diabetes (years)                                                                     | Duration of Diabetes (years)                                                                     | Duration of Diabetes (years)                                                                     | Duration of Diabetes (years)                                                                     | Duration of Diabetes (years)                                                                     |
| N                                                                                                | 87                                                                                               | 67                                                                                               | 17                                                                                               | 84                                                                                               | 171                                                                                              |
| Mean (SD)                                                                                        | 2.3 (1.77)                                                                                       | 1.8 (2.20)                                                                                       | 1.6 (1.29)                                                                                       | 1.7 (2.04)                                                                                       | 2.0 (1.92)                                                                                       |
| Median                                                                                           | 1.9                                                                                              | 1.1                                                                                              | 1.1                                                                                              | 1.1                                                                                              | 1.5                                                                                              |
| Range                                                                                            | (0; 10)                                                                                          | (0; 14)                                                                                          | (0; 4)                                                                                           | (0; 14)                                                                                          | (0; 14)                                                                                          |
| Baseline eGFR (ml/min/1.73 m 2 )                                                                 | Baseline eGFR (ml/min/1.73 m 2 )                                                                 | Baseline eGFR (ml/min/1.73 m 2 )                                                                 | Baseline eGFR (ml/min/1.73 m 2 )                                                                 | Baseline eGFR (ml/min/1.73 m 2 )                                                                 | Baseline eGFR (ml/min/1.73 m 2 )                                                                 |
| N                                                                                                | 87                                                                                               | 67                                                                                               | 17                                                                                               | 84                                                                                               | 171                                                                                              |
| Mean (SD)                                                                                        | 151.1 (29.71)                                                                                    | 163.2 (34.52)                                                                                    | 166.1 (30.85)                                                                                    | 163.8 (33.65)                                                                                    | 157.3 (32.25)                                                                                    |
| Median Range                                                                                     | 146.0 (66; 284)                                                                                  | 165.0 (84; 277)                                                                                  | 169.0 (112; 235)                                                                                 | 166.0 (84; 277)                                                                                  | 155.0 (66; 284)                                                                                  |
| Baseline Systolic Blood Pressure (mmHg)                                                          | Baseline Systolic Blood Pressure (mmHg)                                                          | Baseline Systolic Blood Pressure (mmHg)                                                          | Baseline Systolic Blood Pressure (mmHg)                                                          | Baseline Systolic Blood Pressure (mmHg)                                                          | Baseline Systolic Blood Pressure (mmHg)                                                          |
| N                                                                                                | 87                                                                                               | 67                                                                                               | 17                                                                                               | 84                                                                                               | 171                                                                                              |
| Mean (SD)                                                                                        | 114.9 (12.34)                                                                                    | 116.4                                                                                            | 112.3 (12.10)                                                                                    | 115.5 (13.19)                                                                                    | 115.2 (12.73)                                                                                    |
| Median                                                                                           | 114.3                                                                                            | 115.0                                                                                            | 113.0                                                                                            | 114.5                                                                                            | 114.3                                                                                            |
| Range (80; 149) (93; 152) (91; 139) (91; 152) (80; 152) Baseline Diastolic Blood Pressure (mmHg) | Range (80; 149) (93; 152) (91; 139) (91; 152) (80; 152) Baseline Diastolic Blood Pressure (mmHg) | Range (80; 149) (93; 152) (91; 139) (91; 152) (80; 152) Baseline Diastolic Blood Pressure (mmHg) | Range (80; 149) (93; 152) (91; 139) (91; 152) (80; 152) Baseline Diastolic Blood Pressure (mmHg) | Range (80; 149) (93; 152) (91; 139) (91; 152) (80; 152) Baseline Diastolic Blood Pressure (mmHg) | Range (80; 149) (93; 152) (91; 139) (91; 152) (80; 152) Baseline Diastolic Blood Pressure (mmHg) |
| N                                                                                                | 87                                                                                               | 67                                                                                               | 17                                                                                               | 84                                                                                               | 171                                                                                              |
| Mean (SD)                                                                                        | 72.0 (8.07)                                                                                      | 73.9                                                                                             | 69.5 (8.58)                                                                                      | 73.0 (8.63)                                                                                      | 72.5 (8.34)                                                                                      |
| Median                                                                                           | 72.3                                                                                             | 73.7                                                                                             | 69.0                                                                                             | 72.7                                                                                             | 72.7                                                                                             |
| Range                                                                                            | (51; 94)                                                                                         | (55; 93)                                                                                         | (55; 96)                                                                                         | (55; 96)                                                                                         | (51; 96)                                                                                         |
| Baseline Serum N Mean (SD)                                                                       | Triglycerides (mmol/L) 82 1.6 (1.19)                                                             | - Fasting 61 1.8 (1.06)                                                                          | 17 3.1 (3.90)                                                                                    | 78 2.1 (2.08)                                                                                    | 160 1.8 (1.70)                                                                                   |
| Median                                                                                           | 1.3                                                                                              | 1.6                                                                                              | 2.0                                                                                              | 1.6                                                                                              | 1.4                                                                                              |
|                                                                                                  |                                                                                                  |                                                                                                  |                                                                                                  | (0;                                                                                              | (0; 18)                                                                                          |
| Range                                                                                            | (0; 9)                                                                                           | (0; 6)                                                                                           | (1; 18)                                                                                          | 18)                                                                                              |                                                                                                  |
| Baseline Serum HDL Cholesterol (mmol/L) - Fasting                                                | Baseline Serum HDL Cholesterol (mmol/L) - Fasting                                                | Baseline Serum HDL Cholesterol (mmol/L) - Fasting                                                | Baseline Serum HDL Cholesterol (mmol/L) - Fasting                                                | Baseline Serum HDL Cholesterol (mmol/L) - Fasting                                                | Baseline Serum HDL Cholesterol (mmol/L) - Fasting                                                |
| N                                                                                                | 78                                                                                               | 61                                                                                               | 17                                                                                               | 78                                                                                               | 156                                                                                              |
| Mean (SD)                                                                                        | 1.1 (0.24)                                                                                       | 1.1 (0.25)                                                                                       | 0.9 (0.17)                                                                                       | 1.0 (0.25)                                                                                       | 1.1 (0.25)                                                                                       |
| Median                                                                                           | 1.1                                                                                              | 1.1                                                                                              | 0.9                                                                                              | 1.0                                                                                              | 1.1                                                                                              |
| Range                                                                                            | (1; 2)                                                                                           | (0; 2)                                                                                           | (1; 1)                                                                                           |                                                                                                  | (0; 2)                                                                                           |
|                                                                                                  |                                                                                                  |                                                                                                  |                                                                                                  | (0; 2)                                                                                           |                                                                                                  |
| Baseline Serum LDL Cholesterol (mmol/L) - Fasting                                                | Baseline Serum LDL Cholesterol (mmol/L) - Fasting                                                | Baseline Serum LDL Cholesterol (mmol/L) - Fasting                                                | Baseline Serum LDL Cholesterol (mmol/L) - Fasting                                                | Baseline Serum LDL Cholesterol (mmol/L) - Fasting                                                | Baseline Serum LDL Cholesterol (mmol/L) - Fasting                                                |
| N                                                                                                | 77                                                                                               | 61                                                                                               | 17                                                                                               | 78                                                                                               | 155                                                                                              |
| Mean (SD)                                                                                        | 2.7 (0.82)                                                                                       | 2.5 (0.86)                                                                                       | 2.4 (0.86)                                                                                       | 2.5 (0.86)                                                                                       | 2.6 (0.85)                                                                                       |
| Median                                                                                           | 2.6                                                                                              | 2.5                                                                                              | 2.2                                                                                              | 2.5                                                                                              | 2.5                                                                                              |
| Range                                                                                            | (1; 5)                                                                                           | (1; 5)                                                                                           | (1; 5)                                                                                           | (1; 5)                                                                                           | (1; 5)                                                                                           |
| Baseline Serum Cholesterol (mmol/L) - Fasting                                                    | Baseline Serum Cholesterol (mmol/L) - Fasting                                                    | Baseline Serum Cholesterol (mmol/L) - Fasting                                                    | Baseline Serum Cholesterol (mmol/L) - Fasting                                                    | Baseline Serum Cholesterol (mmol/L) - Fasting                                                    | Baseline Serum Cholesterol (mmol/L) - Fasting                                                    |
| N                                                                                                | 82                                                                                               | 61                                                                                               | 17                                                                                               | 78                                                                                               | 160                                                                                              |
| Mean (SD)                                                                                        | 4.5 (0.91)                                                                                       | 4.4 (1.08)                                                                                       | 4.6 (1.41)                                                                                       | 4.5 (1.15)                                                                                       | 4.5 (1.03)                                                                                       |
| Median                                                                                           | 4.4                                                                                              | 4.4                                                                                              | 4.3                                                                                              | 4.3                                                                                              | 4.4                                                                                              |
| Range                                                                                            | (3; 7)                                                                                           | (2; 7)                                                                                           | (3; 9)                                                                                           | (2; 9)                                                                                           | (2; 9)                                                                                           |
| Baseline Serum Non-HDL Cholesterol (mmol/L) - Fasting                                            | Baseline Serum Non-HDL Cholesterol (mmol/L) - Fasting                                            | Baseline Serum Non-HDL Cholesterol (mmol/L) - Fasting                                            | Baseline Serum Non-HDL Cholesterol (mmol/L) - Fasting                                            | Baseline Serum Non-HDL Cholesterol (mmol/L) - Fasting                                            | Baseline Serum Non-HDL Cholesterol (mmol/L) - Fasting                                            |
| N                                                                                                | 77                                                                                               | 61                                                                                               | 17                                                                                               | 78                                                                                               | 155                                                                                              |
| Mean (SD)                                                                                        |                                                                                                  | 3.4 (1.07)                                                                                       |                                                                                                  |                                                                                                  | 3.4 (1.02)                                                                                       |
|                                                                                                  | 3.3                                                                                              | 3.3                                                                                              | 3.4                                                                                              |                                                                                                  | 3.3                                                                                              |
| Range                                                                                            | (2; 6)                                                                                           | (1; 6)                                                                                           | (2; 8)                                                                                           | (1; 8)                                                                                           | (1; 8)                                                                                           |
| Baseline Serum LDL                                                                               | Cholesterol/HDL                                                                                  | Cholesterol                                                                                      | (mol/mol)                                                                                        | Fasting                                                                                          |                                                                                                  |
| - N 77 61 17 78 155                                                                              | - N 77 61 17 78 155                                                                              | - N 77 61 17 78 155                                                                              | - N 77 61 17 78 155                                                                              | - N 77 61 17 78 155                                                                              | - N 77 61 17 78 155                                                                              |
|                                                                                                  | 3.4 (0.88)                                                                                       |                                                                                                  |                                                                                                  |                                                                                                  |                                                                                                  |
| Median                                                                                           |                                                                                                  |                                                                                                  | 3.7 (1.40)                                                                                       | 3.4 (1.15)                                                                                       |                                                                                                  |
|                                                                                                  |                                                                                                  |                                                                                                  |                                                                                                  | 3.3                                                                                              |                                                                                                  |

<div style=\"page-break-after: always\"></div>

| Mean (SD)                                                              | 2.5 (0.89)                                                             | 2.5 (1.03)                                                             | 2.7 (0.65)                                                             | 2.5 (0.96)                                                             | 2.5 (0.92)                                                             |
|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|
| Median                                                                 | 2.2                                                                    | 2.4                                                                    | 3.0                                                                    | 2.6                                                                    | 2.3                                                                    |
| Range (1; 5) (1; 5) (2; 4) (1; 5) (1; 5)                               | Range (1; 5) (1; 5) (2; 4) (1; 5) (1; 5)                               | Range (1; 5) (1; 5) (2; 4) (1; 5) (1; 5)                               | Range (1; 5) (1; 5) (2; 4) (1; 5) (1; 5)                               | Range (1; 5) (1; 5) (2; 4) (1; 5) (1; 5)                               | Range (1; 5) (1; 5) (2; 4) (1; 5) (1; 5)                               |
| Baseline Serum Non-HDL Cholesterol/LDL Cholesterol (mol/mol) - Fasting | Baseline Serum Non-HDL Cholesterol/LDL Cholesterol (mol/mol) - Fasting | Baseline Serum Non-HDL Cholesterol/LDL Cholesterol (mol/mol) - Fasting | Baseline Serum Non-HDL Cholesterol/LDL Cholesterol (mol/mol) - Fasting | Baseline Serum Non-HDL Cholesterol/LDL Cholesterol (mol/mol) - Fasting | Baseline Serum Non-HDL Cholesterol/LDL Cholesterol (mol/mol) - Fasting |
| N                                                                      | 76                                                                     | 60                                                                     | 15                                                                     | 75                                                                     | 151                                                                    |
| Mean (SD)                                                              | 1.2 (0.30)                                                             | 1.2 (0.29)                                                             | 1.3 (0.39)                                                             | 1.2 (0.31)                                                             | 1.2 (0.30)                                                             |
| Median                                                                 | 1.1                                                                    | 1.2                                                                    | 1.1                                                                    | 1.2                                                                    | 1.1                                                                    |
| Range                                                                  | (1; 2)                                                                 | (1; 2)                                                                 | (1; 2)                                                                 | (1; 2)                                                                 | (1; 2)                                                                 |
| (mmol/L)                                                               | (mmol/L)                                                               | (mmol/L)                                                               | (mmol/L)                                                               | (mmol/L)                                                               | (mmol/L)                                                               |
| Baseline Calcium N                                                     | 87                                                                     | 67                                                                     | 17                                                                     | 84                                                                     | 171                                                                    |
| Mean (SD)                                                              | 2.5 (0.10)                                                             | 2.5 (0.09)                                                             | 2.4 (0.12)                                                             | 2.4 (0.10)                                                             | 2.4 (0.10)                                                             |
| Median                                                                 | 2.5                                                                    | 2.5                                                                    | 2.4                                                                    | 2.5                                                                    | 2.5                                                                    |
| Range                                                                  |                                                                        | (2; 3)                                                                 | (2; 3)                                                                 | (2; 3)                                                                 | (2; 3)                                                                 |
| (2; 3) Baseline Magnesium (mmol/L)                                     | (2; 3) Baseline Magnesium (mmol/L)                                     | (2; 3) Baseline Magnesium (mmol/L)                                     | (2; 3) Baseline Magnesium (mmol/L)                                     | (2; 3) Baseline Magnesium (mmol/L)                                     | (2; 3) Baseline Magnesium (mmol/L)                                     |
| N                                                                      | 87                                                                     | 67                                                                     | 17                                                                     | 84                                                                     | 171                                                                    |
| Mean (SD)                                                              | 0.8 (0.07)                                                             | 0.8 (0.08)                                                             | 0.8 (0.06)                                                             | 0.8 (0.07)                                                             | 0.8 (0.07)                                                             |
| Median                                                                 | 0.8                                                                    | 0.8                                                                    | 0.8                                                                    | 0.8                                                                    | 0.8                                                                    |
| Range                                                                  | (1; 1)                                                                 | (1; 1)                                                                 | (1; 1)                                                                 | (1; 1)                                                                 | (1; 1)                                                                 |
| Baseline Phosphate (mmol/L)                                            | Baseline Phosphate (mmol/L)                                            | Baseline Phosphate (mmol/L)                                            | Baseline Phosphate (mmol/L)                                            | Baseline Phosphate (mmol/L)                                            | Baseline Phosphate (mmol/L)                                            |
| N                                                                      | 87                                                                     | 67                                                                     | 17                                                                     | 84                                                                     | 171                                                                    |
| Mean (SD)                                                              | 1.4 (0.21)                                                             | 1.4 (0.21)                                                             | 1.4 (0.23)                                                             | 1.4 (0.22)                                                             | 1.4 (0.21)                                                             |
| Median                                                                 | 1.4                                                                    | 1.4                                                                    | 1.4                                                                    | 1.4                                                                    | 1.4                                                                    |
| Range                                                                  | (1; 2)                                                                 | (1; 2)                                                                 | (1; 2)                                                                 | (1; 2)                                                                 | (1; 2)                                                                 |
| Baseline Parathyroid Hormone, Intact (pmol/L)                          | Baseline Parathyroid Hormone, Intact (pmol/L)                          | Baseline Parathyroid Hormone, Intact (pmol/L)                          | Baseline Parathyroid Hormone, Intact (pmol/L)                          | Baseline Parathyroid Hormone, Intact (pmol/L)                          | Baseline Parathyroid Hormone, Intact (pmol/L)                          |
| N                                                                      | 82                                                                     | 65                                                                     | 17                                                                     | 82                                                                     | 164                                                                    |
| Mean (SD)                                                              | 4.6 (2.19)                                                             | 5.2 (4.16)                                                             | 3.7 (1.27)                                                             | 4.9 (3.79)                                                             | 4.7 (3.09)                                                             |
| Median                                                                 | 4.2                                                                    | 4.4                                                                    | 3.8                                                                    | 4.0                                                                    | 4.1                                                                    |
| Range                                                                  | (1; 12)                                                                | (1; 33)                                                                | (2; 6)                                                                 | (1; 33)                                                                | (1; 33)                                                                |
| Baseline 25-Hydroxy Vitamin D (nmol/L)                                 | Baseline 25-Hydroxy Vitamin D (nmol/L)                                 | Baseline 25-Hydroxy Vitamin D (nmol/L)                                 | Baseline 25-Hydroxy Vitamin D (nmol/L)                                 | Baseline 25-Hydroxy Vitamin D (nmol/L)                                 | Baseline 25-Hydroxy Vitamin D (nmol/L)                                 |
| N Mean (SD)                                                            | 87 47.4 (23.58)                                                        | 65                                                                     | 17                                                                     | 82 48.1 (17.17)                                                        | 169                                                                    |
| Median                                                                 | 45.0                                                                   | 48.6 (18.24)                                                           | 45.9 (12.52)                                                           | 45.5                                                                   |                                                                        |
| Range                                                                  | (13; 189)                                                              | 45.0 (12; 106)                                                         | 51.0 (23; 61)                                                          | (12; 106)                                                              | 45.0 (12; 189)                                                         |
| Baseline Calcitonin (pmol/L)                                           | Baseline Calcitonin (pmol/L)                                           | Baseline Calcitonin (pmol/L)                                           | Baseline Calcitonin (pmol/L)                                           | Baseline Calcitonin (pmol/L)                                           | Baseline Calcitonin (pmol/L)                                           |
| N                                                                      | 82                                                                     | 64                                                                     | 17                                                                     | 81                                                                     |                                                                        |
| Mean (SD)                                                              | 1.8 (10.69)                                                            | 0.6 (0.07)                                                             | 0.6 (0.00)                                                             | 0.6 (0.06)                                                             | 1.2 (7.58)                                                             |
| Median                                                                 | 0.6                                                                    | 0.6                                                                    | 0.6                                                                    | 0.6                                                                    | 0.6                                                                    |
| Range                                                                  | (1; 97)                                                                | (1; 1)                                                                 | (1; 1)                                                                 | (1; 1)                                                                 | (1; 97)                                                                |
| Baseline Urine Calcium (mmol/L)                                        | Baseline Urine Calcium (mmol/L)                                        | Baseline Urine Calcium (mmol/L)                                        | Baseline Urine Calcium (mmol/L)                                        | Baseline Urine Calcium (mmol/L)                                        | Baseline Urine Calcium (mmol/L)                                        |
| N                                                                      | 83                                                                     | 63                                                                     | 17                                                                     | 80                                                                     | 163                                                                    |
| Mean (SD)                                                              | 2.4 (2.67)                                                             | 2.3 (2.16)                                                             | 3.6 (2.89)                                                             | 2.6 (2.37)                                                             | 2.5 (2.52)                                                             |
| Median                                                                 | 1.7                                                                    | 1.7                                                                    | 3.0                                                                    | 1.9                                                                    | 1.8                                                                    |
| Range                                                                  | (0; 16)                                                                | (0; 12)                                                                | (0; 12)                                                                | (0; 12)                                                                | (0; 16)                                                                |
| Baseline Urine Phosphate (mmol/L)                                      | Baseline Urine Phosphate (mmol/L)                                      | Baseline Urine Phosphate (mmol/L)                                      | Baseline Urine Phosphate (mmol/L)                                      | Baseline Urine Phosphate (mmol/L)                                      | Baseline Urine Phosphate (mmol/L)                                      |
| N Mean (SD)                                                            | 81 19.0 (14.40)                                                        | 56 21.4                                                                | 17 24.5 (18.40)                                                        | 73 22.1 (15.26)                                                        | 154 20.5 (14.84)                                                       |
| Median                                                                 | 16.7                                                                   | (14.28) 23.3                                                           | 19.0                                                                   | 22.5                                                                   | 18.5                                                                   |
| Range                                                                  | (1; 77)                                                                | (1; 61)                                                                | (1; 60)                                                                | (1; 61)                                                                | (1; 77)                                                                |
| Baseline Osteocalcin (ug/L)                                            | Baseline Osteocalcin (ug/L)                                            | Baseline Osteocalcin (ug/L)                                            | Baseline Osteocalcin (ug/L)                                            | Baseline Osteocalcin (ug/L)                                            | Baseline Osteocalcin (ug/L)                                            |
| N                                                                      | 86                                                                     | 65                                                                     | 16                                                                     | 81                                                                     | 167                                                                    |
| Mean (SD)                                                              | 41.6 (32.18)                                                           | 42.9 (31.83)                                                           | 32.2 (18.46)                                                           | 40.8 (29.88)                                                           | 41.2 (31.00)                                                           |
| Median                                                                 | 30.1                                                                   | 32.8                                                                   | 29.4                                                                   | 32.3                                                                   | 30.7                                                                   |
| Range                                                                  | (9; 160)                                                               | (8; 195)                                                               | (9; 72)                                                                | (8; 195)                                                               | (8; 195)                                                               |
| Baseline Serum Collagen Type 1 Beta Carboxy Telopeptide (ug/L)         | Baseline Serum Collagen Type 1 Beta Carboxy Telopeptide (ug/L)         | Baseline Serum Collagen Type 1 Beta Carboxy Telopeptide (ug/L)         | Baseline Serum Collagen Type 1 Beta Carboxy Telopeptide (ug/L)         | Baseline Serum Collagen Type 1 Beta Carboxy Telopeptide (ug/L)         | Baseline Serum Collagen Type 1 Beta Carboxy Telopeptide (ug/L)         |
| N                                                                      | 69                                                                     | 56                                                                     | 14                                                                     | 70                                                                     | 139                                                                    |
| Mean (SD)                                                              | 7.8 (4.10)                                                             | 8.9 (4.40)                                                             | 9.5 (9.39)                                                             | 9.0 (5.67)                                                             | 8.4 (4.97)                                                             |
| Median                                                                 | 6.5                                                                    | 8.7                                                                    | 7.2                                                                    | 8.2                                                                    | 7.6                                                                    |
| Range                                                                  | (2; 20)                                                                | (2; 24)                                                                | (3; 41)                                                                | (2; 41)                                                                | (2; 41)                                                                |
| Baseline Serum Type I Collagen C-Telopeptides MMP (ug/L)               | Baseline Serum Type I Collagen C-Telopeptides MMP (ug/L)               | Baseline Serum Type I Collagen C-Telopeptides MMP (ug/L)               | Baseline Serum Type I Collagen C-Telopeptides MMP (ug/L)               | Baseline Serum Type I Collagen C-Telopeptides MMP (ug/L)               | Baseline Serum Type I Collagen C-Telopeptides MMP (ug/L)               |
| N                                                                      | 13                                                                     | 8                                                                      | 2                                                                      | 10                                                                     | 23                                                                     |
| Mean (SD)                                                              | 6.8 (3.87)                                                             | 6.0 (4.00)                                                             |                                                                        | 5.6 (3.63)                                                             | 6.3 (3.73)                                                             |
| Median                                                                 | 6.3                                                                    | 5.3                                                                    | 4.1                                                                    | 4.4                                                                    | 5.8                                                                    |
|                                                                        | (1; 14)                                                                | (1; 13)                                                                | (4; 4)                                                                 | (1; 13)                                                                | (1; 14)                                                                |
| N 78 58                                                                | N 78 58                                                                | N 78 58                                                                | N 78 58                                                                | N 78 58                                                                | N 78 58                                                                |
|                                                                        |                                                                        |                                                                        | 4.1 (0.49)                                                             |                                                                        |                                                                        |
| 15 73 151                                                              | 15 73 151                                                              | 15 73 151                                                              | 15 73 151                                                              | 15 73 151                                                              | 15 73 151                                                              |
| Baseline Urine Albumin/Creatinine (mg/g)                               | Baseline Urine Albumin/Creatinine (mg/g)                               | Baseline Urine Albumin/Creatinine (mg/g)                               | Baseline Urine Albumin/Creatinine (mg/g)                               | Baseline Urine Albumin/Creatinine (mg/g)                               | Baseline Urine Albumin/Creatinine (mg/g)                               |
| Range                                                                  |                                                                        |                                                                        |                                                                        |                                                                        |                                                                        |
|                                                                        |                                                                        |                                                                        |                                                                        |                                                                        | 163                                                                    |
|                                                                        |                                                                        |                                                                        |                                                                        |                                                                        | 47.8 (20.66)                                                           |

<div style=\"page-break-after: always\"></div>

| Mean (SD)      | 65.0 (278.31)   | 35.8 (101.29)   | 68.2 (191.34)   | 42.4 (124.16)   | 54.1 (217.46)   |
|----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Median         | 8.8             | 9.1             | 15.0            | 10.0            | 9.0             |
| Range          | (2; 2103)       | (3; 605)        | (4; 757)        | (3; 757)        | (2; 2103)       |
| <30 mg/g       | 66 (84.6%)      | 50 (86.2%)      | 11 (73.3%)      | 61 (83.6%)      | 127 (84.1%)     |
| 30 to 300 mg/g | 10 (12.8%)      | 5 (8.6%)        | 3 (20.0%)       | 8 (11.0%)       | 18 (11.9%)      |
| >300 mg/g      | 2 (2.6%)        | 3 (5.2%)        | 1 (6.7%)        | 4 (5.5%)        | 6 (4.0%)        |

Note: N's for each parameter reflect non-missing values.

As shown in Table 9 below, most of the patients (&gt;70%) in study DIA3018 come from a non-European and non-US-American background.

Table 9: Number of Subjects by Country; Full Analysis Set (Study JNJ28431754-DIA3018)

|                    | Placebo    | Canagliflozin   | Canagliflozin   | Canagliflozin   | Total      |
|--------------------|------------|-----------------|-----------------|-----------------|------------|
| Analysis set: Full |            | 100 mg          | 300 mg          | Combined        |            |
| Analysis           | 87         | 67              | 17              | 84              | 171        |
| Brazil             | 8 (9.2%)   | 3 (4.5%)        | 1 (5.9%)        | 4 (4.8%)        | 12 (7.0%)  |
| China              | 3 (3.4%)   | 1 (1.5%)        | 0               | 1 (1.2%)        | 4 (2.3%)   |
| India              | 3 (3.4%)   | 5 (7.5%)        | 1 (5.9%)        | 6 (7.1%)        | 9 (5.3%)   |
| Malaysia           | 18 (20.7%) | 10 (14.9%)      | 2 (11.8%)       | 12 (14.3%)      | 30 (17.5%) |
| Mexico             | 16 (18.4%) | 14 (20.9%)      | 6 (35.3%)       | 20 (23.8%)      | 36 (21.1%) |
| Philippines        | 11 (12.6%) | 10 (14.9%)      | 2 (11.8%)       | 12 (14.3%)      | 23 (13.5%) |
| Poland             | 3 (3.4%)   | 3 (4.5%)        | 0               | 3 (3.6%)        | 6 (3.5%)   |
| Russian Federation | 3 (3.4%)   | 7 (10.4%)       | 0               | 7 (8.3%)        | 10 (5.8%)  |
| United States      | 22 (25.3%) | 14 (20.9%)      | 5 (29.4%)       | 19 (22.6%)      | 41 (24.0%) |

## Prior and Concomitant Therapies

## Prior Therapies

156 out of 171 participants (91.2%) received one or more prior medications, with comparable number of  participants  across  treatment  groups.  Antihyperglycaemic  therapies  were  used  by  148/171 participants (86.5%), of which, biguanides were used by 129 participants (75.4%). Other drugs used in diabetes  included  fast-acting  (76  participants  [44.4%]),  long-acting  (49  participants  [28.7%]), intermediate-  or  long-acting  combined  with  fast-acting  (11  participants  [6.4%]),  and  intermediateacting (10 participants [5.8%]) insulins and analogues for injection. Other diabetes agents were used by &lt;5% of participants.

## Concomitant Therapies

One or more concomitant medications were administered to 171 participants (97.1%), with comparable number of affected participants across treatment groups.

## Antihyperglycemic drugs ( n=153 [89.5%])

- -Metformin (n=132 [77.2%])
- -Insulins and fast-acting insulin analogues (n=78 [45.6%])
- -Long-acting insulins (n=56 [32.7%])
- -Intermediate- or long-acting combined with fast-acting insulins (n=13 [7.6%])
- -Intermediate-acting insulins (n=12 [7.0%])
- -Other diabetes agents: &lt;5% of participants.

## Other medications:

- -Vitamins (n=50 [29.2%]),
- -Analgesics (n=39 [22.8%])
- -Antibacterials for systemic use (n=38 [22.2%]),

<div style=\"page-break-after: always\"></div>

- -Anti-inflammatory and antirheumatic products (n=28 [16.4%])
- -Antihistamines for systemic use (n=28 [16.4%])
- -Vaccines (n=19 [11.1%])
- -Psychoanaleptics (n=16 [9.4%])
- -Lipid-modifying agents (n=17 [9.9%])
- -Drugs for acid-related disorders (n=15 [8.8%])
- -Nasal preparation (n=11 [6.4%])
- -Agents acting on the renin-angiotensin system (n=13 [7.6%])
- -Cough and cold preparation (n=14 [8.2%])
- -Drugs for obstructive airway diseases (n=13 [7.6%])
- -Sex hormones and modulators of the genital system (n=10 [5.8%])
- -Drugs for functional gastrointestinal disorders (n=10 [5.8%])
- -Other medications were received by &lt;5% of study participants.

## Numbers analysed

The sizes of the analysis sets and the proportions of placebo-and canagliflozin-treated patients were taken from Table 1 above (=Table 2 in the clinical study report)

## · Full analysis set (FAS)

All participants who were randomly assigned to a treatment group, who received at least one dose of study agent and had a baseline HbA1c measurement.

- -171 participants randomized
- -Canagliflozin 100 mg or 300 mg: 84/171 (of the 84 participants on canagliflozin, 33 participants were re-randomized at Week 13 (100 mg canagliflozin: n=16; 300 mg canagliflozin: n=17).
- -placebo: 87/171

## · 26-week per protocol (PP) analysis set

All FAS participants who completed the 26-week double-blind treatment period (i.e., who received study  agent  and  had  non-missing  HbA1c  measurement  at  Week  26)  and  had  no  major  protocol deviations  that  could  affect  the  interpretation  of  the  primary  efficacy  endpoint  (e.g,  initiation  of glycaemic rescue therapy) within the 26-week core double-blind treatment period.

- -137 participants belong to the 26-week PP analysis set
- -Canagliflozin 100 mg or 300 mg: 67/137
- -placebo: 70/137

## · 52-week PP analysis set

All FAS participants who completed the 52-week double-blind treatment period and had no major protocol deviations that could affect the interpretation of the efficacy endpoint (e.g., initiation of glycemic rescue therapy) within the 52 weeks of treatment.

- -129 participants belong to the 52-week PP analysis set
- -Canagliflozin: 65/129
- -placebo: 64/129

For further information, see above, section on Participant flow/study disposition.

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

## Primary efficacy endpoint

Canagliflozin  caused  a  statistically  significant  improvement  with  respect  to  change  from  baseline  in HbA1c at Week 26 compared to placebo (LS means difference = -0.76% [SE: 0.249; 95% CI: -1.25, 0.27; p=0.002]) - see Table 10 below.

Table  10: Primary  analysis  of  the  primary  efficacy  endpoint  (primary  estimand,  treatment  policy strategy): change from baseline in HbA1c (%) at Week 26 using pattern mixture model - all subjects; FAS (Study JNJ-28431754DIA3018)

|                                                                                                                | Placebo (N=87)   | Cana (N=84)    |
|----------------------------------------------------------------------------------------------------------------|------------------|----------------|
| Observed Value at Baseline                                                                                     |                  |                |
| N                                                                                                              | 87               | 84             |
| Mean (SD)                                                                                                      | 8.3 (1.35)       | 7.8 (1.31)     |
| Observed Value at Week 26                                                                                      |                  |                |
| N                                                                                                              | 80               | 77             |
| Mean (SD)                                                                                                      | 8.6 (2.01)       | 7.3 (1.78)     |
| Change from Baseline at Week 26                                                                                |                  |                |
| N                                                                                                              | 80               | 77             |
| Mean (SD)                                                                                                      | 0.3 (1.56)       | -0.4 (1.44)    |
| Subjects with intercurrent events                                                                              | 30               | 10             |
| Subjects discontinued treatment prior to Week 26                                                               | 9                | 5              |
| Subjects received rescue medication prior toWeek 26                                                            | 24               | 5              |
| Summary of results at Week 26 applying Rubin's rules to combine the ANCOVA results across the imputed datasets |                  |                |
| based on pattern mixture modela                                                                                |                  |                |
| LS Mean (SE)                                                                                                   | 0.39 (0.191)     | -0.37 (0.194)  |
| Difference [Cana-Placebo] in LS Means (SE)                                                                     |                  | -0.76 (0.249)  |
| 95% CI                                                                                                         |                  | (-1.25, -0.27) |
| p-value                                                                                                        |                  | 0.002          |

a: Imputed datasets are analyzed using analysis of covariance (ANCOVA) with terms for treatment, stratification factors (AHA background and age group), and baseline HbAlc.

A subject is considered to have received rescue medication prior to Week 26 if the day of initiation of the medication is prior to the lower limit of Week 26 Analysis Visit window (Day 163 to 211). Same rule applies for subjects who discontinued treatment prior to Week 26.

]

## Secondary analysis of primary efficacy endpoint on background metformin

Canagliflozin caused a statistically significant improvement in change from baseline in HbA1c at Week 26 compared to placebo in participants on background metformin (with or without insulin; LS means difference = -0.77% [SE: 0.308; 95% CI: -1.38, -0.17; p=0.012]) - see Table 11 below.

<div style=\"page-break-after: always\"></div>

Table 11: Secondary Analysis of  the  primary  efficacy  endpoint  (primary  estimand,  treatment  policy strategy): change from baseline in HbA1c (%) at Week 26 using pattern mixture model - subjects on background metformin (with or without insulin); FAS (Study JNJ-28431754DIA3018)

|                                                                                                            | Placebo (N=67)   | Cana (N=62)    |
|------------------------------------------------------------------------------------------------------------|------------------|----------------|
| ObservedValue atBaseline                                                                                   |                  |                |
| N                                                                                                          | 67               | 62             |
| Mean (SD)                                                                                                  | 8.4 (1.37)       | 7.8 (1.37)     |
| ObservedValue atWeek 26                                                                                    |                  |                |
| N                                                                                                          | 62               | 56             |
| Mean (SD)                                                                                                  | 8.7 (2.10)       | 7.4 (1.82)     |
| Change from Baseline at Week 26                                                                            |                  |                |
| N                                                                                                          | 62               | 56             |
| Mean (SD)                                                                                                  | 0.3 (1.63)       | -0.4 (1.50)    |
|                                                                                                            |                  | 7              |
| Subjects with intercurrent events                                                                          | 26               |                |
| Subjectsdiscontinued treatmentpriortoWeek26                                                                | 8                | 4              |
| SubjectsreceivedrescuemedicationpriortoWeek26                                                              | 20               | 3              |
| Summary of results at Week 26 applying Rubin's rules to combine theANCOVAresults acrosstheimputed datasets |                  |                |
| based on patternmixture modela                                                                             |                  |                |
| LS Mean (SE)                                                                                               | 0.46 (0.221)     | -0.32 (0.220)  |
| Difference [Cana-Placebo] in LS Means (SE)                                                                 |                  | -0.77 (0.308)  |
| 95% CI                                                                                                     |                  | (-1.38, -0.17) |
| p-value                                                                                                    |                  | 0.012          |

a: Imputed datasets are analyzed using analysis of covariance (ANCOVA) with terms for treatment, stratification factors (AHA background and age group), and baseline HbA1c.

Asubject is considered tohavereceivedrescuemedicationprior toWeek26if thedayofinitiationofthemedication isprior to the lower limit of Week 26 Analysis Visit window (Day 163 to 211). Same rule applies for subjects who discontinued treatment prior to Week 26.

[tefa1c03m.itf] [PROD/jnj-28431754b/dia3018/dbr\\_final\\_re2/re\\_csr/tefa1c03m.sas] 28DEC2023, 17:43

## Secondary efficacy endpoints

## Change from Baseline in FPG (LOCF)

The LS mean change in FPG from baseline was significantly greater in the canagliflozin group than in the placebo group at both Week 26 and Week 52 - see Table 12 below

Table 12: Change from Baseline in FPG (Conventional Unit; mg/dL) at Week 26 and 52 - LOCF; Full Analysis Set (Study JNJ28431754-DIA3018)

|                                                                                                                                                                                                                                                                              | Placebo (N=87)                                                                                                                                                                                                                                                               | Placebo (N=87)                                                                                                                                                                                                                                                               | Cana (N=84)                                                                                                                                                                                                                                                                  | Cana (N=84)                                                                                                                                                                                                                                                                  | Difference (Cana-Placebo)                                                                                                                                                                                                                                                    | Difference (Cana-Placebo)                                                                                                                                                                                                                                                    | Difference (Cana-Placebo)                                                                                                                                                                                                                                                    |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                              | N a                                                                                                                                                                                                                                                                          | LS Mean (SE)                                                                                                                                                                                                                                                                 | N a                                                                                                                                                                                                                                                                          | LS Mean (SE)                                                                                                                                                                                                                                                                 | LS Mean (SE)                                                                                                                                                                                                                                                                 | CI b                                                                                                                                                                                                                                                                         | p-value b                                                                                                                                                                                                                                                                    |
| Week 26 (LOCF)                                                                                                                                                                                                                                                               | 82                                                                                                                                                                                                                                                                           | 15.3 (6.68)                                                                                                                                                                                                                                                                  | 76                                                                                                                                                                                                                                                                           | -11.5 (6.86)                                                                                                                                                                                                                                                                 | -26.9 (8.84)                                                                                                                                                                                                                                                                 | (-44.3, -9.4)                                                                                                                                                                                                                                                                | 0.003                                                                                                                                                                                                                                                                        |
| Week 52 (LOCF)                                                                                                                                                                                                                                                               | 83                                                                                                                                                                                                                                                                           | 19.2 (6.90)                                                                                                                                                                                                                                                                  | 79                                                                                                                                                                                                                                                                           | -16.4 (6.98)                                                                                                                                                                                                                                                                 | -35.6 (9.05)                                                                                                                                                                                                                                                                 | (-53.5, -17.8)                                                                                                                                                                                                                                                               | <0.001                                                                                                                                                                                                                                                                       |
| a: Number of subjects with non-missing value of change from baseline. b: CI (confidence interval) and p-value are based on ANCOVA model with treatment and the stratification factors (AHA background and age group) as fixed effects and baseline FPG value as a covariate. | a: Number of subjects with non-missing value of change from baseline. b: CI (confidence interval) and p-value are based on ANCOVA model with treatment and the stratification factors (AHA background and age group) as fixed effects and baseline FPG value as a covariate. | a: Number of subjects with non-missing value of change from baseline. b: CI (confidence interval) and p-value are based on ANCOVA model with treatment and the stratification factors (AHA background and age group) as fixed effects and baseline FPG value as a covariate. | a: Number of subjects with non-missing value of change from baseline. b: CI (confidence interval) and p-value are based on ANCOVA model with treatment and the stratification factors (AHA background and age group) as fixed effects and baseline FPG value as a covariate. | a: Number of subjects with non-missing value of change from baseline. b: CI (confidence interval) and p-value are based on ANCOVA model with treatment and the stratification factors (AHA background and age group) as fixed effects and baseline FPG value as a covariate. | a: Number of subjects with non-missing value of change from baseline. b: CI (confidence interval) and p-value are based on ANCOVA model with treatment and the stratification factors (AHA background and age group) as fixed effects and baseline FPG value as a covariate. | a: Number of subjects with non-missing value of change from baseline. b: CI (confidence interval) and p-value are based on ANCOVA model with treatment and the stratification factors (AHA background and age group) as fixed effects and baseline FPG value as a covariate. | a: Number of subjects with non-missing value of change from baseline. b: CI (confidence interval) and p-value are based on ANCOVA model with treatment and the stratification factors (AHA background and age group) as fixed effects and baseline FPG value as a covariate. |

## Proportion of Participants with HbA1c &lt;7.5%, &lt;7.0%, and &lt;6.5%

## HbA1c &lt;6.5 %:

- -Week 26: 11.3% on placebo and 41.6% on canagliflozin achieved an HbA1c &lt;6.5% (OR [cana vs plc] = 4.81; [95% CI: 1.59, 14.62]; p=0.006).

<div style=\"page-break-after: always\"></div>

- -Week 52: 12 % on placebo and 36.6% on canagliflozin achieved an HbA1c &lt;6.5% (OR = 2.46 [cana vs plc; 95% CI: 0.91, 6.65]; p=0.077).

## HbA1c &lt;7 %:

- -Week 26: slightly more than a quarter of the participants on placebo and more than half of the participants on canagliflozin achieved an HbA1c of &lt;7% (OR = 2.22; [95% CI: 0.74, 6.66]; p=0.153).
- -Week 52: slightly less than a quarter of participants on placebo and more than half on canagliflozin achieved &lt;7% HbA1c (OR = 3.04 [95% CI: 1.07, 8.60]; p=0.037).

## HbA1c &lt; 7.5 %:

- -Week 26: about 40% of participants on placebo and 65% on canagliflozin achieved an HbA1c reduction of &lt;7.5% (OR = 2.26 [95% CI: 0.86, 5.96] p=0.099).
- -Week 52: about 29.3% of participants on placebo and 69% on canagliflozin achieved an HbA1c reduction of &lt;7.5% (OR = 4.96 [95% C1: 1.65, 14.86]; p=0.004).

See also Table 13 below.

Table 13: Proportion of subjects with HbA1c (%) &lt;7.5%, &lt;7% or &lt;6.5% at Week 52; FAS (Study JNJ28431754-DIA3018)

| Category   | Placebo (N=87)   | Placebo (N=87)   | Cana (N=84)   | Cana (N=84)   | Cana vs Placebo   | Cana vs Placebo   | Cana vs Placebo   |
|------------|------------------|------------------|---------------|---------------|-------------------|-------------------|-------------------|
| Category   | N                | %                | N             | %             | Odds Ratio        | 95% CI            | p-value           |
| Week 26    | Week 26          | Week 26          | Week 26       | Week 26       | Week 26           | Week 26           | Week 26           |
| <7.5%      | 32               | 40.0             | 50            | 64.9          |                   |                   |                   |
| ≥7.5%      | 48               | 60.0             | 27            | 35.1          |                   |                   |                   |
| Total      | 80               | 100              | 77            | 100           | 2.26              | (0.86, 5.96)      | 0.099             |
| <7%        | 22               | 27.5             | 40            | 51.9          |                   |                   |                   |
| ≥7%        | 58               | 72.5             | 37            | 48.1          |                   |                   |                   |
| Total      | 80               | 100              | 77            | 100           | 2.22              | (0.74, 6.66)      | 0.153             |
| <6.5%      | 9                | 11.3             | 32            | 41.6          |                   |                   |                   |
| ≥6.5%      | 71               | 88.8             | 45            | 58.4          |                   |                   |                   |
| Total      | 80               | 100              | 77            | 100           | 4.81              | (1.59, 14.62)     | 0.006             |
| Week 52    | Week 52          | Week 52          | Week 52       | Week 52       | Week 52           | Week 52           | Week 52           |
| <7.5%      | 22               | 29.3             | 49            | 69.0          |                   |                   |                   |
| ≥7.5%      | 53               | 70.7             | 22            | 31.0          |                   |                   |                   |
| Total      | 75               | 100              | 71            | 100           | 4.96              | (1.65, 14.86)     | 0.004             |
| <7%        | 17               | 22.7             | 39            | 54.9          |                   |                   |                   |
| ≥7%        | 58               | 77.3             | 32            | 45.1          |                   |                   |                   |
| Total      | 75               | 100              | 71            | 100           | 3.04              | (1.07, 8.60)      | 0.037             |
| <6.5%      | 9                | 12.0             | 26            | 36.6          |                   |                   |                   |
| ≥6.5%      | 66               | 88.0             | 45            | 63.4          |                   |                   |                   |
| Total      | 75               | 100              | 71            | 100           | 2.46              | (0.91, 6.65)      | 0.077             |

Note: Odds ratios are based on the generalized linear mixed model for repeated measures including the fixed categorical effects of treatment, stratification factors (ie, background AHA and age group), visit, treatment-by-visit interaction, baseline value and baseline-by-visit interaction, and subject as a random effect.  A  compound  symmetry  covariance  was  used  since  the  model  did  not  converge  using  the unstructured covariance.

## Time to Rescue and Proportion of Participants Receiving Rescue Therapy

Fewer participants on canagliflozin (10/84 [11.9%]) received rescue medications as compared to placebo (40/87  [46.0%]).  Participants  treated  with  canagliflozin  had  a  longer  time  to  rescue  and  a  smaller proportion of participants received rescue therapy compared to placebo - see Figure 2 below:

<div style=\"page-break-after: always\"></div>

Figure 2: Time to Rescue Medication Initiated; Full Analysis Set (Study JNJ28431754-DIA3018)

<!-- image -->

## Percent Change from Baseline in Body Weight (LOCF)

At Week 26, body weight decreased with canagliflozin (LS mean: -1.6 [SE: 0.51]), but did not change with  placebo  (LS  mean:  0.0,  [SE:  0.51]).  The  difference  in  LS  means  was  statistically  significant (difference in LS means: -1.6 [SE: 0.66; 95% CI: -2.9, -0.3]; p=0.019).

At Week 52, body weight also decreased with canagliflozin, when compared to placebo (LS mean: -0.5 [SE: 0.69], but the difference in LS means was not statistically significant (difference in LS means: -0.9 [SE: 0.90; 95% CI: -2.7, 0.8]; p=0.293) - see Table 14 below.

Table 14: % Change from Baseline in Body Weight at Week 26 and 52 - LOCF; Full Analysis Set (Study JNJ28431754-DIA3018)

|                | Placebo (N=87)   | Placebo (N=87)   | Cana (N=84)   | Cana (N=84)   | Difference (Cana-Placebo)   | Difference (Cana-Placebo)   | Difference (Cana-Placebo)   |
|----------------|------------------|------------------|---------------|---------------|-----------------------------|-----------------------------|-----------------------------|
|                | N a              | LS Mean (SE)     | N a           | LS Mean (SE)  | LS Mean (SE)                | CI b                        | p-value b                   |
| Week 26 (LOCF) | 85               | -0.0 (0.51)      | 84            | -1.6 (0.51)   | -1.6 (0.66)                 | (-2.9, -0.3)                | 0.019                       |
| Week 52 (LOCF) | 85               | 0.4 (0.69)       | 84            | -0.5 (0.69)   | -0.9 (0.90)                 | (-2.7, 0.8)                 | 0.293                       |

a: Number of subjects with non-missing value of change from baseline.

b: CI (confidence interval) and p-value are based on ANCOVA model with treatment and the stratification factors (AHA background and age group) as fixed effects and baseline body weight value as a covariate.

An  analysis  of  weight  loss  over  time  (data  not  shown  here)  indicates  that  the  weight  loss  in  the canagliflozin group was observed from Week 6 and continued gradually to Week 26, after which the weight loss was attenuated until Week 52 (-0.5 kg in the canagliflozin group in weeks 34, 42 and 52). The  differences  in  change  in  weight  at  each  time  point  between  canagliflozin  and  placebo  were statistically  significant  up  to  Week  26.  In  the  placebo  group,  the  weight  gain  continued  over  time throughout the study.

## Change from Baseline in BMI at Week 26 and Week 52 (LOCF approach)

<div style=\"page-break-after: always\"></div>

At week 26, a reduction from baseline in BMI was observed both on placebo (LS mean -0.4 [SE=0.15]) and on canagliflozin (LS mean -0.8 [SE: 0.15]). Although the drop in BMI was more pronounced with canagliflozin, the difference in LS means was not statistically significant (difference in LS means: -0.4 [SE: 0.20; 95% CI: -0.8, 0.0]; p=0.068). Comparable results were observed at Week 52 - see Table 15 below.

Table 15: Change from baseline in BMI (kg/m 2 ) at Week 26 - LOCF; FAS (Study JNJ28431754-DIA3018)

|                | Placebo (N=87)   | Placebo (N=87)   | Cana (N=84)   | Cana (N=84)   | Difference (Cana-Placebo)   | Difference (Cana-Placebo)   | Difference (Cana-Placebo)   |
|----------------|------------------|------------------|---------------|---------------|-----------------------------|-----------------------------|-----------------------------|
|                | N a              | LS Mean (SE)     | N a           | LS Mean (SE)  | LS Mean (SE)                | CI b                        | p-value b                   |
| Week 26 (LOCF) | 85               | -0.4 (0.15)      | 84            | -0.8 (0.15)   | -0.4 (0.20)                 | (-0.8, 0.0)                 | 0.068                       |
| Week 52 (LOCF) | 85               | -0.5 (0.19)      | 84            | -0.7 (0.19)   | -0.2 (0.25)                 | (-0.7, 0.3)                 | 0.352                       |

a: Number of subjects with non-missing value of change from baseline.

b: CI (confidence interval) and p-value are based on ANCOVA model with treatment and the stratification factors (AHA background and age group) as fixed effects and baseline body mass index value as a covariate.

## Percent Change from Baseline Fasting Plasma Lipids (LOCF)

## Week 26:

Analysis of the percent change from baseline showed an increase in HDL-C, total cholesterol, LDL-C, and non-HDL-C in the patients treated with canagliflozin. The changes from baseline in LDL-C/HDL-C and non-HDL-C/LDL-C ratios were slightly higher on canagliflozin as compared to the placebo group.

## Week 52:

LS mean in HDL-C increased clinically significantly on canagliflozin as compared to the placebo group (LS mean difference of 6.9 (SE=3.33), p=0.039). No difference or only minimal difference in LS mean change from baseline was observed in total cholesterol, LDL-C, non-HDL-C at Week 52.

The change from baseline in the LDL-C/HDL-C ratio was lower at week 52 in the canagliflozin group (LS mean=4.2 [SE=4.95] as compared to placebo (LS mean=10.4 [SE=5.07]), but the difference was not statistically significant.

Mean and median triglyceride levels at baseline were higher in the canagliflozin group as compared to placebo. At week 26 and 52, the mean and median decreased on canagliflozin while it increased in the placebo group.

To keep the assessment report short, Table 16 only shows results for week 26 and 52, calculated with LOCF approach.

Table 16: Percent change from baseline for various lipid parameters at Week 26 and 52 - LOCF; Full Analysis Set (Study JNJ28431754-DIA3018)

|                   | Placebo (N=87)    | Placebo (N=87)    | Cana (N=84)       | Cana (N=84)       | Difference (Cana-Placebo)   | Difference (Cana-Placebo)   | Difference (Cana-Placebo)   |
|-------------------|-------------------|-------------------|-------------------|-------------------|-----------------------------|-----------------------------|-----------------------------|
|                   | N a               | LS Mean (SE)      | N a               | LS Mean (SE)      | LS Mean (SE)                | CI b                        | p-value b                   |
| Total cholesterol | Total cholesterol | Total cholesterol | Total cholesterol | Total cholesterol | Total cholesterol           | Total cholesterol           | Total cholesterol           |
| Week 26           | 76                | 1.2 (2.22)        | 72                | 8.2 (2.22)        | 6.9 (2.88)                  | (1.2, 12.6)                 | 0.017                       |
| Week 52           | 78                | 5.6 (2.16)        | 76                | 5.1 (2.13)        | -0.6 (2.77)                 | (-6.0, 4.9)                 | 0.838                       |
| LDL-C             | LDL-C             | LDL-C             | LDL-C             | LDL-C             | LDL-C                       | LDL-C                       | LDL-C                       |
| Week 26           | 67                | 3.3 (3.73)        | 67                | 12.4 (3.58)       | 9.1 (4.77)                  | (-0.3, 18.6)                | 0.057                       |
| Week 52           | 72                | 7.5 (3.57)        | 74                | 8.3 (3.44)        | 0.8 (4.54)                  | (-8.2, 9.8)                 | 0.864                       |
| HDL-C             | HDL-C             | HDL-C             | HDL-C             | HDL-C             | HDL-C                       | HDL-C                       | HDL-C                       |
| Week 26           | 68                | 1.5 (2.40)        | 68                | 6.4 (2.33)        | 4.9 (3.10)                  | (-1.3, 11.0)                | 0.120                       |
| Week 52           | 73                | 1.0 (2.58)        | 74                | 7.9 (2.52)        | 6.9 (3.33)                  | (0.3, 13.5)                 | 0.039                       |
| Non-HDL-C         | Non-HDL-C         | Non-HDL-C         | Non-HDL-C         | Non-HDL-C         | Non-HDL-C                   | Non-HDL-C                   | Non-HDL-C                   |
| Week 26           | 66                | 1.7 (2.69)        | 66                | 6.8 (2.62)        | 5.2 (3.46)                  | (-1.7, 12.0)                | 0.139                       |
| Week 52           | 71                | 7.7 (3.02)        | 74                | 5.0 (2.95)        | -2.7 (3.87)                 | (-10.4, 4.9)                | 0.484                       |
| LDL-C/HDL-C       | LDL-C/HDL-C       | LDL-C/HDL-C       | LDL-C/HDL-C       | LDL-C/HDL-C       | LDL-C/HDL-C                 | LDL-C/HDL-C                 | LDL-C/HDL-C                 |

<div style=\"page-break-after: always\"></div>

| Week 26         | 66              | 6.0 (4.77)      | 66              | 8.3 (4.66)      | 2.3 (6.14)      | (-9.9, 14.4)    | 0.710           |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Week 52         | 71              | 10.4 (5.07)     | 74              | 4.2 (4.95)      | -6.1 (6.49)     | (-19.0, 6.7)    | 0.347           |
| non-HDL-C/LDL-C | non-HDL-C/LDL-C | non-HDL-C/LDL-C | non-HDL-C/LDL-C | non-HDL-C/LDL-C | non-HDL-C/LDL-C | non-HDL-C/LDL-C | non-HDL-C/LDL-C |
| Week 26         | 63              | 0.5 (4.05)      | 60              | 2.4 (4.03)      | 1.8 (5.31)      | (-8.7, 12.3)    | 0.732           |
| Week 52         | 68              | -1.5 (3.20)     | 69              | 4.0 (3.13)      | 5.5 (4.16)      | (-2.7, 13.7)    | 0.189           |
| Triglycerides   | Triglycerides   | Triglycerides   | Triglycerides   | Triglycerides   | Triglycerides   | Triglycerides   | Triglycerides   |
| Week 26         | 76              | 8.6 (6.32)      | 72              | 4.5 (6.28)      | -4.1 (8.23)     | (-20.4, 12.1)   | 0.617           |
| Week 52         | 78              | 18.2 (7.17)     | 76              | 3.4 (7.05)      | -14.9 (9.23)    | (-33.1, 3.3)    | 0.109           |

- a: Number of subjects with non-missing value of change from baseline.

b: CI (confidence interval) and p-value are based on ANCOVA model with treatment and the stratification factors (AHA background and age group) as fixed effects and corresponding baseline lipid parameter value as a covariate.

## Change from Baseline in SBP and DBP

There were no meaningful changes in SBP or DBP with canagliflozin compared to placebo at week 26 or week 52. Please see tabular results for SBP and DBP below. For the sake of brevity, only the LS mean differences  with  CIs  and  p-values  are  shown  in  Table  17  below  but  not  mean/median  change  from baseline and range.

Table 17: Change from Baseline in Systolic and Diastolic Blood Pressure at Week 26 and 52 - LOCF; Full Analysis Set (Study JNJ28431754-DIA3018)

|         | Placebo (N=87)   | Placebo (N=87)   | Cana (N=84)   | Cana (N=84)   | Difference (Cana-Placebo)   | Difference (Cana-Placebo)   | Difference (Cana-Placebo)   |
|---------|------------------|------------------|---------------|---------------|-----------------------------|-----------------------------|-----------------------------|
|         | N a              | LS Mean (SE)     | N a           | LS Mean (SE)  | LS Mean (SE)                | CI b                        | p-value b                   |
| SBP     | SBP              | SBP              | SBP           | SBP           | SBP                         | SBP                         | SBP                         |
| Week 26 | 81               | 1.3 (1.09)       | 80            | 0.6 (1.08)    | -0.7 (1.40)                 | (-3.4, 2.1)                 | 0.632                       |
| Week 52 | 75               | 1.3 (1.12)       | 74            | 0.2 (1.12)    | -1.1 (1.45)                 | (-4.0, 1.8)                 | 0.449                       |
| DBP     | DBP              | DBP              | DBP           | DBP           | DBP                         | DBP                         | DBP                         |
| Week 26 | 81               | -0.4 (0.83)      | 80            | -0.3 (0.83)   | 0.2 (1.08)                  | (-2.0, 2.3)                 | 0.878                       |
| Week 52 | 75               | 0.6 (0.88)       | 74            | 0.2 (0.89)    | -0.5 (1.15)                 | (-2.7, 1.8)                 | 0.685                       |

a: Number of subjects with non-missing value of change from baseline.

b: CI (confidence interval) and p-value are based on ANCOVA model with treatment and the stratification factors (AHA background and age group) as fixed effects and baseline systolic or diastolic blood pressure value as a covariate.

## Change from Baseline in HbA1c at Week 12 and Week 52

At week 12, canagliflozin caused a statistically significant HbA1c reduction from baseline compared to placebo, which was sustained through Week 52 - see Table 18 below, grey shaded lines.

Table 18: Mean and LS mean change from baseline in HbA1c (%) over time (up to Week 12) using mixed model for repeated measures (MMRM) - all subjects; FAS (Study JNJ28431754-DIA3018)

|         | Placebo (N=87)   | Placebo (N=87)   | Cana (N=84)   | Cana (N=84)   | Difference (Cana-Placebo)   | Difference (Cana-Placebo)   | Difference (Cana-Placebo)   |
|---------|------------------|------------------|---------------|---------------|-----------------------------|-----------------------------|-----------------------------|
|         | N a              | LS Mean (SE)     | N a           | LS Mean (SE)  | LS Mean (SE)                | CI b                        | p-value b                   |
| Week 6  | 83               | -0.08 (0.098)    | 84            | -0.67 (0.098) | -0.59 (0.129)               | (-0.85, -0.34)              | <0.001                      |
| Week 12 | 83               | 0.09 (0.137)     | 84            | -0.58 (0.137) | -0.67 (0.187)               | (-1.05, -0.30)              | <0.001                      |
| Week 20 | 78               | 0.26 (0.158)     | 76            | -0.43 (0.159) | -0.69 (0.220)               | (-1.13, -0.26)              | 0.002                       |
| Week 26 | 80               | 0.32 (0.168)     | 77            | -0.41 (0.169) | -0.73 (0.234)               | (-1.20, -0.27)              | 0.002                       |
| Week 34 | 73               | 0.28 (0.171)     | 76            | -0.15 (0.170) | -0.43 (0.238)               | (-0.90, 0.04)               | 0.072                       |
| Week 42 | 73               | 0.41 (0.165)     | 75            | -0.23 (0.164) | -0.65 (0.229)               | (-1.10, -0.19)              | 0.005                       |
| Week 52 | 75               | 0.70 (0.182)     | 71            | -0.32 (0.184) | -1.02 (0.256)               | (-1.52, -0.51)              | <0.001                      |

- a: Number of subjects with non-missing value of change from baseline.

b: CIs (confidence interval) and p-values are based on a mixed model for repeated measures including the fixed effects of treatment, stratification factors (i.e., background AHA and age group), visit, and treatment-by-visit interaction, as well as the fixed, continuous covariates of baseline and baseline-by-visit interaction. An unstructured covariance is used to model the within-patient errors.

## Other efficacy analyses

Change from baseline in HbA1c at week 26 between canagliflozin 100 mg and placebo.

<div style=\"page-break-after: always\"></div>

Participants on 100 mg of canagliflozin who remained at the same dose at week 12 re-randomization showed a statistically significant improvement in HbA1c at Week 26 compared to placebo (LS means difference of-0.58 [SE: 0.250; 95% CI -1.08, -0.09]; p=0.02; see Table 19 below).

Table 19: Change from Baseline in HbA1c (%) at Week 26 between canagliflozin 100 mg and placebo using MMRM; FAS (Study JNJ28431754- DIA3018)

|         | Placebo (N=87)   | Placebo (N=87)   | Cana (N=84)   | Cana (N=84)   | Difference (Cana-Placebo)   | Difference (Cana-Placebo)   | Difference (Cana-Placebo)   |
|---------|------------------|------------------|---------------|---------------|-----------------------------|-----------------------------|-----------------------------|
|         | N a              | LS Mean (SE)     | N a           | LS Mean (SE)  | LS Mean (SE)                | CI b                        | p-value b                   |
| Week 6  | 83               | -0.05 (0.099)    | 84            | -0.62 (0.097) | -0.57 (0.129)               | (-0.83, -0.32)              | <.001                       |
| Week 12 | 83               | 0.12 (0.138)     | 84            | -0.52 (0.135) | -0.64 (0.187)               | (-1.01, -0.27)              | <.001                       |
| Week 20 | 78               | 0.29 (0.161)     | 76            | -0.29 (0.151) | -0.58 (0.216)               | (-1.01, -0.15)              | 0.008                       |
| Week 26 | 80               | 0.34 (0.184)     | 77            | -0.25 (0.173) | -0.58 (0.250)               | (-1.08, -0.09)              | 0.020                       |

a : Number of subjects with non-missing value of change from baseline.

b : CIs (confidence interval) and p-values are based on a mixed model for repeated measures including the fixed effects of treatment, stratification factors (i.e., background AHA and age group), visit, and treatment-by-visit interaction, as well as the fixed, continuous covariates of baseline and baseline-by-visit interaction. An unstructured covariance is used to model the within-patient errors.

Comparison of canagliflozin (100 mg with no dose increase after week12) to placebo is made by using the weights in the analysis as follows: All subjects start with a weight of 1. After Week 12, subjects who are re-randomized to continue canagliflozin 100 mg will have a weight of 2. The subjects who are re-randomized to up-titrate to canagliflozin 300 mg will have a weight of 0.

## Change from baseline in HbA1c at week 26 between canagliflozin 100 mg followed by a dose increase to 300 mg and placebo.

Participants who started on 100 mg and were re-randomized at Week 12 to 300 mg of canagliflozin showed a statistically significant improvement in HbA1c at Week 26 compared to placebo (LS means difference of-0.74, [SE: 0.237; 95% CI: -1.21, -0.28]; p=0.002; see Table 20 below).

Table 20 :  Change from baseline in HbA1c (%) at Week 26 between canagliflozin 100 mg followed by a dose increase to 300 mg and placebo using MMRM; FAS (Study JNJ28431754-DIA3018)

|         | Placebo (N=87)   | Placebo (N=87)   | Cana (N=84)   | Cana (N=84)   | Difference (Cana-Placebo)   | Difference (Cana-Placebo)   | Difference (Cana-Placebo)   |
|---------|------------------|------------------|---------------|---------------|-----------------------------|-----------------------------|-----------------------------|
|         | N a              | LS Mean (SE)     | N a           | LS Mean (SE)  | LS Mean (SE)                | CI b                        | p-value b                   |
| Week 6  | 83               | -0.07 (0.099)    | 84            | -0.65 (0.098) | -0.59 (0.129)               | (-0.84, -0.33)              | <.001                       |
| Week 12 | 83               | 0.10 (0.137)     | 84            | -0.55 (0.135) | -0.65 (0.186)               | (-1.02, -0.28)              | <.001                       |
| Week 20 | 78               | 0.29 (0.184)     | 76            | -0.33 (0.171) | -0.62 (0.246)               | (-1.11, -0.14)              | 0.012                       |
| Week 26 | 80               | 0.33 (0.175)     | 77            | -0.41 (0.167) | -0.74 (0.237)               | (-1.21, -0.28)              | 0.002                       |

- a : Number of subjects with non-missing value of change from baseline.

b : CIs (confidence interval) and p-values are based on a mixed model for repeated measures including the fixed effects of treatment, stratification factors (i.e., background AHA and age group), visit, and treatment-by-visit interaction, as well as the fixed, continuous covariates of baseline and baseline-by-visit interaction. An unstructured covariance is used to model the within-patient errors.

Comparison of canagliflozin (100 mg up-titrate to 300 mg after week 12) to placebo is made by using the weights in the analysis as follows: All subjects start with a weight of 1. After Week 12, subjects who are re-randomized to continue canagliflozin 100 mg will have a weight of 0 and those who are re-randomized to up-titrate to canagliflozin 300 mg will have a weight of 2.

## Ancillary analyses

## Subgroup analyses for the primary efficacy endpoint

In order to assess the interaction of the treatment effect with each of the subgroups, the p-value for the interaction was also assessed based on the same PMM (pattern mixture model) methodology used for the  primary  analysis  of  the  primary  efficacy  endpoint.  Additionally,  treatment  effects  for  each  level (category) within each of the subgroups were estimated using the same ANCOVA model containing the treatment by subgroup interaction term. The results of PMM-based analyses for each of subgroup are described below.

Treatment by Background AHA

<div style=\"page-break-after: always\"></div>

The treatment by background AHA interaction effect was not significant (p-value=0.29). The change from baseline in HbA1c for canagliflozin was consistently better as compared to placebo, as indicated by differences  in  LS  means  (-0.46,  -0.96,  -0.88,  and  -0.65  for  the  diet  and  exercise  only,  insulin monotherapy, metformin and insulin, and metformin monotherapy subgroups, respectively), although not statistically significant due to increased standard error/smaller sample size. For the sake of brevity, the detailed tabular representation is omitted in this AR.

## Treatment by Age Group

The p-value for the treatment by age group interaction was not statistically significant (p-value=0.463). While there was an improvement in HbA1c as observed by the change from baseline with canagliflozin when compared to placebo in both categories of the age group, the improvement in the ≥ 15 to &lt;18year-old  age  group  was  statistically  significant  (LS  means  difference  =  -1.05  [SE:  0.351],  pvalue=0.003) (see Table 21 below).

Table 21: Change from baseline in HbA1c(%) at Week 26 - age subgroup analysis based on pattern mixture model; FAS (Study JNJ28431754-DIA3018)

|                                                                                         | Placebo (N=87)   | Cana (N=84)    |
|-----------------------------------------------------------------------------------------|------------------|----------------|
| Treatment-by-Age group interaction p-value applying Rubin's                             |                  |                |
| Rulea                                                                                   |                  | 0.463          |
| Summary ofresults for each subgroup level ofAge group at Week 26 applying Rubin's Rulea |                  |                |
| >=10T0<15YEARSOLD                                                                       |                  |                |
| ObservedValue atBaseline                                                                |                  |                |
| N                                                                                       | 42               | 39             |
| Mean (SD)                                                                               | 8.1 (1.45)       | 7.8 (1.18)     |
| Change from Baseline at Week 26                                                         |                  |                |
| LS Mean (SE)                                                                            | 0.23 (0.257)     | -0.21 (0.252)  |
| Diff. (Cana - Placebo) of LS Means (SE)                                                 |                  | -0.45 (0.360)  |
| p-valuea                                                                                |                  | 0.212          |
| 95% CI                                                                                  |                  | (-1.16, 0.26)  |
| >=15T0<18YEARSOLD                                                                       |                  |                |
| ObservedValueatBaseline                                                                 |                  |                |
| N                                                                                       | 45               | 45             |
| Mean (SD)                                                                               | 8.5 (1.23)       | 7.8 (1.42)     |
| Change fromBaseline at Week 26                                                          |                  |                |
| LS Mean (SE)                                                                            | 0.49 (0.242)     | -0.56 (0.245)  |
| Diff. (Cana -Placebo) of LS Means (SE)                                                  |                  | -1.05 (0.351)  |
| p-valuea                                                                                |                  | 0.003          |
| 95% CI                                                                                  |                  | (-1.74, -0.36) |

## Treatment by Sex

The treatment by sex interaction effect was not statistically significant (p-value=0.944). There was an improvement in HbA1c (change from baseline cana vs. placebo) in both females and males, but only the effect in females was statistically significant (difference in LS means= -0.90 [SE: 0.308], p-value=0.004) (see Table 22 below).

Table 22: Change from baseline in HbA1c (%) at Week 26 - sex subgroup analysis based on pattern mixture model; FAS (Study JNJ28431754-DIA3018)

<div style=\"page-break-after: always\"></div>

|                                                                          | Placebo (N=87)   | Cana (N=84)   |
|--------------------------------------------------------------------------|------------------|---------------|
| Treatment-by-Sex interaction p-value applying Rubin's Rulea              |                  | 0.944         |
| SummaryofresultsforeachsubgrouplevelofSexatWeek26 applying Rubin's Rulea |                  |               |
| Female                                                                   |                  |               |
| ObservedValue atBaseline                                                 |                  |               |
| N                                                                        | 60               | 57            |
| Mean (SD)                                                                | 8.4 (1.41)       | 7.8 (1.23)    |
| Change fromBaseline at Week 26                                           |                  |               |
| LS Mean (SE)                                                             | 0.43 (0.212)     | -0.47 (0.219) |
| Diff. (Cana - Placebo) of LS Means (SE)                                  |                  | -0.90 (0.308) |
| p-valuea                                                                 |                  | 0.004         |
| 95% CIa                                                                  |                  | (-1.50,-0.30) |
| Male                                                                     |                  |               |
| Observed Value atBaseline                                                |                  |               |
| N                                                                        | 27               | 27            |
| Mean (SD)                                                                | 8.1 (1.22)       | 7.8 (1.49)    |
| Change from Baseline at Week 26                                          |                  |               |
| LS Mean (SE)                                                             | 0.28 (0.321)     | -0.28 (0.301) |
| Diff. (Cana - Placebo) of LS Means (SE)                                  |                  | -0.56 (0.440) |
| p-valuea                                                                 |                  | 0.205         |
| 95% CIa                                                                  |                  | (-1.42, 0.30) |

Results using the MMRM analysis are not shown in this AR. However, these results were consistent with the  above-shown  results  based  on  the  PMM  methodology.  Specifically,  there  was  no  treatment  by subgroup interaction for any of the subgroups. In addition, the respective treatment effects for each category within a subgroup were mostly similar for each subgroup.

## Sensitivity analyses of the primary endpoint

Additional sensitivity analyses were conducted for the primary analysis of the primary efficacy endpoint for all participants as well as for those on background metformin (with or without insulin) in the FAS. For the sake of brevity, only the summary of results for the total randomized population are presented in the following (for the population on background metformin with or without insulin, see clinical study report):

## Copy reference multiple imputation model

Based on this method of analysis, canagliflozin showed a statistically significant improvement with respect to change from baseline in HbA1c at Week 26 compared to placebo in all participants (Table 23 below) and in participants on background metformin with or without insulin (data not shown in this AR).

Table 23: Summary of results at Week 26 applying Rubin's rules to combine the ANCOVA results across the imputed datasets based on pattern mixture model (Table shortened) a

|                                            | Placebo (N=87)   | Cana (N=84)    |
|--------------------------------------------|------------------|----------------|
| LS Mean (SE)                               | 0.38 (0.180)     | -0.33 (0.182)  |
| Difference [Cana-Placebo] in LS Means (SE) |                  | -0.71 (0.236)  |
| 95% CI                                     |                  | (-1.17, -0.25) |
| p-value                                    |                  | 0.003          |

<div style=\"page-break-after: always\"></div>

A subject is considered to have received rescue medication prior to Week 26 if the day of initiation of the medication is prior to the lower limit of  Week 26 Analysis Visit window (Day 163 to 211). Same rule applies for subjects who discontinued treatment prior to Week 26.

## Mixed Model for Repeated Measures (MMRM)

Canagliflozin showed a statistically significant improvement with respect to change from baseline in HbA1c at Week 26 compared to placebo in all participants. The improvement in HbA1c change from baseline was observed as early as Week 6 with gradual improvement to Week 26. The difference in LS means (relative to placebo) was statistically significant at each time point starting at Week 6 in all participants - see Table 23 below.

Table 23: LS Mean Change from Baseline in HbA1c (%) Over Time (Up to Week 26)

|         | Placebo (N=87)   | Placebo (N=87)   | Cana (N=84)   | Cana (N=84)   | Difference (Cana-Placebo)   | Difference (Cana-Placebo)   | Difference (Cana-Placebo)   |
|---------|------------------|------------------|---------------|---------------|-----------------------------|-----------------------------|-----------------------------|
|         | N a              | LS Mean (SE)     | N a           | LS Mean (SE)  | LS Mean (SE)                | CI b                        | p-value b                   |
| WEEK 6  | 83               | -0.07 (0.099)    | 84            | -0.66 (0.098) | -0.59 (0.129)               | (-0.85, -0.34)              | <.001                       |
| WEEK 12 | 83               | 0.10 (0.137)     | 84            | -0.57 (0.137) | -0.68 (0.187)               | (-1.05, -0.31)              | <.001                       |
| WEEK 20 | 78               | 0.29 (0.159)     | 76            | -0.41 (0.160) | -0.70 (0.221)               | (-1.14, -0.26)              | 0.002                       |
| WEEK 26 | 80               | 0.33 (0.168)     | 77            | -0.40 (0.169) | -0.73 (0.234)               | (-1.19, -0.27)              | 0.002                       |

a: Number of subjects with non-missing value of change from baseline.

b: CIs (confidence interval) and p-values are based on a mixed model for repeated measures including the fixed effects of treatment, stratification factors (i.e., background AHA and age group), visit, and treatment-by-visit interaction, as well as the fixed, continuous covariates ofbaseline and baseline-by-visit interaction. An unstructured covariance is used to model the withinpatient errors.

## Tipping point analyses

Tipping point analyses were performed to assess the impact of the missing at random (MAR) assumption in  the  multiple imputation. For all participants, the tipping point of results changing from statistical significance to non-significance corresponds to a delta of 2.6 (see Table 24 below). The scenarios, where imputed values in canagliflozin are worse by a magnitude of 2.6 to reach the tipping point would not be considered plausible values, and the results under MAR assumption (analysis based on MMRM) would be supported.

Table  24: Tipping  point  analysis  of  primary  efficacy  endpoint  (primary  estimand,  treatment  policy strategy): change from baseline in HbA1c (%) at Week 26 using Delta adjustment applied to missing at random MI - all subjects; FAS (Study JNJ28431754-DIA3018)

|        | Change from Baseline   | Change from Baseline   | Change from Baseline   | Change from Baseline   | Change from Baseline      | Change from Baseline      | Change from Baseline      |
|--------|------------------------|------------------------|------------------------|------------------------|---------------------------|---------------------------|---------------------------|
|        | Placebo (N=87)         | Placebo (N=87)         | Cana (N=84)            | Cana (N=84)            | Difference (Cana-Placebo) | Difference (Cana-Placebo) | Difference (Cana-Placebo) |
| Delta  | LS Mean                | SE                     | LS Mean                | SE                     | LS Mean                   | SE                        | p-value a                 |
| 2.1000 | 0.38                   | 0.186                  | -0.16                  | 0.188                  | -0.53                     | 0.245                     | 0.029 *                   |
| 2.2000 | 0.38                   | 0.187                  | -0.15                  | 0.189                  | -0.52                     | 0.246                     | 0.033 *                   |
| 2.3000 | 0.38                   | 0.188                  | -0.14                  | 0.190                  | -0.52                     | 0.247                     | 0.037 *                   |
| 2.4000 | 0.38                   | 0.188                  | -0.13                  | 0.190                  | -0.51                     | 0.248                     | 0.041 *                   |
| 2.5000 | 0.37                   | 0.189                  | -0.12                  | 0.191                  | -0.50                     | 0.249                     | 0.046 *                   |
| 2.6000 | 0.37                   | 0.190                  | -0.11                  | 0.192                  | -0.49                     | 0.250                     | 0.051                     |
| 2.7000 | 0.37                   | 0.191                  | -0.11                  | 0.193                  | -0.48                     | 0.251                     | 0.056                     |
| 2.8000 | 0.37                   | 0.191                  | -0.10                  | 0.193                  | -0.47                     | 0.252                     | 0.062                     |
| 2.9000 | 0.37                   | 0.192                  | -0.09                  | 0.194                  | -0.46                     | 0.253                     | 0.069                     |
| 3.0000 | 0.37                   | 0.193                  | -0.08                  | 0.195                  | -0.45                     | 0.254                     | 0.076                     |

Note: Last 10 observations are displayed.

a:  Imputed  datasets  are  analyzed  using  analysis  of  covariance  (ANCOVA)  with  terms  for  treatment, stratification factors (AHA background and age group), and baseline HbA1c. * indicates significance (p&lt;0.05).

<div style=\"page-break-after: always\"></div>

For the subset of participants on background metformin (with or without insulin), the tipping point corresponds to a delta of 1.6 (data not shown in this AR).

## Last Observation Carried Forward (LOCF)

Canagliflozin showed a statistically significant improvement with respect to change from baseline in HbA1c at Week 26 compared to placebo in all participants. All participants-LS means difference = -0.79% (SE: 0.233; 95% CI: -1.25, -0.33; p = &lt;0.001; Table 25 below).

Table 25: Analysis of the primary efficacy endpoint - change from baseline in HbA1c (%) at Week 26 LOCF - all subjects; FAS (Study JNJ28431754-DIA3018)

|                | Placebo (N=87)   | Placebo (N=87)   | Cana (N=84)   | Cana (N=84)   | Difference (Cana-Placebo)   | Difference (Cana-Placebo)   | Difference (Cana-Placebo)   |
|----------------|------------------|------------------|---------------|---------------|-----------------------------|-----------------------------|-----------------------------|
|                | N a              | LS Mean (SE)     | N a           | LS Mean (SE)  | LS Mean (SE)                | CI b                        | p-value b                   |
| Week 26 (LOCF) | 85               | 0.42 (0.178)     | 84            | -0.37 (0.178) | -0.79 (0.233)               | (-1.25, -0.33)              | <0.001                      |

a: Number of subjects with non-missing value of change from baseline.

b: CI (confidence interval) and p-value are based on ANCOVA model with treatment and the stratification factors (AHA background and age group) as fixed effects and baseline HbA1c value as a covariate.

## Supportive Analyses of the Primary Efficacy Endpoint

## Re-randomization Test

Since dynamic randomization using minimization algorithm was employed, a re-randomization test was performed to determine the p-value for the treatment comparison of the primary efficacy endpoint. One thousand iterations of the re-randomization were performed using the same minimization algorithm. For each iteration, the test statistic for the treatment comparison was determined using the MMRM method. The p-value corresponding to the re-randomization test for all participants is 0.001 (see Table 26).

Table 26: Change from Baseline in HbA1c (%) at Week 26 by Using Re-Randomization Test - All Subjects; Full Analysis Set (Study JNJ28431754-DIA3018)

|                                           | Placebo (N=87)          | Placebo (N=87)          | Cana (N=84)             | Cana (N=84)             | Difference (Cana-Placebo)   | Difference (Cana-Placebo)   | Difference (Cana-Placebo)   |
|-------------------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-----------------------------|-----------------------------|-----------------------------|
|                                           | N                       | LS Mean (SE)            | N                       | LS Mean (SE)            | LS Mean (SE)                | CIa                         | p-valuea                    |
| Week 26 (observed results)                | 80                      | 0.33 (0.168)            | 77                      | -0.40 (0.169)           | -0.73 (0.234)               | (-1.19, -0.27)              | 0.002                       |
| Re-randomization Test b                   | Re-randomization Test b | Re-randomization Test b | Re-randomization Test b | Re-randomization Test b | Re-randomization Test b     | Re-randomization Test b     | Re-randomization Test b     |
| Number of iterations                      | 1000                    | 1000                    | 1000                    | 1000                    | 1000                        | 1000                        | 1000                        |
| p-values based on re-randomization test c | 0.001                   | 0.001                   | 0.001                   | 0.001                   | 0.001                       | 0.001                       | 0.001                       |

a: CIs and p-values are based on a mixed model for repeated measures including the fixed effects of treatment, stratification factors (i.e., background AHA and age group), visit, and treatment-by-visit interaction, as well as the fixed, continuous covariates of baseline and baseline-by-visit interaction. An unstructured covariance was used to model the within-patient errors.

b: The re-randomization test would fix the observed HbA1c data, regenerate treatment assignments for the entire study using the same minimization algorithm employed in the study and compute the test statistics corresponding to the primary efficacy comparison using MMRM method.

c: The p-value for the primary efficacy comparison is defined as the proportion of re-randomized studies whose test statistic (difference in LS means) for that comparison is at least as extreme as that of the test statistic based on the original treatment assignment.

## 2.5.1. Discussion on clinical efficacy

## JNJ-28431754DIA3018 (DIA3018)

Design and conduct of clinical study

<div style=\"page-break-after: always\"></div>

This was a randomized, double blind, placebo-controlled, 2-arm, parallel group, multi-center study that evaluated canagliflozin in male or female participants ≥ 10 to&lt;18 years of age with T2DM. The 52-week treatment  phase  consisted  of  a  26-week  core  double-blind  treatment  period  (relevant  for  primary endpoint), followed by a 26-week double-blind treatment extension. Patients on canagliflozin with HbA1c ≥7.0% at Week 12 (i.e. non responders) and an eGFR ≥60 mL/min/1.73m 2  were re-randomized 1:1 at week 13 to either remain on double-blind canagliflozin 100 mg (or matching placebo) or to up-titrate to double-blind canagliflozin 300 mg (or matching placebo). The primary objective was to demonstrate the superiority of canagliflozin 100 mg and 300 mg against placebo regarding HbA1c reduction from baseline at week 26.

The study design is adequate and in line with the recommendations of the EU guideline on medicinal products  for  treatment  or  prevention  of  diabetes  mellitus  (CPMP/EWP/1080/00  Rev.2).  Given  the challenges  regarding  recruitment  in  this  population,  the  re-randomization  design  is  considered appropriate to obtain the maximum amount of information with a limited number of patients. However, due to the up-titration step after week 12, the estimated effect is a mixture of two different treatment strategies: (1) increasing the dose to 300 mg or (2) remaining on 100 mg in case of insufficient glycaemic control. Thus, it is important that the applicant has individually assessed each treatment strategy (see effects table section 5.6).

## Studied population

In total, 171 patients were randomised to once daily treatment with canagliflozin (n=84) or placebo (n=87), with stratified randomization according to diet and exercise only as well as diet and exercise plus either metformin monotherapy, or insulin monotherapy or a combination of metformin and insulin. Moreover, strata were generated for age group (≥10 to &lt;15 years; ≥15 to &lt;18 years). This approach is endorsed, as it ensures sufficient coverage of the entire target age range, and the background therapies largely reflect the therapies recommended in the 2022 ISPAD guideline ( Pediatr Diabetes. 2022; 23:872902). The distribution of anti-diabetic background treatments was balanced across the treatment groups. The majority of patients took metformin with or without insulin.

As prespecified by the study protocol, ≥30% of participants between ≥10 and &lt;15 years of age were randomized (n=81 [47.4%]). The pre-planned upper limit of 65% of female participants per age group was slightly exceeded (67.9% for ≥10 to &lt;15 years and 68.9% for ≥15 to &lt;18 years), which, however, is still considered acceptable. A larger proportion of female in comparison to male participants reflects the distribution of paediatric T2DM patients reported in the literature (see e.g., Pinhas-Hamiel O (2023), https://www.ncbi.nlm.nih.gov/books/NBK597439/).

The study was conducted in North America, South America, Europe and Asia, but only 3.4% of the participants were from Europe (Poland). If the patients from the United States are considered to have a 'European-like' lifestyle, the pre-defined criterion to reach 30% of participants with ethnicity and lifestyle comparable to Europe may have been met (Participants from US and Europe: 28.7%).

Demographic and baseline characteristics were largely comparable across treatment groups. About half of the patients had baseline HbA1c values &lt;8% (n=92 [53.8]); for the remaining patients, approximately similar proportions had either HbA1c values of 8.0% to &lt;9.0% (n=31 [18.1%]) or 9.0 to ≤10.0% (n=32 [18.7%]). It is noted that 16 patients (9.4%) had a baseline HbA1c of &gt;10%. Mean baseline HbA1c was lower in the canagliflozin arm (7.8%) as compared to placebo-treated patients (8.3%), which went along with  a  slightly  shorter  mean  duration  of  disease,  a  higher  baseline  eGFR  and  higher  fasting  serum triglycerides in comparison to the placebo arm. As the effect size of HbA1c reduction depends on the baseline HbA1c, this imbalance favoured the placebo arm.

Although body weight was relatively high in a large proportion of the included population (mean BMI of 30.8 ± 7.43 kg/m 2 ; obesity in 46.2%), 24.0 % of the patients had normal weight. Exposure was 4- to 5-fold higher with the 300 mg as compared to the 100 mg dose (AUC τ [ h*ng/mL]: 28,392 vs. 6,190) in

<div style=\"page-break-after: always\"></div>

the overall population of the PK/PD study DIA1055. Further data provided by the MAH indicated that in lower-weight paediatric patients (&lt;50 kg), exposure with the 300 mg dose may exceed levels observed in adults at the same dose. For example, in the 30-40 kg subgroup, the AUC 50th percentile approached the adult 95th percentile, and Cmax values in this subgroup were even higher, with the 25th percentile already exceeding the adult 95th percentile (see also Section 2.6.1).

Due to its small size (only n=17), the baseline characteristics of the canagliflozin 300 mg up-titration group (i.e., non-responders at week 12) differed from the characteristics of the other treatment groups in  several  aspects.  The  percentage  of  overweight  or  obese  individuals  was  higher  than  in  the  other treatment groups, which may reflect higher disease severity. This is supported by the observation that the highest baseline HbA1c and FPG values were reported for the up-titration group. Only 6 patients (35.3%) aged &lt;15 years were up-titrated to 300 mg, while all other patients in the 300 mg group were older than 15 years (n=11; 64.7%). Thus, the evidence for efficacy of 300 mg of canagliflozin in the younger age group is rather limited.

## Statistical methods

The statistical methods are generally considered adequate. However, the estimand currently used for the primary endpoint does not fully correspond to the recommendations of the EMA Guideline CPMP/EWP/1080/00 Rev. 2, which recommends targeting the effect regardless of treatment discontinuation (treatment policy strategy) and had rescue medication not been introduced (hypothetical strategy). Nonetheless, the chosen estimand was considered acceptable, as the number of patients experiencing intercurrent events was limited, particularly in the active treatment arm, and the majority of patients maintained available HbA1c data at the key timepoints. Additional analyses aligned with alternative estimands were conducted and consistently supported the efficacy conclusions. Thus, despite some deviation from the guideline-recommended strategies, the overall evidence base and robustness of results justify the acceptability of the current estimand.

## Conduct

The majority of patients remained on treatment with trial drug up to Week 26 (n=149 [87.1%]) and up to Week 52 (n=142 [83.0%]). The frequency of premature treatment discontinuations was generally comparable across treatment groups.

## Results

## Primary endpoint

The LS mean difference of the HbA1c change from baseline at week 26 was -0.76 % (SE: 0.249) for pooled canagliflozin vs. placebo (95% CI -1.25 to -0.27; p=0.002), which indicated clinically relevant anti-hyperglycaemic efficacy. The secondary analysis of the primary efficacy endpoint in the subgroup on background metformin (with or without insulin) yielded almost identical results.

## Primary endpoint in subgroups

Although the treatment by background AHA effect did not reach significance, there was a tendency towards increased treatment effect of canagliflozin in the patients receiving background medication as compared to those being on diet and exercise only, i.e., canagliflozin seems to become more effective with increasing disease severity. This is confirmed by the data on the requirement of rescue therapy in the different AHA background treatment subgroups. Regarding age group, the improvement in HbA1c (change from baseline with canagliflozin vs. placebo at week 26) was only significant in the ≥ 15 to &lt;18year-old age group (-1.05%; 95% CI -1.74, -0.36) but not in the patients aged &lt;15 years (-0.45%; 95% CI -1.16, 0.26). Nevertheless, the difference with regard to age group was not significant, and efficacy was still clinically relevant in patients aged &lt; 15 years, and thus, no concern regarding efficacy

<div style=\"page-break-after: always\"></div>

in the younger age group is warranted. Canagliflozin seemed to be more effective in female than in male patients, but this difference was not significant.

## Main secondary and exploratory endpoints and other efficacy analyses

The blood glucose-related main secondary endpoints confirmed superiority of canagliflozin over placebo. The changes in HbA1c over time demonstrate early onset of the treatment effect as well as maintenance of HbA1c reduction through 52 weeks. Compared to the 26-week analysis, the effect is further enhanced after 52 weeks. Likewise, the reduction in FPG from baseline was significantly higher with canagliflozin than with placebo at week 26 (-26.9 mg/dL) and further enhanced at week 52 (-35.6 mg/dL).

In  the  HbA1c  responder  analysis,  the  lowest  category  of  HbA1c  &lt;6.5  was  achieved  by  ~42%  of canagliflozin-treated patients, but by only 11.3% of the placebo-treated subjects. Fewer participants on canagliflozin received rescue medications as compared to placebo.

Canagliflozin caused significant body weight loss/ BMI reduction in comparison to placebo at week 26 (possibly due to the caloric deficit caused by increased urinary glucose excretion), which was, however, attenuated at week 52. No relevant effect of canagliflozin on systolic and diastolic blood pressure was observed.

Regarding plasma lipids, canagliflozin caused an increase in HDL-, LDL-, and total cholesterol at week 26 in comparison to placebo, while plasma triglycerides were reduced. This is in accordance with previous findings  from  the  adult  study  programme.  It  is  reassuring  that  the  dyslipidaemia  did  not  get  more pronounced at week 52 and that the LDL-C/HDL-C ratio even showed a reduction from baseline in the canagliflozin-treated group.

HbA1c change from baseline at week 26 in the non-responder population up-titrated to canagliflozin 300 mg  was  -0.74  (SE:  0.237)  in  comparison  to  placebo  (95%  C,  -1.21  to  -0.28;  p=0.002).  The corresponding  HbA1c  change  from  baseline  in  those  who  remained  on  100  mg  of  canagliflozin was -0.58% (SD: 0.250); 95% Cl -1.08 to -0.09; p=0.020). This supports the notion that up-titration to 300 mg may provide additional benefit, although the evidence is rather limited for the participants aged &lt;15 years (only n=6). Moreover, this analysis complements the primary endpoint, which is difficult to interpret, since it represents a mixture of both approaches (remaining on 100 mg and up-titrating to 300 mg).

## 2.5.2. Conclusions on the clinical efficacy

In children from 10 to ≤ 18 years of age, canagliflozin (100 mg and 300 mg) causes a significant and clinically relevant decrease in HbA1c compared to placebo. This effect was confirmed by various blood glucose-related  secondary  endpoints.  Up-titration  of  non-responders  from  100  mg  to  300  mg  of canagliflozin  seems  to  provide  additional  benefit,  although  the  evidence  is  somewhat  limited  in  the younger age group of ≥10 to &lt;15 years (small group size of n=6). Subgroup analyses did not show significant differences with regard to background medication, age and sex. There seems to be a tendency towards reduced efficacy in participants aged ≥10 to &lt;15 years, but the treatment effect is still clinically relevant.

In summary, canagliflozin 100 mg and 300 mg is efficacious at improving blood glucose control in the paediatric population with T2DM, and the intended extension of indication to the paediatric population aged ≥10 to &lt;18 years is considered sufficiently justified from the efficacy perspective.

<div style=\"page-break-after: always\"></div>

## 2.6. Clinical safety

## Introduction

This application to extend the indication for Invokana to the paediatric patients ≥ 10 to &lt;18 years of age with T2DM is based on the final results from the following two clinical trials:

- Study JNJ-28431754DIA3018 (hereafter referred to as Study DIA3018) was a randomized, doubleblind, placebo-controlled, 2-arm, parallel-group, multicenter Phase 3 study in participants with T2DM ≥ 10 and &lt;18 years of age who had inadequate glycaemic control (i.e. HbA1c of ≥ 6.5% to ≤ 11.0%). The total duration of the study was approximately 59 weeks.
- Study JNJ-28431754DIA1055 (hereafter referred to as Study DIA1055), was an open-label, sequential, multiple-dose (14 days of dosing), multicenter Phase 1 study of canagliflozin in 2 treatment groups in children and adolescents ( ≥ 10 to &lt;18 years of age) who were diagnosed with T2DM and on a stable regimen of metformin (at a dose of at least 1,000 mg per day) for at least 8 weeks before screening.

| Table l:                               | Overview of the Completed Studies with T2DMin the Pediatric Population   | Overview of the Completed Studies with T2DMin the Pediatric Population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Overview of the Completed Studies with T2DMin the Pediatric Population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|----------------------------------------|--------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study Number                           | Study Number                                                             | StudyPopulation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Treatment Groups (Nunbers of Treated Participants)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| (Phase) JNJ- 28431754DLA3018 (Phase 3) | (Phase) JNJ- 28431754DLA3018 (Phase 3)                                   | Male or female paiticipants ranging in age from ≥10 to <18 years, with diagnosis of T2DM, who were on a stable regimen of metformin or injectable insulin within 8 weeks of the first dose of study drug. All participants had to have HbA1c of ≥6.5% to ≤11.0% and who were either: a. on diet and exercise for 4 weeks or, b. on diet and exercise and a stable dose of metfomin monotherapy or, C. on diet and exercise and a stable insulin monotherapy or, d. on diet and exercise and a stable combination therapy with metformin and insulin for at least 8 weeks prior to screening, as described above. | Participants were randomly assigned in a 1:1 ratio (n=171) to once daily administration of canagliflozin 100 mg, or placebo and entered a 52 week double-blindplacebo-controlled treatment phase consisting of a 26-week core double-blind treatment period, followed by a 26-week double- blind extension treatment period. Randomization was stratified by AHA background and age group (10 to <15 years old; 15 to <18 years old). Participants who at Week 12 had an HbAlc of ≥7.0% and an eGFR ≥60 mL/min/1.73m2 were re- randomized at Week 13 in a 1:1 ratio to either remain on double-blind canagliflozin 100 mg (or matching placebo) or to up-titrate to double-blind canagliflozin 300 mg (or matching placebo). |
| JNJ- 28431754DLA1055 (Phase 1)         | JNJ- 28431754DLA1055 (Phase 1)                                           | Male or female participants ranging in age from ≥10 to <18 years, with diagnosis of T2DM according to ADA criteria for at least 3 months before screening. without pancreatic autoimmunity and who were on a stable regimen of metformin IR monotherapy of at 1east 1,000 mg/day for at least 8 weeks before screening were enrolled in the study. Participants had to have normal renal function (eGFR ≥90 ml/min/1.73 m² as assessed by Schwaitz formula),ALT or AST ≤2.0xULN, a hemoglobin A1c (HbA1c) of ≥6.1% to ≤10% and a fasting C-peptide of >0.6 ng/mL at screening.                                   | Canagliflozin, 100 mg (as 1x100 mg tablet) daily for 14 days (n=8). Canagliflozin, 300 mg (as 1x300 mg tablet) daily for 14 days (n=9).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

In addition, the comprehensive Phase 3 studies conducted in adults with T2DM (date of first authorisation: 15 November 2013) offer substantial confirmatory evidence for the safety of canagliflozin.

## Patient exposure

## Patient exposure in Phase 3 study (DIA3018)

A total of 84 participants received canagliflozin with a mean treatment duration of 337.8 (SD=79.01) days. The mean duration of exposure was comparable for the 87 participants receiving placebo (335 [SD=85.79] days) and participants receiving canagliflozin 100 mg and canagliflozin 300 mg (333.4 [SD=85.34] and 355.2 [SD=44.03] days, respectively). 9 participants receiving placebo (10.3%) and 5 participants (6.0%) receiving canagliflozin had less than 26 weeks of exposure. 50 participants (57.5%) receiving placebo and 57 participants (67.9%) receiving canagliflozin had at least 52 weeks of exposure.

## Patient exposure in Phase 1 study (DIA1055)

A total of 17 participants were enrolled: 8 participants received canagliflozin 100 mg/d for 14 days and 9 participants received canagliflozin 300 mg/d for 14 days. All 17 participants enrolled completed the study.

## Adverse events

## Treatment-Emergent Adverse Events (TEAEs) during the Phase 3 study DIA3018

Table 4 provides an overall summary of TEAEs (regardless of rescue medication) for participants in the safety analysis set. The proportion of participants reporting 1 or more TEAEs, TEAEs that were considered by the investigator to be related to study drug, SAEs, and AEs leading to discontinuation was comparable between participants receiving placebo and participants receiving canagliflozin.

Table 4: Overall Summary of Treatment-emergent Adverse Events Regardless of Rescue MIedication; Safety Analysis Set (Study JNJ-28431754-DIA3018)

| Analysis set: Safety                                  | Placebo 87   | 100 mg 67   | Canagliflozin 300 mg 17   | Combined 84   |
|-------------------------------------------------------|--------------|-------------|---------------------------|---------------|
| Subjects with 1 or more:                              |              |             |                           |               |
| AEs                                                   | 65 (74.7%)   | 51 (76.1%)  | 14 (82.4%)                | 65 (77.4%)    |
| Related AEs d                                         | 14 (16.1%)   | 6 (9.0%)    | 3 (17.6%)                 | 9 (10.7%)     |
| AEs leading to death b                                | 0            | 0           | 0                         | 0             |
| Related AEs leading to death a.b                      | 0            | 0           | 0                         | 0             |
| Serious AEs                                           | 5 (5.7%)     | 7 (10.4%)   | 1 (5.9%)                  | 8 (9.5%)      |
| Related serious AEs                                   | 1 (1.1%)     | 0           | 0                         | 0             |
| AEsleading to discontinuation of study agent          | 1 (1.1%)     | 1 (1.5%)    | 0                         | 1 (1.2%)      |
| Related AEs leading to discontinuation of study agent | 0            | 0           | 0                         | 0             |

Key: AE = adverse event

[tsfae01.rtf] [PROD/jnj-28431754b/dia3018/dbr\\_final\\_re2/re\\_csr/tsfae01.sas] 28DEC2023, 17:43

An AE is categorized as related if assessed by the investigator as possibly, probably, or very likely related to study agent. b AEs leading to death are based on AE outcome of Fatal.

Table 5 shows that in the Phase 3 study (DIA3018) more commonly ( ≥ 2%) reported TEAEs in participants receiving canagliflozin versus placebo included headache (10.7% vs. 3.4%), dizziness (3.6% vs. 1.1%), nasopharyngitis (9.5% vs. 5.7%), rhinitis (4.8% vs. 2.3%), urinary tract infection

<div style=\"page-break-after: always\"></div>

(7.1% vs. 4.6%), vomiting (6.0% vs. 2.3%), nausea (4.8% vs. 1.1%) and abdominal pain (3.6% vs. 0%).

In addition, various TEAEs of genital mycotic or bacterial infections were reported in paediatric patients receiving canagliflozin and none with placebo: balanitis candida (2.4% vs. 0%), vulvovaginal candidiasis (2.4% vs. 0%), bacterial vaginosis (1.2% vs. 0%) and genital infection fungal (1.2% vs. 0%).

Hypoglycemia as a TEAE was reported more frequently in participants receiving placebo (9.2%) as compared with participants receiving canagliflozin (3.6%). All 3 hypoglycemia TEAEs were reported by participants who received canagliflozin 100 mg. None of the hypoglycemia TEAEs were serious.

Table 5: Number of Subjects with Treatment-emergent Adverse Events with Frequency of at Least 2% in Any Treatment Group by System Organ Class and Preferred Term Regardless of Rescue Medication; Safety Analysis Set (Study JNJ-28431754DIA3018)

| Analysis set: Safety                    | Placebo 87   | 100 mg 67   | Canagliflozin 300 mg 17   | Combined 84   |
|-----------------------------------------|--------------|-------------|---------------------------|---------------|
| Subjects with 1 or more AEs             | 65 (74.7%)   | 51 (76.1%)  | 14 (82.4%)                | 65 (77.4%)    |
| System organ class                      |              |             |                           |               |
| Infections and infestations             | 35 (40.2%)   | 27 (40.3%)  | 12 (70.6%)                | 39 (46.4%)    |
| Nasopharyngitis                         | 5 (5.7%)     | 8 (11.9%)   | 0                         | 8 (9.5%)      |
| Urinary tract infection                 | 4 (4.6%)     | 1 (1.5%)    | 5 (29.4%)                 | 6 (7.1%)      |
| Rhinitis                                | 2 (2.3%)     | 3 (4.5%)    | 1 (5.9%)                  | 4 (4.8%)      |
| Upper respiratory tract infection       | 11 (12.6%)   | 3 (4.5%)    | 1 (5.9%)                  | 4 (4.8%)      |
| Influenza                               | 4 (4.6%)     | 2 (3.0%)    | 1 (5.9%)                  | 3 (3.6%)      |
| Viral upper respiratory tract infection | 1 (1.1%)     | 2 (3.0%)    | 1 (5.9%)                  | 3 (3.6%)      |
| Balanitis candida                       | 0            | 1 (1.5%)    | 1 (5.9%)                  | 2 (2.4%)      |
| COVID-19                                | 2 (2.3%)     | 1 (1.5%)    | 1 (5.9%)                  | 2 (2.4%)      |
| Pharyngotonsillitis                     | 1 (1.1%)     | 1 (1.5%)    | 1 (5.9%)                  | 2 (2.4%)      |
| Vulvovaginal candidiasis                | 0            | 1 (1.5%)    | 1 (5.9%)                  | 2 (2.4%)      |
| Bacterial vaginosis                     | 0            | 0           | 1 (5.9%)                  | 1 (1.2%)      |
| Extermal ear cellulitis                 | 0            | 0           | 1 (5.9%)                  | 1 (1.2%)      |
| Gastroenteritis viral                   | 0            | 0           | 1 (5.9%)                  | 1 (1.2%)      |
| Genital herpes                          | 0            | 0           | 1 (5.9%)                  | 1 (1.2%)      |
| Genital herpes simplex                  | 0            | 0           | 1 (5.9%)                  | 1 (1.2%)      |
| Genital infection fungal                | 0            | 0           | 1 (5.9%)                  | 1 (1.2%)      |
| Pharyngitis streptococcal               | 0            | 0           | 1 (5.9%)                  | 1 (1.2%)      |
| Urinary tract infection bacterial       | 0            | 0           | 1 (5.9%)                  | 1 (1.2%)      |
| Viral infection                         | 2 (2.3%)     | 0           | 1 (5.9%)                  | 1 (1.2%)      |
| Impetigo                                | 2 (2.3%)     | 0           | 0                         | 0             |
| Otitis media acute                      | 2 (2.3%)     | 0           | 0                         | 0             |
| Tonsillitis                             | 2 (2.3%)     | 0           | 0                         | 0             |
| Gastrointestinal disorders              | 13 (14.9%)   | 12 (17.9%)  | 5 (29.4%)                 | 17 (20.2%)    |
| Vomiting                                | 2 (2.3%)     | 3 (4.5%)    | 2 (11.8%)                 | 5 (6.0%)      |
| Diarrhoea                               | 5 (5.7%)     | 3 (4.5%)    | 1 (5.9%)                  | 4 (4.8%)      |
| Nausea                                  | 1 (1.1%)     | 2 (3.0%)    | 2 (11.8%)                 | 4 (4.8%)      |
| Abdominal pain                          | 0            | 2 (3.0%)    | 1 (5.9%)                  | 3 (3.6%)      |
| Gastritis                               | 2 (2.3%)     | 2 (3.0%)    | 0                         | 2 (2.4%)      |
| Pancreatitis acute                      | 0            | 0           | 1 (5.9%)                  | 1 (1.2%)      |
| Metabolism and nutrition disorders      | 26 (29.9%)   | 13 (19.4%)  | 4 (23.5%)                 | 17 (20.2%)    |
| Vitamin D deficiency                    | 6 (6.9%)     | 3 (4.5%)    | 1 (5.9%)                  | 4 (4.8%)      |
| Hyperglycaemia                          | 5 (5.7%)     | 2 (3.0%)    | 1 (5.9%)                  | 3 (3.6%)      |
| Hypoglycaemia                           | 8 (9.2%)     | 3 (4.5%)    | 0                         | 3 (3.6%)      |
| Ketosis                                 | 1 (1.1%)     | 2 (3.0%)    | 0                         | 2 (2.4%)      |

<div style=\"page-break-after: always\"></div>

Table 5: Number of Subjects with Treatment-emergent Adverse Events with Frequency of at Least 2% in Any Treatment Group by System Organ Class and Preferred Term Regardless of Rescue Medication; Safety Analysis Set (Study JNJ-28431754DIA3018)

|                                           | Placebo    | 100 mg     | Canagliflozin 300 mg   | Combined   |
|-------------------------------------------|------------|------------|------------------------|------------|
| Dehydration                               | 1 (1.1%)   | 0          | 1 (5.9%)               | 1 (1.2%)   |
| Diabetes mellitus inadequate control      | 1 (1.1%)   | 0          | 1 (5.9%)               | 1 (1.2%)   |
| Hypertriglyceridaemia                     | 2 (2.3%)   | 0          | 1 (5.9%)               | 1 (1.2%)   |
| Acetonaemia                               | 4 (4.6%)   | 0          | 0                      | 0          |
| Hyperlipidaemia                           | 2 (2.3%)   | 0          | 0                      | 0          |
| Hyperuricaemia                            | 2 (2.3%)   | 0          | 0                      | 0          |
| Nervous system disorders                  | 3 (3.4%)   | 14 (20.9%) | 2 (11.8%)              | 16 (19.0%) |
| Headache                                  | 3 (3.4%)   | 8 (11.9%)  | 1 (5.9%)               | 9 (10.7%)  |
| Dizziness                                 | 1 (1.1%)   | 2 (3.0%)   | 1 (5.9%)               | 3 (3.6%)   |
| Investigations                            | 10 (11.5%) | 5 (7.5%)   | 3 (17.6%)              | 8 (9.5%)   |
| Blood ketone body increased               | 2 (2.3%)   | 1 (1.5%)   | 1 (5.9%)               | 2 (2.4%)   |
| Blood glucose increased                   | 0          | 0          | 1 (5.9%)               | 1 (1.2%)   |
| High density lipoprotein decreased        | 0          | 0          | 1 (5.9%)               | 1 (1.2%)   |
| Respiratory, thoracic and mediastinal     |            |            |                        |            |
| disorders                                 | 7 (8.0%)   | 7 (10.4%)  | 1 (5.9%)               | 8 (9.5%)   |
| Epistaxis                                 | 0          | 2 (3.0%)   | 0                      | 2 (2.4%)   |
| Cough                                     | 4 (4.6%)   | 1 (1.5%)   | 0                      | 1 (1.2%)   |
| Rhinorrhoea                               | 2 (2.3%)   | 0          | 1 (5.9%)               | 1 (1.2%)   |
| Skin and subcutaneous tissue disorders    | 4 (4.6%)   | 6 (9.0%)   | 2 (11.8%)              | 8 (9.5%)   |
| Skin lesion                               | 0          | 0          | 1 (5.9%)               | 1 (1.2%)   |
| Urticaria                                 | 0          | 0          | 1 (5.9%)               | 1 (1.2%)   |
| General disorders and administration site |            |            |                        |            |
| conditions                                | 4 (4.6%)   | 6 (9.0%)   | 1 (5.9%)               | 7 (8.3%)   |
| Pyrexia                                   | 3 (3.4%)   | 4 (6.0%)   | 0                      | 4 (4.8%)   |
| Malaise                                   | 0          | 2 (3.0%)   | 0                      | 2 (2.4%)   |
| Fatigue                                   | 0          | 0          | 1 (5.9%)               | 1 (1.2%)   |
| Thirst                                    | 0          | 0          | 1 (5.9%)               | 1 (1.2%)   |
| Musculoskeletal and connective tissue     |            |            |                        |            |
| disorders                                 | 2 (2.3%)   | 5 (7.5%)   | 2 (11.8%)              | 7 (8.3%)   |
| Pain in extremity                         | 0          | 3 (4.5%)   | 0                      | 3 (3.6%)   |
| Myalgia                                   | 1 (1.1%)   | 1 (1.5%)   | 1 (5.9%)               | 2 (2.4%)   |
| Musculoskeletal pain                      | 0          | 0          | 1 (5.9%)               | 1 (1.2%)   |
| Injury, poisoning and procedural          |            |            |                        |            |
| complications                             | 4 (4.6%)   | 4 (6.0%)   | 1 (5.9%)               | 5 (6.0%)   |
| Skin abrasion                             | 1 (1.1%)   | 0          | 1 (5.9%)               | 1 (1.2%)   |
| Skin laceration                           | 0          | 0          | 1 (5.9%)               | 1 (1.2%)   |
| Psychiatric disorders                     | 6 (6.9%)   | 3 (4.5%)   | 1 (5.9%)               | 4 (4.8%)   |
| Anxiety                                   | 2 (2.3%)   | 2 (3.0%)   | 0                      | 2 (2.4%)   |
| Autism spectrum disorder                  | 0          | 0          | 1 (5.9%)               | 1 (1.2%)   |
| Renal and urinary disorders               | 4 (4.6%)   | 3 (4.5%)   | 1 (5.9%)               | 4 (4.8%)   |
| Ketonuria                                 | 0          | 0          | 1 (5.9%)               | 1 (1.2%)   |
| Pollakiuria                               | 2 (2.3%)   | 0          | 0                      | 0          |
| Reproductive system and breast disorders  | 2 (2.3%)   | 3 (4.5%)   | 1 (5.9%)               | 4 (4.8%)   |
| Balanoposthitis                           | 0          | 0          | 1 (5.9%)               | 1 (1.2%)   |
| Vulvovaginal pruritus                     | 2 (2.3%)   | 0          | 0                      | 0          |
| Endocrine disorders                       | 0          | 3 (4.5%)   | 0                      | 3 (3.6%)   |

<div style=\"page-break-after: always\"></div>

Table 5: Number of Subjects with Treatment-emergent Adverse Events with Frequency of at Least 2% in Any Treatment Group by System Organ Class and Preferred Term Regardless of Rescue Medication; Safety Analysis Set (Study JNJ-28431754DIA3018)

|                                      | Placebo   | 100 mg   | Canagliflozin 300 mg   | Combined   |
|--------------------------------------|-----------|----------|------------------------|------------|
| Ear and labyrinth disorders          | 1 (1.1%)  | 1 (1.5%) | 1 (5.9%)               | 2 (2.4%)   |
| Vertigo                              | 1 (1.1%)  | 0        | 1 (5.9%)               | 1 (1.2%)   |
| Hepatobiliary disorders              | 1 (1.1%)  | 2 (3.0%) | 0                      | 2 (2.4%)   |
| Immune system disorders              | 0         | 1 (1.5%) | 1 (5.9%)               | 2 (2.4%)   |
| Seasonal allergy                     | 0         | 0        | 1 (5.9%)               | 1 (1.2%)   |
| Vascular disorders                   | 1 (1.1%)  | 2 (3.0%) | 0                      | 2 (2.4%)   |
| Blood and lymphatic system disorders | 2 (2.3%)  | 1 (1.5%) | 0                      | 1 (1.2%)   |
| Eye disorders                        | 2 (2.3%)  | 1 (1.5%) | 0                      | 1 (1.2%)   |

Key: AE = adverse event

Note: Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event. Adverse events are coded using MedDRA Version 26.0.

## Hypoglycemia

Table 6 shows the number of participants with treatment-emergent hypoglycemia that was documented by blood glucose measurements, whether symptomatic or not.

| Table 6:                | Treatment-Emergent Biochemically Documented Hypoglycemia Prior to Rescue Medication; Safety Analysis Set (Study JNJ-28431754DIA3018)   | Treatment-Emergent Biochemically Documented Hypoglycemia Prior to Rescue Medication; Safety Analysis Set (Study JNJ-28431754DIA3018)   | Treatment-Emergent Biochemically Documented Hypoglycemia Prior to Rescue Medication; Safety Analysis Set (Study JNJ-28431754DIA3018)   | Treatment-Emergent Biochemically Documented Hypoglycemia Prior to Rescue Medication; Safety Analysis Set (Study JNJ-28431754DIA3018)   |
|-------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|
|                         | Placebo                                                                                                                                | 100mg                                                                                                                                  | Canagliflozin 300mg                                                                                                                    | Combined                                                                                                                               |
| Analysis set: Safety    | 87                                                                                                                                     | 67                                                                                                                                     | 17                                                                                                                                     | 84                                                                                                                                     |
| Subjects with episodes* | 14 (16.1%)                                                                                                                             | 14 (20.9%)                                                                                                                             | 1 (5.9%)                                                                                                                               | 15 (17.9%)                                                                                                                             |
| <=70 mg/dL (3.9 mmol/L) | 14 (16.1%)                                                                                                                             | 14 (20.9%)                                                                                                                             | 1 (5.9%)                                                                                                                               | 15 (17.9%)                                                                                                                             |

## Table 6: Treatment-Emergent Biochemically Documented Hypoglycemia Prior to Rescue

## Medication; Safety Analysis Set (Study JNJ-28431754DIA3018)

|                                                   |                  | Canagliflozin   | Canagliflozin   | Canagliflozin     |
|---------------------------------------------------|------------------|-----------------|-----------------|-------------------|
| <56 mg/dL (3.1 mmol/L)                            | Placebo 7 (8.0%) | 100 mg 6 (9.0%) | 300 mg 0        | Combined 6 (7.1%) |
| <36 mg/dL (2.0 mmol/L)                            | 2 (2.3%)         | 0               | 0               | 0                 |
| Total mumber of episodes                          | 74               | 57              |                 | 58                |
| Subjects with numbers of biochemically documented |                  |                 |                 |                   |
| hypoglycemia                                      | 14 (16.1%)       | 14 (20.9%)      | 1 (5.9%)        | 15 (17.9%)        |
| 1 episode                                         | 4 (4.6%)         | 5 (7.5%)        | 1 (5.9%)        | 6 (7.1%)          |
| 2 episodes                                        | 6 (6.9%)         | 3 (4.5%)        | 0               | 3 (3.6%)          |
| >=3 episodes                                      | 4 (4.6%)         | 6 (9.0%)        | 0               | 6 (7.1%)          |
| Event rate per subject-year exposure              | 1.24             | 0.98            | 0.07            | 0.8               |

Note: Count (%o) is based on Number of Subjects, Not Number of Episodes.

A subject may be counted in each of the 3 glucose categories listed below;

*Subjects with any treatment-emergent biochemically documented hypoglycemia episodes;

Results of LOW is included in all the 3 glucose categories (i.e., ≤ 70, &lt;56, and/or &lt;36 mg/dL).

Glucose data could be reported in either mg/dL or mmol/L units. No conversion between the 2 units was made. The comparison between the reported glucose values and the cutoffs was based on the units in which the glucose values were reported.

The number of hypoglycemic episodes per participant prior to rescue medications were comparable between participants receiving placebo and those receiving canagliflozin.

<div style=\"page-break-after: always\"></div>

## Urinary albumin-creatinine ratio (ACR)

As indicated in the table below, urine ACR results over time were generally comparable across the treatment groups. There was a trend towards increased ACR geometric mean in the Cana 300 mg group as compared to Cana 100 mg and placebo.

| Table 65:                                  | ACR Over Time; Safety Analysis Set (Study JNJ28431754-DIA3018)   | ACR Over Time; Safety Analysis Set (Study JNJ28431754-DIA3018)   | ACR Over Time; Safety Analysis Set (Study JNJ28431754-DIA3018)   | ACR Over Time; Safety Analysis Set (Study JNJ28431754-DIA3018)   | ACR Over Time; Safety Analysis Set (Study JNJ28431754-DIA3018)   | ACR Over Time; Safety Analysis Set (Study JNJ28431754-DIA3018)   | ACR Over Time; Safety Analysis Set (Study JNJ28431754-DIA3018)   | ACR Over Time; Safety Analysis Set (Study JNJ28431754-DIA3018)   | ACR Over Time; Safety Analysis Set (Study JNJ28431754-DIA3018)   | ACR Over Time; Safety Analysis Set (Study JNJ28431754-DIA3018)   | ACR Over Time; Safety Analysis Set (Study JNJ28431754-DIA3018)   | ACR Over Time; Safety Analysis Set (Study JNJ28431754-DIA3018)   |
|--------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|
|                                            | Placebo                                                          | Placebo                                                          | Placebo                                                          | Placebo                                                          |                                                                  |                                                                  |                                                                  |                                                                  | Cana 300 mg                                                      | Cana 300 mg                                                      | Cana 300 mg                                                      | Cana 300 mg                                                      |
|                                            | N                                                                | Median  GM(a)                                                    |                                                                  | (95% CI)                                                         | N                                                                | Median GM(a)                                                     |                                                                  | (95% CI)                                                         | N                                                                | Median  GM(a)                                                    |                                                                  | (95% CI                                                          |
| Parameter: Urine Albumin/Creatinine (mg/g) |                                                                  |                                                                  |                                                                  |                                                                  |                                                                  |                                                                  |                                                                  |                                                                  |                                                                  |                                                                  |                                                                  |                                                                  |
| Baseline                                   | 72                                                               | 8.15                                                             | 11.87                                                            | (8.84; 15.94)                                                    | 55                                                               | 8.57                                                             | 13.83                                                            | (9.84; 19.45)                                                    | 13                                                               | 14.06                                                            | 17.05                                                            | (8.79; 33.07)                                                    |
| Week 26                                    | 64                                                               | 9.90                                                             | 15.62                                                            | (11.24; 21.71) (10.97;                                           | 48                                                               | 11.01                                                            | 14.41                                                            | (9.85; 21.07) (10.75;                                            | 12                                                               | 9.82                                                             | 24.84                                                            | (11.81; 52.26) (10.42;                                           |
| Week 52                                    | 65                                                               | 11.49                                                            | 14.98                                                            | 20.46)                                                           | 47                                                               | 10.61                                                            | 15.45                                                            | 22.22)                                                           | 11                                                               | 10.96                                                            | 21.27                                                            | 43.45)                                                           |

Note: [a] GM=Geometric mean estimated from the mixed model for repeated measures including the fixed effects of treatment, stratification factors (ie, background AHA and age group), visit, treatment-by-visit interaction.

ACRislogtransformed.

[tsfacr01.rtf] [PROD/jnj-28431754b/dia3018/dbr\\_final\\_re2/re\\_csr/tsfacr01.sas] 28DEC2023,17:43

## Adverse events regarding growth and development

## Tanner staging

Girls (breast development):

At Week 26, compared to baseline,

- Placebo: 6 girls increased by 1 stage
- Canagliflozin 100 mg: 13 girls increased by 1 stage; 1 girl increasing by ≥ 2 stages

At Week 52, compared to baseline,

- Placebo: 12 girls increased by 1 stage; 1 girl increased by ≥2 stages
- Canagliflozin 100 mg: 14 girls increased by 1 stage

Canagliflozin 300 mg: 2 girls increased by 1 stage at both Week 26 and 52.

## Boys (genital development)

At Week 26, compared to baseline,

- Placebo: 3 boys increased by 1 stage; 1 boy increased by ≥ 2 stages.
- Canagliflozin 100 mg: 4 boys increased by 1 stage; 1 boy increased by ≥ 2 stages.

At Week 52, compared to baseline,

- Placebo: 8 boys increased by 1 stage; 3 boys increased by ≥ 2 stages
- Canagliflozin 100 mg: 5 boys increased by 1 stage; 2 increased by ≥ 2 stages.

Canagliflozin 300 mg: 1 boy increased by 1 stage at both Week 26 and 52.

## Growth velocity

At week 26, growth velocity was 1.99, 2.00 and 1.00 cm/year for placebo, canagliflozin 100 mg and 300 mg, respectively.

At week 52, growth velocity was 1.63, 1.57 and 1.76 cm/year for placebo, canagliflozin 100 mg and 300 mg, respectively.

<div style=\"page-break-after: always\"></div>

## Biomarkers

## Bone turnover markers

The data on bone turnover markers suggest no apparent clinically meaningful differences from placebo, given the wide standard deviations on osteocalcin, and noting the relatively low numbers on the Type 1 collagen C-telopeptides.

## Markers of calcium and phosphate homeostasis:

The following results pertain to the median changes from baseline at week 26 and 52 and within 2 days after last study agent:

- For calcium, calcitonin, phosphate and parathyroid hormone, no relevant difference in median change from baseline seemed to occur at week 26 and 52 for canagliflozin vs. placebo.
- Regarding urine calcium and phosphate, the excretion appeared to be reduced at week 26 and 52 in the canagliflozin-treated patients as compared to placebo (median change from baseline):
- 25-hydroxy vitamin D showed a more pronounced reduction from baseline in the canagliflozintreated patients as compared to the placebo-treated arm at both week 26 and 52:
- -week 26: -3.0 nmol/l and -4 nmol/l with canagliflozin 100 mg and 300 mg, respectively, vs. +1.5 nmol/l with placebo
- -week 52: -1.0 nmol/l and -3 nmol/l with canagliflozin 100 mg and 300 mg, respectively, vs. +1.0 nmol/l with placebo
- Magnesium appeared to be slightly increased from baseline with canagliflozin as compared to placebo (0.0 mg/dL with placebo vs. +0.1 mg/dL with canagliflozin at both week 26 and 52).

- Urine calcium: week 26: +1.4 mg/dL with placebo; 0.00 mg/dL with canagliflozin

```
week 52: +1.5 mg/dL with placebo; +0.10 mg/dL with canagliflozin
```

- -

- Urine phosphate: week 26: +8.5 mg/dL with placebo; - 7.60 mg/dL with canagliflozin

week 52: +6.6 mg/dL with placebo; -10.20 mg/dL with canagliflozin

## Treatment-Emergent Adverse Events (TEAEs) during the Phase 1 study DIA1055

The most frequently reported TEAE ( ≥ 2 participants) by preferred term was nausea (n=3); all other TEAEs were reported as single incident. Overall, the incidence of TEAEs was balanced between both treatment groups (Table 8).

<div style=\"page-break-after: always\"></div>

Table 8: Treatment-Emergent Adverse Events by Body System or Organ Class and Dictionaryderived Term Safety Analysis Set (Study JNJ-28431754DIA1055)

| Body System Or Organ Class                               | Canagliflozin 100 mg Canagliflozin 300 mg (N=8)   | (6=N)    | Total (N=17)   |
|----------------------------------------------------------|---------------------------------------------------|----------|----------------|
| Dictionary-Derived Term                                  | n (%)                                             | n (%)    | n (%)          |
| Total no. participants with adverse events               | 4 (50.0)                                          | 5 (55.6) | 9 (52.9)       |
| GASTROINTESTINALDISORDERS                                | 2 (25.0)                                          | 3 (33.3) | 5 (29.4)       |
| Nausea                                                   | 1 (12.5)                                          | 2 (22.2) | 3 (17.6)       |
| Abdominal pain                                           | 1 (12.5)                                          | 0        | 1 (5.9)        |
| Vomiting                                                 | 0                                                 | 1 (11.1) | 1 (5.9)        |
| METABOLISM AND NUTRITION DISORDERS                       | 1 (12.5)                                          | 1 (11.1) | 2 (11.8)       |
| Hypoglycemia                                             | 0                                                 | 1 (11.1) | 1 (5.9)        |
| Metabolic acidosis                                       | 1 (12.5)                                          | 0        | 1 (5.9)        |
| SKINAND SUBCUTANEOUS TISSUE                              | 1 (12.5)                                          | 1 (11.1) | 2 (11.8)       |
| DISORDERS Onycholysis                                    | 1 (12.5)                                          | 0        | 1 (5.9)        |
| Rash                                                     | 0                                                 | 1 (11.1) | 1 (5.9)        |
| INFECTIONS ANDINFESTATIONS                               | 1 (12.5)                                          | 0        | 1 (5.9)        |
|                                                          | 1 (12.5)                                          | 0        | 1 (5.9)        |
| Upper respiratory tract infection NERVOUSSYSTEMDISORDERS | 0                                                 | 1 (11.1) | 1 (5.9)        |
| Headache                                                 | 0                                                 | 1 (11.1) | 1 (5.9)        |

Reported dictionary version: MedDRA 18.1

Note: Incidence is based on the number of participants, not the number of events.

## Serious adverse event/deaths/other significant events

## Deaths

There were no deaths reported in either of the two paediatric studies (DIA3018 and DIA1055).

## Serious Adverse Events (SAEs) during the Phase 3 study DIA3018

A summary of participants in the safety analysis set with serious TEAEs by SOC and PT regardless of rescue medication is provided in Table 9. Eight participants receiving canagliflozin (9.5%) and 5 participants receiving placebo (5.7%) reported serious TEAEs. Seven of these 8 events occurred in participants receiving canagliflozin 100 mg and 1 in canagliflozin 300 mg. The events were balanced across several SOCs. None of the serious TEAEs were considered by the investigator to be related to canagliflozin.

Table 9: Number of Participants with Treatment-emergent Serious Adverse Events by System Organ Class and Preferred Term Regardless of Rescue Mledication; Safety Analysis Set (Study JNJ28431754D1A3018)

|                                  |          | Canagliflozin   | Canagliflozin   | Canagliflozin   |
|----------------------------------|----------|-----------------|-----------------|-----------------|
|                                  | Placebo  | 100mg           | 300 mg          | Combined        |
| Analysisset: Safety              | 87       | 67              | 17              | 84              |
| Paiticipants with 1 or more SAEs | 5 (5.7%) | 7 (10.4%)       | 1 (5.9%)        | 8 (9.5%)        |

<div style=\"page-break-after: always\"></div>

Table 9: Number of Participants with Treatment-emergent Serious Adverse Events by System Organ Class and Preferred Term Regardless of Rescue Medication; Safety Analysis Set (Study JNJ28431754DIA3018)

|                                       | Placebo   | 100 mg   | Canagliflozin 300 mg   | Combined   |
|---------------------------------------|-----------|----------|------------------------|------------|
| System organ class                    |           |          |                        |            |
| Preferred term                        |           |          |                        |            |
| Infections and infestations           | 0         | 2 (3.0%) | 0                      | 2 (2.4%)   |
| Erysipelas                            | 0         | 1 (1.5%) | 0                      | 1 (1.2%)   |
| Pneumonia                             | 0         | 1 (1.5%) | 0                      | 1 (1.2%)   |
| Metabolism and nutrition disorders    | 2 (2.3%)  | 2 (3.0%) | 0                      | 2 (2.4%)   |
| Diabetic ketoacidosis                 | 1 (1.1%)  | 1 (1.5%) | 0                      | 1 (1.2%)   |
| Hyperglycaemia                        | 0         | 1 (1.5%) | 0                      | 1 (1.2%)   |
| Diabetes mellitus inadequate control  | 1 (1.1%)  | 0        | 0                      | 0          |
| Gastrointestinal disorders            | 0         | 0        | 1 (5.9%)               | 1 (1.2%)   |
| Pancreatitis acute                    | 0         | 0        | 1 (5.9%)               | 1 (1.2%)   |
| Hepatobiliary disorders               | 0         | 1 (1.5%) | 0                      | 1 (1.2%)   |
| Cholelithiasis                        | 0         | 1 (1.5%) | 0                      | 1 (1.2%)   |
| Immune system disorders               | 0         | 1 (1.5%) | 0                      | 1 (1.2%)   |
| Anaphylactic reaction                 |           | 1 (1.5%) | 0                      | 1 (1.2%)   |
| Psychiatric disorders                 | 0         | 1 (1.5%) | 0                      | 1 (1.2%)   |
| Suicide attempt                       | 0         | 1 (1.5%) | 0                      | 1 (1.2%)   |
| Injury, poisoning and procedural      |           |          |                        |            |
| complications                         | 1 (1.1%)  | 0        | 0                      | 0          |
| Ankle fracture                        | 1 (1.1%)  | 0        | 0                      | 0          |
| Pregnancy, puerperium and perinatal   |           |          |                        |            |
| conditions                            | 1 (1.1%)  | 0        | 0                      | 0          |
| Abortion spontaneous                  | 1 (1.1%)  | 0        | 0                      | 0          |
| Respiratory, thoracic and mediastinal |           |          |                        |            |
| disorders                             | 1 (1.1%)  | 0        | 0                      | 0          |
| Tonsillar hypertrophy                 | 1 (1.1%)  | 0        | 0                      |            |

Key: SAE = serious adverse event

Note: Participants are counted only once for any given event, regardless of the number of times they actually experienced the event. Adverse events are coded using MedDRA Version 26.0.

## Serious Adverse Events during the Phase 1 study (DIA1055)

There were no serious adverse events reported during the Phase 1 study (DIA1055). None of the participants discontinued the study drug due to an adverse event.

<div style=\"page-break-after: always\"></div>

## Adverse Events of Special Interest during the Phase 3 study (DIA3018)

## Diabetic Ketoacidosis

The incidence of ketosis/acidosis-related adverse events was balanced in the canagliflozin and placebo groups (Table 10). Two of these events were serious, 1 was reported in a participant receiving placebo and the second, in a participant receiving canagliflozin 100 mg.

Table 10: Treatment-Emergent Ketosis/Acidosis by Preferred Term Regardless of Rescue Medication; Safety Analysis Set (Study JNJ-28431754DIA3018)

|                                    |            | Canagliflozin   | Canagliflozin   | Canagliflozin   |
|------------------------------------|------------|-----------------|-----------------|-----------------|
| Analysis set: Safety               | Placebo 87 | 100 mg 67       | 300 mg 17       | Combined 84     |
| Participants with 1 or more        |            |                 |                 |                 |
| ketosis/acidosis-related AEs       | 5 (5.7%)   | 4 (6.0%)        | 1 (5.9%)        | 5 (6.0%)        |
| System organ class Preferred term  |            |                 |                 |                 |
| Metabolism and nutrition disorders | 3 (3.4%)   | 3 (4.5%)        |                 | 3 (3.6%)        |
| Ketosis                            | 1 (1.1%)   | 2 (3.0%)        | 0               | 2 (2.4%)        |
| Diabetic ketoacidosis              | 1 (1.1%)   | 1 (1.5%)        | 0               | 1 (1.2%)        |
| Metabolic acidosis                 | 1 (1.1%)   | 0               | 0               | 0               |
| Investigations                     | 2 (2.3%)   | 1 (1.5%)        | 1 (5.9%)        | 2 (2.4%)        |
| Blood ketone body increased        | 2 (2.3%)   | 1 (1.5%)        | 1 (5.9%)        | 2 (2.4%)        |
| Renal and urinary disorders        | 0          | 0               | 1 (5.9%)        | 1 (1.2%)        |
| Ketonuria                          | 0          | 0               | 1 (5.9%)        | 1 (1.2%)        |

Note: Percentages Calculated with The Number of Participants In Each treatment group As Denominator.

Note: Incidence Is Based On The Number of Participants Experiencing At Least One Adverse Event, Not The Number of

Events.

## Fractures

Three participants experienced bone fractures during the study. Two of these participants received placebo and one received canagliflozin 100 mg. The subject on canagliflozin 100 mg reported a thumb fracture which could not be confirmed by an external adjudication. The event was non-serious, mild in severity, and not considered by the investigator to be related to canagliflozin.

## Pancreatitis

One participant who had a history of acute pancreatitis prior to enrolment experienced another episode of pancreatitis during the study, when the participant was receiving 100 mg canagliflozin, and was hospitalized. The acute pancreatitis was resolved on temporary withdrawal of study drug and did not re-occur after re-initiation of the study drug. The AE was moderate in severity and was considered by the investigator to be doubtfully related to the study drug. The endpoint adjudication committee confirmed the event to be pancreatitis. The participant resumed study drug and was later rerandomized to canagliflozin 300 mg and completed the study without any recurrence.

## Adverse Events of Special Interest during the Phase 1 study (DIA1055)

There were no pre-defined AESIs for the study. A few AEs of clinical interest were reported which included asymptomatic hypoglycemia, metabolic acidosis, and rash.

One participant who was receiving canagliflozin 300 mg experienced 4 episodes of asymptomatic hypoglycemia based on fingerstick blood glucose measurements on Day 3 (3.88 mmol/L [70 mg/dL]), Day 11 (3.61 mmol/L [65 mg/dL]), Day 15 (3.55 mmol/L [64 mg/dL]), and Day 23 (3.83 mmol/L [69

<div style=\"page-break-after: always\"></div>

mg/dL]) with resolution of each episode within less than 3.5 hours. These events were considered to be mild in intensity and doubtfully related to the study drug by the investigator.

One participant who was receiving canagliflozin 100 mg experienced an episode of metabolic acidosis on Day 14. At that time, the participant was asymptomatic, had normal glucose levels, and no ketones present in the urinalysis. The subject's bicarbonate level was within the normal range at the follow-up visit (i.e. 10 days after Day 14). The adverse event of metabolic acidosis was considered to be moderate in intensity and very likely related to the study drug by the investigator.

One participant who was receiving canagliflozin 300 mg experienced a rash on Day 9. The rash was described as a slightly pruritic, papular lesion localized to the right anterior wrist and forearm.

The investigator judged this event as contact dermatitis or eczema, mild in intensity, and doubtfully related to study drug. The rash was treated with a topical hydrocortisone cream and had resolved by the follow-up visit.

## Laboratory findings

There were no clinically important differences between canagliflozin and placebo regarding changes over time in laboratory parameters.

## Safety in special populations

## Elderly

Renal function and risk of volume depletion should be taken into account. This is already included in the SmPC (see SmPC section 4.4).

## Renal impairment

For treatment of diabetic kidney disease as add on to standard of care (e.g. ACE-inhibitors or ARBs), a dose of 100 mg canagliflozin once daily should be used (see Table 1). Because the glycaemic lowering efficacy of canagliflozin is reduced in patients with moderate renal impairment and likely absent in patients with severe renal impairment, if further glycaemic control is needed, the addition of other anti-hyperglycaemic agents should be considered. For dose adjustment recommendations according to eGFR refer to Table 1.

Table 1: Dose adjustment recommendations in adults and children aged 10years and older*

| eGFR (mL/min/1.73 m²) or CrCl (mL/min)   | Total daily dose of canagliflozin                                                                                                    |
|------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|
| ≥60                                      | Initiate with 100 mg. In patients tolerating 100 mg and requiring additional glycaemic control, the dose can be increased to 300 mg. |
| 30 to < 60b                              | Use 100 mg.                                                                                                                          |
| <30b,c                                   | Continue 100 mg for patients already taking Invokanad. Invokana should not be initiated.                                             |

a See sections 4.4,4.8,5.1, and 5.2

b If further glycaemic control is needed, the addition of other anti hyperglycaemic agents should be considered

- With urinary albumin/creatinine ratio &gt; 300 mg/g

d Continue dosing until dialysis or renal transplantation.

## Hepatic impairment

For patients with mild or moderate hepatic impairment, no dose adjustment is required.

Canagliflozin has not been studied in patients with severe hepatic impairment and is not recommended

<div style=\"page-break-after: always\"></div>

for use in these patients. This is reflected accordingly in the SmPC (see SmPC sections 4.2 and 5.2).

## Paediatric population

No dose adjustment is required for the treatment of type 2 diabetes mellitus in children aged 10 years and above. This is reflected accordingly in the SmPC. (see SmPC sections 4.2 5.1 and 5.2). Clinical efficacy and safety of Invokana have not been established in children below 10 years of age.

## Safety related to drug-drug interactions and other interactions

Interaction studies have only been performed in adults.

## Discontinuation due to adverse events

In the Phase 3 study (DIA3018), of 87 participants receiving placebo and 84 receiving canagliflozin 1 in each treatment group (1.1% vs 1.2%) reported 1 or more TEAEs leading to discontinuation.

The participant on placebo reported MedDRA PT Mood swings while the participant on canagliflozin reported MedDRA PT Generalized tonic-clonic seizures; the participant with the seizure event had a history of epilepsy and the event was considered by the investigator not to be related to canagliflozin.

In the Phase 1 study (DIA1055), none of the participants discontinued the study drug due to an adverse event.

## Post-marketing experience

A cumulative search of the MAH's global safety database retrieved 20 cases involving the use of canagliflozin in paediatric patients aged ≥ 10 years and &lt;18 years old or where age group is reported as adolescent/child. None of the post-marketing cases retrieved in this search reported any new significant safety information on the paediatric age group.

## 2.6.1. Discussion on clinical safety

Results from the Phase 1 study (DIA1055) showed that PK/PD profiles in the paediatric population were consistent with those observed in adults.

In the Phase 3 study (DIA3018) more commonly ( ≥ 2%) reported TEAEs in participants receiving canagliflozin versus placebo included headache (10.7% vs. 3.4%), dizziness (3.6% vs. 1.1%), nasopharyngitis (9.5% vs. 5.7%), rhinitis (4.8% vs. 2.3%), urinary tract infection (7.1% vs. 4.6%), vomiting (6.0% vs. 2.3%), nausea (4.8% vs. 1.1%) and abdominal pain (3.6% vs. 0%).

In addition, various TEAEs of genital mycotic or bacterial infections were reported in paediatric patients receiving canagliflozin and none with placebo: balanitis candida (2.4% vs. 0%), vulvovaginal candidiasis (2.4% vs. 0%), bacterial vaginosis (1.2% vs. 0%) and genital infection fungal (1.2% vs. 0%).

Vitamin D levels seemed to be slightly reduced in canagliflozin-treated subjects. Indeed, in Study DIA3018, a modest reduction in 25-hydroxy Vitamin D was observed at Week 26 in the canagliflozin group compared to placebo. However, this laboratory finding did not translate into a higher incidence of TEAEs related to Vitamin D deficiency. On the contrary, the incidence of Vitamin D deficiency reported as a TEAE was slightly lower in the canagliflozin group (4 participants, 4.8%) than in the placebo group (6 participants, 6.9%). Moreover, Vitamin D deficiency is a known comorbidity in

<div style=\"page-break-after: always\"></div>

paediatric patients with T2DM, and supplementation is recommended for this population regardless of antidiabetic treatment. Therefore, the observed reduction is not considered clinically meaningful, and no update to the product information was deemed necessary.

Adverse events of special interest (AESI) across both studies (DIA3018 and DIA1055) included:

- Hypoglycemia that was documented by blood glucose measurements occurred in both groups (17.9% in canagliflozin vs. 16.1% in placebo) in study DIA3018 and in 1 participant on 300 mg canagliflozin in study DIA1055.

- Ketosis/acidosis-related AEs were comparable in the canagliflozin and placebo groups. Three DKA events were confirmed by external adjudication in study DIA3018. Two of the DKA events were serious, 1 was reported in a participant receiving placebo and 1 in a participant receiving canagliflozin 100 mg. In study DIA1055 one participant receiving canagliflozin 100 mg experienced an episode of metabolic acidosis. A DKA warning including information on how to manage this condition is already part of SmPC section 4.4. Moreover, in response to the observed events and based on pharmacokinetic considerations, a warning was added to Section 4.4 of the SmPC indicating that the risk of DKA may be increased in children with low body weight when receiving the 300 mg dose of canagliflozin.

- One SAE of pancreatitis was reported in Study DIA3018 in a participant receiving canagliflozin 100 mg. There were no reports of pancreatitis in Study DIA1055.

No deaths, amputations, or malignancies were reported in Study DIA3018 and Study DIA1055.

Overall, the results of the two paediatric studies show that the safety profile for canagliflozin in children and adolescents aged 10 to less than 18 years with T2DM is similar to the established safety profile in adults with T2DM, with no new adverse drug reactions (ADRs) or new safety signals identified.

Once approved canagliflozin would be the third SGLT-2 inhibitor besides dapagliflozin and empagliflozin which are already marketed in the EU for the treatment of children and adolescents with type 2 diabetes aged 10 to less than 18 years.

## 2.6.2. Conclusions on clinical safety

Study DIA3018 and Study DIA1055 confirm that the safety profile of Invokana in children and adolescents ( ≥ 10 to &lt;18 years) with T2DM is consistent with the known safety profile in adults with T2DM.

Available post-marketing data suggest intended off-label treatment in paediatric patients who were mostly treated for T2DM (where reported). No clinically important new risks were identified from the review of the post-marketing cases in children and adolescents ( ≥ 10 to &lt;18 years) with T2DM.

Except for the potential effect of canagliflozin on vitamin D levels, there were no clinically important differences between canagliflozin and placebo regarding changes over time in laboratory parameters, vital signs, developmental parameters or other observations related to safety in the two paediatric studies DIA3018 and DIA1055.

In conclusion, based on the review of available data presented in this application, Invokana (canagliflozin 100 mg and 300 mg once daily) is considered to have an acceptable safety profile in children and adolescents ( ≥ 10 to &lt;18 years) with T2DM.

<div style=\"page-break-after: always\"></div>

## 2.6.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 3. Risk management plan

The MAH submitted an RMP version 13.1 and an updated RMP version 13.2 during the assessment.

## 3.1. Safety Specification

## Summary of the safety concerns

Not changed

## 3.2. Pharmacovigilance plan

Not changed

## 3.3. Risk minimisation measures

Routine risk minimisation measures

Not changed

## Additional risk minimisation measures

Not changed

## 3.4. Overall conclusion on the RMP

The CHMP endorsed the Risk Management Plan version 13.2 (Date of sign-off 14 January 2025).

## 4. Changes to the Product Information

As a result of this type 2 variation, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. In addition, the MAH took the opportunity to update the information of local representative in the package leaflet.

## 4.1.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

- Full user testing in compliance with the legislative requirements was successfully completed in January 2013, on the original INVOKANA patient leaflet (100 mg and 300 mg tablets).

<div style=\"page-break-after: always\"></div>

- A supplementary Focus Test was also successfully completed in May 2013 following revisions to the INVOKANA patient leaflet at D120.
- The package leaflet in the current application has the same format as previously tested.
- No additional safety issues have been identified.
- No new route of administration is proposed.
- With the proposed variation application, only minor changes were introduced in the patient leaflet to list the new indication.
- The proposed changes to the package leaflet reflect language that is consistent with the currently approved leaflet.

## 4.2. Significance of paediatric studies

NA

## 5. Benefit-Risk Balance

## 5.1. Therapeutic Context

## 5.1.1. Disease or condition

Current approved clinical indication in adults:

INVOKANA (canagliflozin) is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
- in addition to other medicinal products for the treatment of diabetes.

For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see SmPC sections 4.4, 4.5 and 5.1.

## Proposed new paediatric indication ( in bold )

INVOKANA (canagliflozin) is indicated for the treatment of adults and children aged 10 years and older with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
- in addition to other medicinal products for the treatment of diabetes.

For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see SmPC sections 4.4, 4.5 and 5.1.

The applicant does not propose any changes to the dosage form, route of administration, or dosing regimen via this application.

## 5.1.2. Available therapies and unmet medical need

The recommended treatment for paediatric T2DM is similar to that on for the adults population, with emphasis on a step-wise approach starting with lifestyle modifications, particularly diet and exercise,

<div style=\"page-break-after: always\"></div>

followed by the use of a single medical therapy and later by two therapies in combination. The aim is that the patient achieves and maintains low levels of glucose in the blood in order to prevent long-term complications.

For a long time, the only two approved treatment options for paediatric patients with T2DM in most countries were metformin and insulin. Recently, additional treatment options have become available in the EU for children and adolescents aged 10 to less than 18 years, e.g. the GLP-1 receptor agonists Liraglutide (Victoza), Exenatide extended-release  once-weekly  injection  (Bydureon), Dulaglutide (Trulicity) and the SGLT-2 inhibitors Dapagliflozin (Forxiga) and Empagliflozin (Jardiance).

## 5.1.3. Main clinical studies

Thought this variation application, the MAH is seeking to extend the indication for Invokana (canagliflozin 100 mg and 300 mg once daily) to the paediatric patients ≥ 10 to &lt;18 years of age with T2DM based on the final results from the following two clinical trials:

- Study  JNJ-28431754DIA3018  (Study  DIA3018),  that  was  a  randomized,  double-blind,  placebocontrolled, 2-arm, parallel-group, multicenter Phase 3 study in participants with T2DM ≥ 10 and &lt;18 years of age who had inadequate glycaemic control (i.e. HbA1c of ≥ 6.5% to ≤ 11.0%). The total duration of the study was approximately 59 weeks.
- Study JNJ-28431754DIA1055 (Study DIA1055), that was an open-label, sequential, multiple-dose (14 days of dosing), multicenter Phase 1 study of canagliflozin in 2 treatment groups in children and adolescents ( ≥ 10 to &lt;18 years of age) who were diagnosed with T2DM and on a stable regimen of metformin (at a dose of at least 1,000 mg per day) for at least 8 weeks before screening.

The studies were part of the completed PIP.

## 5.2. Favourable effects

The primary endpoint results and the secondary endpoint analyses from the phase 3 study DIA3018 clearly show that canagliflozin is effective at reducing HbA1c and plasma glucose levels in paediatric T2DM patients between 10 and 18 years of age. In case no sufficient  anti-hyperglycaemic  effect  is achieved with the 100 mg dose, the DIA3018 data suggest that up-titration to 300 mg is beneficial to further improve blood glucose control. Treatment with canagliflozin was also associated with a slight reduction in body weight, which is considered a favourable effect in overweight/obese paediatric T2DM patients. Moreover, plasma triglycerides were reduced in canagliflozin-treated patients.

## 5.3. Uncertainties and limitations about favourable effects

The patient group that was up-titrated from 100 mg to 300 mg was relatively small (n=17), specifically the subgroup of patients aged ≥10 to &lt;15 years ( n=6). Thus, evidence for a benefit of the 300 mg dose in the younger age group is only limited.

While about 75% of the included population were overweight or obese, 24.0 % of the patients had normal weight (one patient even with underweight). It is uncertain whether the currently proposed doses (that are identical with the adult doses) can be transferred to the normal weight paediatric population without safety concerns or whether a dose of ≤100 mg might be warranted in normal weight paediatric T2DM patients. A statement in the SmPC section 4.2 is added to indicate that in children (specifically those weighing &lt;50 kg), caution is advised when up-titrating to the 300 mg dose, since safety data is limited for the resulting exposure levels. Statements in the SmPC sections 4.4 and 5.2 are also included.

<div style=\"page-break-after: always\"></div>

## 5.4. Unfavourable effects

Results from the Phase 1 study (DIA1055) showed that the safety profile in the paediatric population was consistent with the corresponding information available for the adult populations.

In  the  Phase  3  study  (DIA3018)  more  commonly  ( ≥ 2%)  reported  TEAEs  in  participants  receiving canagliflozin  versus  placebo  included  headache  (10.7%  vs.  3.4%),  dizziness  (3.6%  vs.  1.1%), nasopharyngitis (9.5% vs. 5.7%), rhinitis (4.8% vs. 2.3%), urinary tract infection (7.1% vs. 4.6%), vomiting (6.0% vs. 2.3%), nausea (4.8% vs. 1.1%) and abdominal pain (3.6% vs. 0%).

In addition, various TEAEs of genital mycotic or bacterial infections were reported in paediatric patients receiving canagliflozin and none with placebo: balanitis candida (2.4% vs. 0%), vulvovaginal candidiasis (2.4% vs. 0%), bacterial vaginosis (1.2% vs. 0%) and genital infection fungal (1.2% vs. 0%).

Canagliflozin seemed to slightly reduce Vitamin D levels at week 26 and 52 as compared to placebo.

Adverse events of special interest (AESI) across both studies (DIA3018 and DIA1055) included:

- -Hypoglycemia  that  was  documented  by  blood  glucose  measurements  occurred  in  both  groups (17.9% in canagliflozin vs. 16.1% in placebo) in Study DIA3018 and in 1 participant on 300 mg canagliflozin in Study DIA1055.
- -Ketosis/acidosis-related AEs were comparable in the canagliflozin and placebo groups. Three DKA events were confirmed by external adjudication in study DIA3018. Two of the DKA events were serious, 1 was reported in a participant receiving placebo and 1 in a participant receiving canagliflozin 100 mg. In study DIA1055 one participant receiving canagliflozin 100 mg experienced an episode of metabolic acidosis. A DKA warning including information on how to manage this condition is already part  of  SmPC  section  4.4.  In  response  to  the  observed  events  and  based  on  pharmacokinetic considerations, a warning was also added to Section 4.4 of the SmPC indicating that the risk of DKA may be increased in children with low body weight when receiving the 300 mg dose of canagliflozin.
- -One SAE of pancreatitis was reported in Study DIA3018 in a participant receiving canagliflozin 100 mg. There were no reports of pancreatitis in Study DIA1055.
- -No deaths, amputations, or malignancies were reported in either study.

Overall, the results of the two paediatric studies show that the safety profile for canagliflozin in children and adolescents aged 10 to less than 18 years with T2DM is similar to the established safety profile in adults with T2DM, with no new adverse drug reactions (ADRs) or new safety signals identified.

## 5.5. Uncertainties and limitations about unfavourable effects

No uncertainties and limitations about unfavourable effects have been identified.

## 5.6. Effects Table

## Table 1. Effects Table for Invokana (canagliflozin) for the treatment of T2DM in children and adolescents ( ≥ 10 to &lt;18 years)

Table 2.

<div style=\"page-break-after: always\"></div>

| Effect   | Short descripti on Unit Canaglifloz in N=84 Placebo N=87 Uncertainties Strength of evidence References   |
|----------|----------------------------------------------------------------------------------------------------------|

## Favourable Effects

| at 26 weeks                                                                                         | at 26 weeks              | at 26 weeks          | at 26 weeks                            | at 26 weeks                            | at 26 weeks                    | at 26 weeks             |
|-----------------------------------------------------------------------------------------------------|--------------------------|----------------------|----------------------------------------|----------------------------------------|--------------------------------|-------------------------|
| Change in HbA1c from baseline at week 26                                                            | Primary endpoint         | % mean (SD)          | -0.4 (1.44)                            | +0.3 (1.56)                            | Phase 3 data; p = 0.002        | Study DIA 3018          |
| Change in HbA1c from baseline at week 26 in participants taking metformin (with or without insulin) | Major secondary endpoint | % mean (SD)          | -0.4 (1.50)                            | +0.3 (1.63)                            | Phase 3 data; p = 0.012        | Study DIA 3018          |
| Effect on fasting plasma glucose (FPG) after 26 weeks                                               | Major secondary endpoint | mg/dL mean (SE)      | -11.5 (6.86)                           | 15.3 (6.68)                            | Phase 3 data; (LOCF) p = 0.003 | Study DIA 3018          |
| Proportion of participants with HbA1c <7.5%, <7.0% and <6.5% after 26 weeks                         | Major secondary endpoint | %                    | <7.5%: 64.9% <7.0%: 51.9% <6.5%: 41.6% | <7.5%: 40.0% <7.0%: 27.5% <6.5%: 11.3% | Phase 3 data                   | Study DIA 3018          |
| Proportion of participants receiving rescue therapy after 26 weeks                                  | Major secondary endpoint | %                    | 6.0%                                   | 27.6%                                  | Phase 3 data                   | Study DIA 3018          |
| %change from baseline in body weight after 26 weeks                                                 | Major secondary endpoint | % (SD)               | -1.6 (0.51)                            | -0.0 (0.51)                            | Phase 3 data (LOCF) p = 0.019  | Study DIA 3018          |
| %change from baseline in body weight after 26 weeks, cana 100 mg vs. placebo                        | Other efficacy analysis  | % (SD)               | -0.25 (0.173)                          | +0.34 (0.184)                          | Phase 3 data (MMRM) p = 0.020  | Study DIA 3018          |
| %change from baseline in body weight after 26 weeks, up-titrated to cana 300 mg vs. placebo         | Other efficacy analysis  | % (SD)               | -0.41 (0.167)                          | +0.33 (0.175)                          | Phase 3 data (MMRM) p = 0.002  | Study DIA 3018          |
| at 52 weeks                                                                                         | at 52 weeks              | at 52 weeks          | at 52 weeks                            | at 52 weeks                            | at 52 weeks                    | at 52 weeks             |
| Change in HbA1c from baseline at week 52                                                            | Major secondary endpoint | % (SE)               | -0.32 (0.184)                          | +0.70 (0.182)                          | Phase 3 data (MMRM) p < 0.001  | Study DIA 3018          |
| Effect on FPG after 52 weeks                                                                        | Major secondary endpoint | mg/dL                | -16.4 (6.98)                           | 19.2 (6.90)                            | Phase 3 data; (LOCF) p <0.001  | Study DIA 3018          |
| Proportion of participants with HbA1c <7.5%, <7.0% and <6.5% after 52                               | Major secondary endpoint | %                    | <7.5%: 69.0% <7.0%: 54.9% <6.5%: 36.6% | <7.5%: 29.3% <7.0%: 22.7% <6.5%: 12.0% | Phase 3 data                   | Study DIA 3018          |
| Proportion of participants receiving rescue therapy after 52 weeks                                  | Major secondary endpoint | %                    | 11.9%                                  | 46.0%                                  | Phase 3 data                   | Study DIA 3018          |
| %change from baseline in body weight after 52 weeks                                                 | Major secondary endpoint | % (SD)               | -0.5 (0.69)                            | 0.4 (0.69)                             | Phase 3 data (LOCF) p = 0.293  | Study DIA 3018          |
| Unfavourable Effects                                                                                | Unfavourable Effects     | Unfavourable Effects | Unfavourable Effects                   | Unfavourable Effects                   | Unfavourable Effects           | Unfavourable Effects    |
| Hypoglycemia (documented by blood glucose measurements)                                             | Treatment- emergent AE   | n (%)                | 15 (17.9%)                             | 14 (16.1%)                             | Phase 3 data                   | Phase 3 study (DIA3018) |
| Headache                                                                                            | Treatment- emergent AE   | n (%)                | 9 (10.7%)                              | 3 (3.4%)                               | Phase 3 data                   | Phase 3 study (DIA3018) |
| Dizziness                                                                                           | Treatment-               | n (%)                | 3 (3.6%)                               | 1 (1.1%)                               | Phase 3 data                   | Phase 3 study           |

<div style=\"page-break-after: always\"></div>

| Effect                             | Short descripti on                     | Unit   | Canaglifloz in N=84   | Placebo N=87   | Uncertainties Strength of evidence   | References              |
|------------------------------------|----------------------------------------|--------|-----------------------|----------------|--------------------------------------|-------------------------|
|                                    | emergent AE                            |        |                       |                |                                      | (DIA3018)               |
| Nasopharyngitis                    | Treatment- emergent AE                 | n (%)  | 8 (9.5%)              | 5 (5.7%)       | Phase 3 data                         | Phase 3 study (DIA3018) |
| Rhinitis                           | Treatment- emergent AE                 | n (%)  | 4 (4.8%)              | 2 (2.3%)       | Phase 3 data                         | Phase 3 study (DIA3018) |
| Urinary tract infection            | Treatment- emergent AE                 | n (%)  | 6 (7.1%)              | 4 (4.6%)       | Phase 3 data                         | Phase 3 study (DIA3018) |
| Balanitis candida                  | Treatment- emergent AE                 | n (%)  | 2 (2.4%)              | 0 (0%)         | Phase 3 data                         | Phase 3 study (DIA3018) |
| Vulvovaginal candidiasis           | Treatment- emergent AE                 | n (%)  | 2 (2.4%)              | 0 (0%)         | Phase 3 data                         | Phase 3 study (DIA3018) |
| Vomiting                           | Treatment- emergent AE                 | n (%)  | 5 (6.0%)              | 2 (2.3%)       | Phase 3 data                         | Phase 3 study (DIA3018) |
| Nausea                             | Treatment- emergent AE                 | n (%)  | 4 (4.8%)              | 1 (1.1%)       | Phase 3 data                         | Phase 3 study (DIA3018) |
| Abdominal pain                     | Treatment- emergent AE                 | n (%)  | 3 (3.6%)              | 0 (0%)         | Phase 3 data                         | Phase 3 study (DIA3018) |
| Ketosis/ diabetic ketoacidosis     | Treatment- emergent AE                 | n (%)  | 2 (2.4%)              | 1 (1.1%)       | Phase 3 data                         | Phase 3 study (DIA3018) |
| Pancreatitis acute                 | Treatment- emergent AE                 | n (%)  | 1 (1.2%)              | 0 (0%)         | Phase 3 data                         | Phase 3 study (DIA3018) |
| Reduction of 25- hydroxy Vitamin D | Median change from baseline at week 26 | nmol/l | -3.0                  | +1.5           | Phase 3 data                         | Phase 3 study (DIA3018) |

## 5.7. Benefit-risk assessment and discussion

## 5.7.1. Importance of favourable and unfavourable effects

## Importance of favourable effects

The key favourable effect is a clinically relevant and significant reduction in HbA1C after 26 weeks of treatment  with  100  mg  or  300  mg  of  canagliflozin  (difference  canagliflozin  vs.  placebo:  -0.76%). Improvement of blood glucose control by canagliflozin is further confirmed by reduction in fasting plasma glucose, by shifts towards lower HbA1c categories in the responder analysis as well as by a considerable reduction of the proportion of participants requiring rescue medication. Additional favourable effects are a reduction in plasma triglycerides and, specifically in the overweight/obese population, a slight reduction in body weight.

## Importance of unfavourable effects

The most important unfavourable effect would be diabetic ketoacidosis (DKA), which, however, occurred at  comparable  frequency  in  placebo-  and  canagliflozin-treated  patients.  A  DKA  warning  including information on how to manage this condition is already part of SmPC section 4.4. In addition, a warning

<div style=\"page-break-after: always\"></div>

has been added in 4.4 of the SmPC in relation to children with low body weight when they receive the 300 mg dose of canagliflozin, since the exposure may exceed the levels observed in adults with the 300 mg dose.

The second most important unfavourable effect is an increase in genital and urinary tract infections, which was more pronounced with canagliflozin than with placebo, probably due to increased urinary glucose excretion. Although most of these adverse events are considered to be temporary and can be treated with antibiotic/antimycotic medications, it cannot be excluded that severe complications may occur in individual cases.

The slight reduction of vitamin D levels by canagliflozin was discussed, since it may be important for individuals with low vitamin D at baseline. Although the effects of reduced Vitamin D levels may not immediately become visible in terms of fractures in the paediatric population, the build-up of bone mass may be slowed down, leading to a lower peak bone mass, which potentially favours bone-related complications in later adulthood. However, this laboratory finding did not translate into a higher incidence of TEAEs related to Vitamin D deficiency. Moreover, Vitamin D deficiency is a known comorbidity in paediatric patients with T2DM, and supplementation is recommended for this population regardless of antidiabetic treatment. Therefore, the observed reduction is not considered clinically meaningful, and no update to the product information was deemed necessary.

Hypoglycaemia (documented by blood glucose measurements) occurred at comparable frequency in canagliflozin- and placebo-treated participants; no severe events occurred, and moderate hypoglycaemia can  be  quickly  managed  without  serious  long-term  consequences.  Of  note,  hypoglycaemia  is  rather unlikely under canagliflozin monotherapy.

The other adverse events detected with a frequency of ≥2% (i.e., headache, dizziness, nasopharyngitis, rhinitis, vomiting, nausea and abdominal pain) are mostly temporary, can be easily managed and do not lead to negative long-term consequences.

Except for the slight reduction of vitamin D levels, no new safety signals were identified in the paediatric population and the observed important unfavourable effects are already adequately addressed in the SmPC.

## 5.7.2. Balance of benefits and risks

Study  DIA3018  showed  superior  efficacy  of  Invokana  for  the  treatment  of  T2DM  in  children  and adolescents ( ≥ 10 to &lt;18 years) when compared to placebo. Treatment with canagliflozin resulted in a statistically significant improvement with respect to change from baseline in HbA1c at Week 26 compared to placebo in the overall study population.

A clinically meaningful reduction in HbA1c was observed as early as Week 12 and was sustained up to the end of the trial at Week 52. These results were supported by statistically significant improvements in key secondary efficacy endpoints and were consistent with the efficacy outcomes in adults with T2DM.

The outcomes of these clinical studies support the efficacy of Invokana for the treatment of T2DM in children and adolescents ( ≥ 10 to &lt;18 years).

Results from the Phase 1 study DIA1055 showed that PK/PD profiles in the paediatric population were largely consistent with those observed in the adult population.

The results from the Phase 3 study DIA3018 confirmed that at the recommended dose, the safety profile of Invokana (canagliflozin 100 mg and 300 mg once daily) in children and adolescents ( ≥ 10 to &lt;18 years) with T2DM is consistent with the known safety profile in adults with T2DM.

<div style=\"page-break-after: always\"></div>

Except for a reduction of vitamin D levels, no new risks or new safety signals were identified in children and adolescents aged 10 to less than 18 years with T2DM.

In conclusion, based on the review of the provided efficacy and safety data from the two additionally conducted paediatric studies, Invokana   is considered to have a positive benefit-risk profile in children and adolescents ( ≥ 10 to &lt;18 years) with T2DM.

## 5.8. Conclusions

The overall benefit-risk profile of Invokana for the treatment of children and adolescents ( ≥ 10 to &lt;18 years) with insufficiently controlled T2DM is positive.

## 6. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends by consensus the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include treatment of paediatric patients with type 2 diabetes mellitus aged 10 years old and older for INVOKANA, based on final results from study JNJ-28431754DIA3018 as well as study JNJ-28431754DIA1055. Study JNJ-28431754DIA3018 is a double-blind, placebo-controlled, 2-arm, parallel-group, multicenter Phase 3 study in participants with T2DM &gt;10 and &lt;18 years of age who had inadequate glycemic control (i.e, HbA1c of &gt;6.5% to &lt;11.0%). As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 13.2 of the RMP has also been agreed.

In addition, the Marketing authorisation holder (MAH) took the opportunity to the update the list of local representatives in the Package Leaflet.

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP) are recommended.

## Paediatric data

Furthermore, the CHMP reviewed the available paediatric data of studies subject to the agreed Paediatric Investigation Plan P/0208/2022 and the results of these studies are reflected in the Summary of Product Characteristics (SmPC) and, as appropriate, the Package Leaflet.

<div style=\"page-break-after: always\"></div>

## 7. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion Invokana - EMEA/H/C/002649/II/0069